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Introduction
This is our seventh annual report. Normally this publication
marks the culmination of a busy year and draws a line under
a body of work undertaken in the fight against communicable
disease. However this year it also marks the sad loss of our
friend and colleague Dr Max Di Renzi, who was tragically killed
in a car accident in Turkey last June. Max worked at HPSC
throughout 2004 and 2005 and is sadly missed and fondly
remembered by all who were lucky enough to know him.
2005 was a busy year on the disease front. Cryptosporidiosis,
which has only recently become notifiable in Ireland, rose by
32.5%. As the highest rate occurred in the HSE Western
Area, a research project at University College Galway to
examine the relationship between drinking water supply and
cryptosporidium infection in the region is a very welcome.
Our understanding of this pathogen will remain limited
without adequate information and as with many other
pathogens there is a need for improved reference laboratories
in Ireland. A HSE working group has been set up to examine
these issues.
The importance of good surveillance was highlighted in 2005
when increasing failures of the Hib vaccine in children were
detected. A catch-up campaign was initiated and already in
2006 we have seen a marked reduction in cases of Hib
disease in young children.
The World Health Organisation has set 2010 as the deadline
for the eradication of measles in Europe. Ireland continues to
have one of the highest incidence in Europe - despite
reporting our lowest ever number of cases in 2005. To
eradicate measles we need to fully investigate every sporadic
case. Of the 93 notifications in 2005 only11 were confirmed.
The rest either had no laboratory investigations reported or
were unclassified. Previous HPSC research has shown that a
considerable number of children are susceptible to measles
highlighting the need for a catch up vaccination programme
in our schools. Immunisation uptake rates continue to
improve in Ireland. However we don't have the full picture.
We have no national data on the second dose of MMR or any
other school delivered vaccine. This data is essential for the
control of vaccine preventable diseases and highlights the
need for a properly funded and implemented vaccine registry.
A 10% decrease in the numbers of newly diagnosed HIV
cases, is likely to reflect a fall in the number of immigrants
presenting for screening in 2005. Ongoing transmission of
HIV in injecting drug users (IDU) and men who sex with men
(MSM) as well as heterosexual transmission in Ireland
demonstrate the need for continuing education and
awareness programmes.
A report on the Surveillance of STIs was published by HPSC's
Scientific Advisory Committee in 2005. The number of
sexually transmitted infections continues to rise unabated and
HPSC is working with the Health Research Board to
commission a feasibility project to screen for chlamydia. This
should help to inform future practice and should decrease the
incidence of this pathogen. Anogenital warts were the most
commonly notified STI in 2004. The arrival of the new human
papilloma virus (HPV) vaccine will hopefully reduce the rates
of warts but more importantly should reduce the incidence of
cervical cancer caused by HPV. A national sexual health
strategy is needed to provide a framework to prevent,
diagnose and treat STIs.
In other jurisdictions pneumococcal conjugate vaccines,
hexavalent vaccines which facilitate the introduction of
vaccines against hepatitis B, and the use of vaccines to
protect against chickenpox and rotavirus caused by
gastroenteritis, are being developed. The National
Immunisation Advisory Committee is considering the evidence
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for these vaccines and it is essential that surveillance is
improved so that we are well informed on the decisions that
we make.
High numbers of verocytotoxigenic E.coli (VTEC) were
reported in 2005. VTEC can cause serious health problems
such as haemolytic uraemic syndrome (HUS). 17 HUS cases
were reported in 2005 compared with 4-6 cases annually for
each of the previous four years. The link between VTEC and
many HUS cases may not have been made using the usual
methods and this highlights the importance of thorough
microbiological investigation of all HUS cases.
The HPSC Scientific Advisory Committee set up a
multidisciplinary sub-committee in mid 2005 to produce
guidelines on the detection, surveillance and management of
invasive Group A streptococcal disease (iGAS) in Ireland.
These have now been published and are available at
www.hpsc.ie. iGAS infections cover a wide range of illnesses
including necrotizing fasciitis.
Antimicrobial resistance remains a challenge for the HSE. Two
new pathogens were added to the list for surveillance in 2005.
The continuing high prevalence of resistance including
increasing resistance levels of E.coli and enterococci underline
the importance of fully implementing the Strategy for the
control of Anti microbial Resistance in Ireland (SARI).
Antibiotic consumption continues to rise both in the
community and in our hospitals. Some hospitals have
managed to reduce antibiotic use but we need to build on
and extend this progress.
Information on travel related disease continues to improve
and is reflected in an increase in malaria cases notified in
2005. It is essential that holidaymakers and business
travellers take appropriate treatment before visiting regions
affected by malaria. This also applies to recent immigrants to
Ireland who may not realize that any immunity they may
have will fall after living for some time in a non-malarious
area.
The HPSC and the HSE continue to strengthen preparedness
against the on-going threat of avian influenza mutating to
start a new influenza pandemic   Sentinel GPs now monitor
influenza like illness on a year round basis and all influenza
outbreaks are now notifiable.
Tuberculosis in 2004 increased to a crude incidence rate of 
11/100,000 population - up from a rate of 10.4. The rate in
the indigenous population was 8.4/100,000. The fact that TB
rates have not been falling in recent years coupled with the
increasing risk of complication from drug resistant forms of
tuberculosis continues to be a cause of concern. The public
health infrastructure to control tuberculosis needs
strengthening.
Finally, I would like to thank the scientific advisory
committees and the HPSC sub-committees for all their hard
work. They are a great example of what can be achieved
through hard work in a multi-disciplinary environment.
I would also like to extend my thanks to all the staff at HPSC
whose endevour and professionalism is reflected throughout
this report.
Dr Darina O'Flanagan
Director
Health Protection Surveillance Centre
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The Epidemiology of
Verocytotoxigenic E. coli in Ireland,
2005
Introduction
Verotoxigenic E. coli (VTEC) are so-called because of their
ability to produce one or both of two verotoxins (VT1 and
VT2). They are an important cause of gastroenteric illness
because of the severity of illness they can cause and in the
requirement for prompt public health action to prevent
further transmission. About 9% of cases develop haemolytic
uraemic syndrome (HUS), a life-threatening complication. E.
coli O157 was the first E. coli serogroup to be associated with
this distinctive illness. Additional VT-producing serogroups
frequently reported include O26, O111, O103 and O145.
Infection can be transmitted through food, contaminated
water, the environment and by direct contact with animal
carriers. Person-to-person spread is an important mode of
transmission in households, child-care facilities and
institutions.
Data sources and methods
Enhanced information on notified VTEC cases was supplied as
in previous years by HSE personnel, and typing data were
provided by the Public Health Laboratory HSE Dublin Mid
Leinster at Cherry Orchard Hospital which offers specialist
diagnostic and typing services for VTEC. Although not
notifiable, clinicians were also requested to report suspected
cases of VTEC, i.e. cases of HUS or TTP of possible infective
aetiology, for which there was no laboratory or
epidemiological evidence of VTEC infection.
Results
In 2005, 125 confirmed cases of VTEC were notified to HPSC,
a crude incidence rate (CIR) of 3.2 per 100,000 (table 1). There
were 108 cases of VTEC O157 (2.8/100,000), 12 VTEC O26,
Key points:
• In 2005, there were 125 cases of VTEC reported, 32%
higher than the number reported in 2003 (the highest
year prior to this) and over twice the number reported in
2004
• Increasing numbers of cases of non-O157 are reported
(17 this year), possibly reflecting increased awareness of
non-O157 VTEC and improved diagnosis and reporting
• High numbers of VTEC-confirmed HUS cases were
reported in 2005 -17 HUS cases versus 4-6 per annum in
the years 2001-2004, demonstrating the benefits of
thorough microbiological investigation of HUS cases
• Private water supplies again raise concern as the MW
report a large outbreak (18 confirmed cases) that was
linked with a private group water scheme 
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two VTEC O ungroupable, and one each of VTEC O152, O21
and O123. In addition, five HUS cases were reported as
suspected VTEC cases which are not included in the following
analyses.
Regional and seasonal distribution
Regional variation was noted in the numbers of cases reported
(table 2), with the highest incidence rates in the HSE-MW and
HSE-M. A single outbreak was largely responsible for the
atypically high incidence in the HSE-MW, while three small
family outbreaks accounted for 8 of the 12 cases in the HSE-
M1. In the HSE-ER in 2005, the number of VTEC cases was
almost 3-fold higher than reported in previous years (35 cases
in 2005 versus 12 cases in each year 2002-2004)2. Seven of
these cases were non-O157 VTEC. Non-O157 VTEC were
widely distributed throughout the country with cases reported
from 7 of the 8 HSE areas. Large numbers of VTEC cases were
notified in quarter 3, and atypically also in quarter 4, in
particular in November (table 2).
Age-sex distribution
The highest incidence was recorded in young children, which
is consistent with previous years (Figure 1). There were similar
numbers of male (n=65) and female (n=59) cases. As in 2004,
a higher proportion of VTEC infections notified in persons less
than 5 years were due to non-O157 VTEC (10/50) than for
other older groups (7/75), possibly reflecting the likelihood
that children less than 5 years are tested for non-O157 VTEC
more often than older patients.
Clinical features
Information on symptoms was available for 117 cases, of
whom 87 (74%) were reported as symptomatic. Reported
symptoms included bloody diarrhoea in 53 cases, and HUS in
17 cases. HUS cases ranged from 8 months to 68 years, and
as in previous years, a higher proportion of paediatric (13/70)
than adult (4/55) cases developed HUS. Notably, four HUS
cases were caused by non-O157 VTEC -three by VTEC O26
and one by VTEC O21.
Travel-association
Nine infections were travel-associated. The countries visited
within the potential incubation period were Spain (2), Greece
(2), UK (1), Croatia (1), Hungary (1), Belgium (1) and Turkey
(1), reflecting to some extent the frequency of travel by Irish
residents to these destinations.
Microbiology
Among the 108 VTEC O157 infections reported, typical non-
sorbitol fermenting (NSF) VTEC O157 were isolated from 103
cases, sorbitol-fermenting (SF) VTEC O157 from three cases,
and two confirmed E. coli O157 cases were diagnosed by
serodiagnosis alone. All 17 non-O157 VTEC cases were culture
confirmed. Table 3 showed the number of HUS and non-HUS
cases by method of laboratory confirmation.
Table 4 shows the phage types of the VTEC O157 strains
isolated in 2005. As in previous years, PT32 was the
commonest phage type reported, accounting for 56% of the
VTEC O157 reported.
Table 1. Number and crude incidence rates confirmed VTEC and VTEC O157 infection, 
Ireland 2001-2005
Year Nos. of VTEC   CIR VTEC O157*    Number VTEC ‡   CIR VTEC* 
 O157 cases    (95% CI)  cases    (95% CI) 
2001 52  1.3 (0.9-1.6) N/A   N/A
2002 70  1.7 (1.3-2.2) N/A   N/A
2003 88   2.2 (1.8-2.7) 95   2.4 (1.9-2.9)
2004 52  1.3 (1.0-1.7) 61   1.6 (1.2-2.0)
2005 108  2.8 (2.3-3.3) 125   3.2 (2.6-3.8)
* Data from the 2002 census were used to calculate rates  
‡ Includes serogroup O157
Quarter E M MW NE NW SE S W Total
Q1 2 1 0 0 0 1 1 1 6
Q2 5 1 1 1 3 3 2 3 19
Q3 15 7 4 2 2 10 6 4 50
Q4 13 3 21 4 0 2 1 6 50
Total 35 12 26 7 5 16 10 14 125
CIR 2.5 5.3 7.7 2.0 2.3 3.8 1.7 3.7 3.2
(95% CI) (1.7-3.3) (2.3-8.3) (4.8-10.6) (0.5-3.5) (0.3-4.3) (1.9-5.7) (0.6-2.8) (1.8-5.6) (2.6-3.8)
ASIR 2.5 5.0 7.7 2.0 2.2 3.7 1.7 3.7 -
(95% CI) (1.7-3.4) (2.2-7.8) (4.7-10.6) (0.5-3.6) (0.3-4.1) (1.9-5.5) (0.7-2.8) (1.7-5.6) -
Table 2. Number of confirmed VTEC cases by quarter and HSE area, CIR and 
age-standardised incidence rate (ASIR) by HSE area, Ireland 2005
Table 3. Confirmed VTEC cases by method of laboratory confirmation, Ireland 2005.
 HUS Non-HUS Total
Isolation of NSF VTEC O157 9 94 103
Isolation of SF VTEC O157  2 1 3
Serodiagnosed as E. coli O157 2 0 2
Isolation of non-O157 VTEC 4 13 17
Total 17 108 125
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In 2005, 89% of VTEC O157 strains carried the genes for VT2
only while 11% carried the genes for both VT1 and VT2 (table
5). In contrast, 41% of non-O157 VTEC isolates carried the
genes for VT1 only, 12% for VT2 only, and 47% VT1 and VT2.
Outbreak investigations
In 2005, 19 outbreaks were reported, comprising 65 of the
125 confirmed cases reported. Four outbreaks were described
as general outbreaks and 15 as family outbreaks. Seventeen
were due to VTEC O157 and two to VTEC O26. The suspected
modes of transmission reported are listed in table 6.
The most significant VTEC O157 outbreak in Ireland in 2005
occurred in the MW in October/November 2005.1 Nine
people were reported ill, including 2 children who developed
HUS. A further nine asymptomatic contacts were confirmed
as being infected with the outbreak strain and two persons
with non-O157 VTEC strains. All cases recovered. This was the
largest VTEC outbreak reported in Ireland to date. No food or
water samples tested positive for VTEC, but results from a
case-control study indicated that potential exposure to
drinking water from a vulnerable local private group water
scheme was a risk. The implicated GWS drew water from
areas of agricultural land with close proximity to cattle and
slurry spreading. VTEC O157 indistinguishable from the
outbreak strain was isolated from an animal/farm sample.
Discussion
In 2005, 125 confirmed cases of VTEC were notified to HPSC
(CIR 3.2 per 100,000). This is 32% higher than the number
reported in 2003 (the highest year prior to this) and is over
twice the number notified in 2004. Non-O157 VTEC have
been recognised for many years in continental Europe as
causing a significant proportion of VTEC infections, notably in
Germany and Denmark.3 The rise in the reported incidence of
non-O157 infection in Ireland may be due to increased
awareness nationally of non-O157 VTEC and improved
diagnosis and reporting.
The seasonal distribution of cases was unusual in 2005, with
an atypically high number of cases in quarter 4. This was due
in part to a single large outbreak that occurred in the MW at
this time, and also to the large number of VTEC O157 cases
that were notified in the HSE-ER in November.1 Three family
outbreaks accounted for ten of the 13 ER cases. The existence
of one large undetected outbreak in the ER at this time is
unlikely as, in all, 5 different phage types were represented
among the 13 cases reported.
For the first time in Ireland, cases of VTEC O157 due to
sorbitol-fermenting VTEC O157 were reported. There were
three cases, two of which were epidemiologically linked and
were foreign travel-associated. Typically, most VTEC O157 are
unable to ferment sorbitol, and it is this feature that
facilitates their identification. Human infections due to
sorbitol-fermenting VTEC O157 strains have been reported
from Germany and the Czech Republic and most recently in
the UK.4
In 2005, high numbers of VTEC-confirmed HUS cases were
reported –17 HUS cases versus 4-6 per annum in the years
2001-2004. Eight of the 17 HUS cases notified in 2005 were
diagnosed as VTEC either by serodiagnosis alone (n=2), by
investigation for non-O157 VTEC (n=4) or by investigation for
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Figure 1. Age-specific incidence rate (per 100,000 population) of confirmed cases of VTEC,
Ireland 2005
Males Females
Table 4 Phage Types of VTEC O157 isolates referred to the PHL HSE Dublin Mid Leinster, 
Cherry Orchard Hospital in 2005
Phage type Number (%)
PT32 59 (56%)
PT21/28 13 (12%)
PT8 12 (11%)
PT31 6 (6%)
PT4 4 (4%)
PT14 4 (4%)
PT88 3 (3%)
PT1 1 (1%)
RDNC 1 (1%)
PT51 1 (1%)
PT49 1 (1%)
PT54 1 (1%)
Total 106 (100%)
Note that 2 E. coli O157 infections were diagnosed by serodiagnosis and thus isolates 
were not available for typing.
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SF VTEC O157 (n=2), and would not have been recognised as
VTEC had they been examined solely for the typical NSF
VTEC O157. This demonstrates the benefits of thorough
microbiological investigation of HUS cases.
A variety of sources and transmission routes have been
demonstrated worldwide for VTEC, including food, water,
environmental and direct animal contact as well as person-to-
person transmission. For the VTEC outbreaks reported in
Ireland 2005, multiple possible transmission routes were
reported for many of the outbreaks, with person-to-person
transmission suspected to have played a role in ten, food in
five, water in two and animal contact in three outbreaks. For
most of the outbreaks, the evidence for these transmission
routes was circumstantial, but for the large outbreak in the
HSE MW, there was epidemiological evidence both for person-
to-person transmission and for waterborne spread. This re-
enforces the concerns raised in the 2004 HPSC VTEC annual
report in relation to the proper management of private water
supplies (both private wells and private group schemes),
especially those that have the potential to serve large
numbers of people.2
Internationally, there were several foodborne outbreaks of
VTEC in 2005. Notable VTEC outbreaks include a large
outbreak of VTEC O157 in Wales in which sliced cooked
meats were implicated.5 Another VTEC O157 outbreak was
associated with beef burgers in France in October 2005.6 In
Sweden, an outbreak VTEC O157 was epidemiologically linked
to lettuce that had been irrigated with water from a small
stream.7 And more recently an outbreak of VTEC O103 was
reported in Norway associated with a cured meat sausage.8
These outbreaks serve as reminders of the potential role of a
variety of foods in both VTEC O157 and non-O157 outbreaks.
In February 2006, the HPSC sub-committee on VTEC
published a document for health professionals on VTEC.9 It
provides guidance for clinicians, public health professionals,
environmental health professional and infection control
personnel in relation to VTEC. Further guidance for laboratory
personnel is in preparation.
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 VT1 only VT2 only VT1 and VT2 Total
O157 0 94 12 106
O26 4 0 8 12
O21 0 1 0 1
O123 1 0 0 1
O152 1 0 0 1
O ungroupable 1 1 0 2
Note that two E. coli O157 infections were diagnosed by serodiagnosis and thus
isolates were not available for typing.
Table 5. Verotoxin typing results for VTEC isolates referred to the PHL HSE Dublin Mid 
Leinster, Cherry Orchard Hospital in 2005 Table 6. VTEC outbreaks in Ireland 2005 by suspected mode of transmission.
Suspected modes of transmission* Number of  Confirmed  Number
 outbreaks  cases  ill
P-P 4 12 7
P-P and animal contact 2 4 6
P-P and foodborne 2 4 4
Foodborne 2 6 3
P-P and waterborne 1 3 2
P-P, waterborne and animal contact 1 18 9
Foodborne and animal contact 1 2 2
Unknown/Not specified 6 16 17
Total 19 65 50
*P-P denotes person-to-person transmission
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Epidemiology of Cryptosporidiosis 
in Ireland, 2005
Key Points
• In 2005, there was a 32% increase in the number of
cryptosporidiosis cases notified in Ireland relative to
2004, with the crude incidence rate rising from 11.0 to
14.6 per 100,000 population
• Much of the excess in cases was concentrated in the
months of April and May, a time when the incidence
would be expected to be at its' highest
• Infection was reported most frequently in children under
5 years of age
• The lowest incidence was in the Eastern Region and the
highest in the Western Area
Introduction
Cryptosporidium is a protozoal parasite that causes a
diarrhoeal illness in humans known as cryptosporidiosis. In
immunocompetent patients it causes watery non-bloody
diarrhoea, sometimes accompanied by abdominal pain,
nausea, anorexia, fever and weight loss. In immuno-
compromised individuals, especially those with AIDS,
diarrhoea can be chronic and persistent, causing clinically
significant fluid and electrolyte depletion. Weight loss, wasting
and abdominal pain may be severe.
C. parvum (formerly known as C. parvum type II) and C.
hominis (formerly known as C. parvum type I) are the main
species associated with human infection, although a minority
of human infections have been linked with other species such
as C. felis and C. meleagridis. The primary reservoir for C.
hominis is humans while both livestock (calves and lambs in
particular) and humans serve as reservoirs for C. parvum. Thus,
speciation can be used to indicate a likely source of infection
for individual cases.
With both humans and animals serving as potential reservoirs,
multiple routes of transmission are possible. The consumption
of contaminated water is regarded as being an important
transmission route, but infection has also been associated
with swimming pools, farm animal contact, food and person-
to-person spread.1-6 A primary public health concern regarding
Cryptosporidium is its relative resistance to chlorination.
Methods
Cases of cryptosporidiosis are notified, by both clinicians and
laboratory directors, to the Medical Officer of Health in each
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HSE area. These weekly notifications form the basis of the
analyses presented here. The case definition used is that
outlined in the HPSC booklet ‘Case definitions for notifiable
diseases’ (http://www.ndsc.ie/hpsc/NotifiableDiseases
/CaseDefinitions/). Census data from 2002 (CSO) were used
to calculate incidence rates.
Results
Incidence 
In 2005, 570 cases of cryptosporidiosis were notified in
Ireland, a crude incidence rate of 14.6 per 100,000 population.
This was a 32% increase on the number of cases notified in
2004.
Geographical distribution 
The crude incidence (CIR) and age standardised incidence
(ASIR) rates by HSE area for 2005 are reported in table 1. As
per 2004, the HSE-ER reported the lowest crude incidence
rate, while a 42% decrease in notifications occurred in the
Midlands where a large outbreak in 2004 undoubtedly
contributed to the higher incidence in that year. The main
increases were reported in the HSE-NE, where the rate rose
from 8.7 in 2004 to 18.0 per 100,000 in 2005 (a rate now
similar to most other HSE areas), and in the HSE-W where
the rate rose from 20.2 in 2004 to 34.4 per 100,000 in 2005,
substantially higher that all other HSE areas (figure 1). In
addition to a true difference in incidence, regional variation in
incidence may also reflect regional variation in laboratory
screening and case-finding policies.
Age distribution 
The highest reported incidence was in children between the
ages of 1 and 5 years (figure 2). This was found to be the case
in almost all HSE areas although the age-specific incidence
varied between 7.76 per 100,000 in this age group in the HSE
-ER to 427.60 per 100,000 in the HSE-W (table 2). The
incidence among males was slightly higher than for females in
younger age groups (figure 2).
Seasonality
As in 2004, the disease displayed a pronounced seasonal
distribution with 61% of cases notified during the 3 months
April to June (figure 3). It was in this quarter in 2005 that the
excess in cases were clustered.
Outbreaks of cryptosporidiosis 
Six outbreaks of cryptosporidiosis were reported in 2005: four
general outbreaks and two family outbreaks. Forty-nine
people were reported ill as a result of these outbreaks, and 13
were hospitalised (an admission rate of 26%). The suspected
mode of transmission for four outbreaks was unknown,
however, for two general outbreaks, water was suspected to
have played a role in transmission. The water supplies in both
instances were public supplies and boil water notices were
issued. Speciation of human isolates was undertaken for the
SE outbreak, which was reported to be due to C. hominis.7,8
Discussion
Overall, there was a 32% increase in the number of
cryptosporidiosis cases notified in Ireland in 2005 relative to
2004, with the crude incidence rate rising from 11.0 to 14.6
per 100,000. Much of the excess in cases was concentrated in
the months of April and May, a time when the incidence
would be expected to be at its’ highest. At first, it was unclear
Table 1. Number of notified cases, crude incidence rate and age-standardised incidence 
rate of cryptosporidiosis by HSE area, 2005.
HSE area No. notifications CIR (95% CI) ASIR (95% CI)
ER 38 2.7 (1.8-3.6) 2.6 (1.8-3.4)
M 36 16.0 (10.8-21.2) 14.7 (9.9-19.4)
MW 56 16.5 (12.2-20.8) 16.6 (12.3-21.0)
NE 62 18.0 (13.5-22.5) 16.8 (12.6-21.0)
NW 43 19.4 (13.6-25.2) 18.4 (12.8-23.9)
SE 99 23.4 (18.8-28.0) 23.1 (18.6-27.7)
S 105 18.1 (14.6-21.6) 18.6 (15.1-22.2)
W 131 34.4 (28.5-40.3) 35.7 (29.6-41.9)
Total 570 14.6 (13.4-15.8) -
Table 2. Age-specific incidence rate of cryptosporidiosis by HSE area 2005.
Age group HSE-ER HSE-M HSE-MW HSE-NE HSE-NW HSE-SE HSE-S HSE-W
<1  0.0 87.49 175.28 91.59 66.14 99.73 91.31 267.88
1-4  7.76 192.46 160.26 136.49 162.45 212.62 159.38 427.60
5-9  2.25 24.17 34.44 32.04 56.19 30.15 51.33 54.38
10-14  0.0 5.60 16.11 7.41 22.47 18.20 14.31 20.69
>=15  2.67 0.58 1.87 6.40 3.49 7.57 4.56 3.59
Total  2.71 15.97 16.49 17.97 19.41 23.37 18.09 34.45
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if this just reflected improved reporting as notifiers became
more familiar with the revised list of notifiable diseases and
the new requirements of SI 707. However, provisional data
show that the number of cryptosporidiosis cases notified in
the second quarter 2006 mirrors more closely the number of
cases reported in 2004 rather than in 2005, indicating that
there was probably a real excess of cases in 2005.9
In 2005, the HSE-W reported the highest crude incidence rate
-more than twice the national rate. There were 2 small
general outbreaks reported from the region but the majority
of cases appear to have been sporadic. Given the high rate of
cryptosporidiosis reported in the HSE-W in 2005, a major new
research project entitled ‘Enhancing Human Health through
Improved Water Quality’ funded by the EPA at the
Environmental Change Institute in National University of
Ireland Galway (NUIG) is an interesting initiative. Led by Prof.
Martin Cormican, researchers will examine the relationship
between drinking water supply and the occurrence of
cryptosporidium infection in the West of Ireland, and the
effect of seasonal and environmental factors on ground water
quality (http://www.nuigalway.ie/research/ehh/ehhtiwq
_home.php). Another interesting study is being undertaken in
Northern Ireland, where the CDSC (NI) has commenced a
case control study to identify the risk factors for
cryptosporidiosis infection.10
Drinking water is an important transmission route in
outbreaks of cryptosporidiosis. Two outbreaks in Ireland in
2005 reported drinking water as being suspected of having
played a role in transmission, and drinking water was also the
suspected mode of transmission for four outbreaks in 2004.
The importance of water as a potential transmission route is
reflected in a recommendation by the EPA that risk
assessment should be carried out by each sanitary authority
to determine the vulnerability of public water supplies to
Cryptosporidium.11 In 2005, the EPA reported that risk
assessments had already been carried on 331 individual public
water supplies in Ireland.12
Other potential transmission routes for cryptosporidiosis
include direct animal contact, food, recreational water
contact, and person-to-person spread. Significant outbreaks
reported internationally in 2005 include a national outbreak
in Scotland with 129 laboratory-confirmed cases. Infection
was believed to be transmitted by infected lambs at a wildlife
park where there were inadequate handwashing facilities.5 A
foodborne outbreak of C. hominis in Denmark was associated
with whole carrots served in water at a salad bar in a
company canteen.6 And a recent review of waterborne
outbreaks in England and Wales has reported that swimming
pools were associated with 32 of 62 waterborne
cryptosporidiosis outbreaks in England and Wales between
1992 and 2003.4 These reports serve as reminders of the
variety of transmission routes for Cryptosporidium infection.
A particularly interesting aspect of the HSE SE outbreak was
the fact that it was due to C. hominis. In the absence of
reference facilities for Cryptosporidium in Ireland, isolates
from human cases are rarely typed except in the event of
outbreaks. Given the very strong seasonal peak here in spring,
it has seemed reasonable to suspect that C. parvum would be
the predominant species in Ireland. Data from Northern
Ireland and Scotland has shown C. parvum to predominate in
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these areas, however, in England, C. hominis is also important
and accounts for over 40% of cases.13-15 There is still much to
learn about the epidemiology of Cryptosporidium in Ireland,
and our understanding will remain limited in the absence of
adequate typing information. A Cryptosporidium reference
service would also be invaluable to sanitary authorities in
assessing the risk to water supplies from Cryptosporidium.
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Table 2. Age-specific incidence rate of cryptosporidiosis by HSE area 2005.
Month HSE area Transmission route* Location Type Number ill Number hospitalised
Mar SE P-P and WB Community General 31 8
April W WB Other General 7 2
July S Unknown Private house Family 2 2
July MW Unknown Private house Family 2 -
Oct W Unknown Travel related General 4 -
Dec S Unknown Community General 3 1
* P-P denotes person-to-person transmission; WB denotes waterborne transmission
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Malaria in Ireland 2005
Key Points
• In 2005, 44 cases of malaria were notified, an increase of
62% on the number reported in 2004
• The most common species reported was P. falciparum,
accounting for 75% of cases notified 
• The majority of cases became ill after exposure in sub-
Saharan Africa
• Visiting family in country of origin was the most
common reason reported for travel
• Only one malaria case in Ireland in 2005 reported full
compliance with their prescribed course of malaria
prophylaxis. The remaining cases either failed to take
any malaria prophylaxis prior to exposure or failed to
continue prophylaxis for the required time period.
• It is important that travellers to endemic areas are made
aware of the need to be properly compliant with their
antimalarial medication and anti-mosquito measures,
and the potential health consequences of non- or partial
compliance.
Introduction
Malaria is the most important vectorborne disease in the
world, with 400 million infections and around 1 million deaths
annually. It is endemic in over 100 countries in sub-tropical
and tropical areas of Africa, Central and South America, Asia,
the Middle East and Oceania, with 90% of deaths occurring in
Sub-Saharan Africa, mostly among young children.
Infection is caused by transmission of one of 4 species of
Plasmodium (P. falciparum, P.ovale, P.vivax or P. malariae)
through the bite of infected female anopheline mosquitoes.
The species vary in their clinical effects, P. falciparum causing
the most severe form of malaria, and the most deaths.
TropNetEurop reported a case fatality of 1.4% for P.
falciparum infections imported into Europe.1 Malaria caused
by other Plasmodium species is less severe. P.ovale and P.vivax
also differ in that they have persistent liver stages, which can
resist conventional treatment and can produce relapses up to
a year after the initial infection.
Worldwide each year, up to 30,000 travellers fall ill with
malaria on their return from visiting countries where the
disease is endemic.2 Pregnant woman, young children and the
elderly are particularly at risk. Malaria in pregnancy increases
the risk of maternal death, miscarriage, stillbirth and neonatal
death. As malaria is a relatively rare disease in Ireland, a high
level of suspicion is necessary when travel to endemic areas
has occurred in either the recent or distant past.
Increasing numbers of Irish residents are travelling to
malarious regions for holiday and business travel. An 
HPSC Annual Report 2005 21
increasing proportion of the population in Ireland originates
from malaria endemic regions and regularly travels home.
Malaria surveillance aims to document the burden of illness in
Ireland, to define the characteristics of those most at risk, and
to identify those who could benefit most from preventive
messages. In addition, the data collected permit monitoring
for prophylaxis failures that might indicate emergence of drug
resistance. There is potential also to identify cryptic cases;
these are cases where the route of transmission is unclear or
unusual.
Materials and Methods
Malaria has been notifiable in Ireland since 1948. The case
definition adopted since 2004 is based on the EU case
definition.3 Since 2001, public health physicians have provided
enhanced surveillance data, e.g. country of infection, reason
for travel and use of chemoprophylaxis, where available to
HPSC. Notification and enhanced surveillance data are
maintained in the CIDR (Computerised Infectious Disease
Reporting) database. The data used in this report are based on
information retrieved from the CIDR database on malaria
cases in 2005.
Results
Malaria incidence 
In 2005, 44 cases of malaria were notified (figure 1). This is an
increase of 62% on the number reported in 2004, and
equates to a crude annual incidence rate of 1.1 per 100,000
(95% CI 0.79-1.45).
Areas reporting the highest number of cases were the HSE-E
(n=12), HSE-NE (n=10) and HSE-S (n=10). There were also 5
cases in the HSE-M, 1 in the HSE-MW, 2 in the HSE-NW, 2 in
the HSE-SE and 2 in the HSE-W.
Species of Plasmodium
As in previous years, the most common species reported was
P. falciparum, accounting for 75% of all cases notified (n=33).
There were also three P. vivax, one P. ovale, one P. malariae
and one mixed P. vivax/P. ovale infection. This is similar to the
species distribution reported by the UK and in Europe for
cases of imported malaria.4, 5
Age and sex distribution 
Twenty-one cases were male and 21 were female
(unknown/unspecified=2). Cases ranged in age from 1 to 64
years. Females in the 25-34 age group were the most
common age-sex group reported, and there were ten
notifications (23%) in children under the age of 15 (figure 2).
Clinical features
Twenty-one cases were hospitalised, one case was described
as a GP patient, and for 22 cases this information was not
specified. In 2005 one death in an adult was reported as being
due P. falciparum.
Country of infection
In 2005, there were no cases of airport, congenital, induced or
introduced malaria reported. One relapsed case of P. vivax was
reported. The remaining 43 cases were either reported as
being, or were assumed to be, imported. Country of infection
was recorded for 33 cases, the majority of whom were
exposed in sub-Saharan Africa, with the remainder exposed in
Asia (table 1).
Table 1. Malaria notifications, Ireland 2005 by country of exposure
Country of exposure          Number of notifications % of all cases
Sub-saharan Africa 30 68%
   Nigeria 22 50%
   Other than Nigeria 8 18%
Asia 3 7%
Not reported 11 25%
Total 44 100%
Year
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Figure 1. Number of malaria notifications, Ireland 1982-2005
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Reason for travel
Reason for travel was recorded for 28 cases. The largest
subgroup identified in 2005 was people who had travelled to
visit family in their country of origin –over half of those for
whom the information was available (n=15). New entrants
made up a further quarter of cases (n=7), with the remainder
reported as holidaymakers (n=1), business travellers (n=1),
armed services (n=1), Irish citizen living abroad (n=1), other
(n=2) and not specified (n=16).
Use of chemoprophylaxis
Excluding new entrants (those who had spent their lives to
date living in an endemic region would not be expected to be
taking chemoprophylaxis), information on malaria prophylaxis
was available for 21 of the remaining 37 cases. Of these, 17
(81%) took no prophylaxis, 3 (14%) took prophylaxis but
failed to continue for the required period. Only one case
reported full compliance with prescribed course of
prophylaxis.
Interval between arrival in Ireland and onset of symptoms
Malarial infections can occur up to several months following
exposure. For 19 cases, data were available both for the date
of arrival from malarious region and date of onset of illness.
The interval between these dates varied between 0 and 181
days (median 7). Eighty-eight per cent of P. falciparum
infections had an interval of less than 2 weeks although
intervals of 6 months and longer can occur 6. The longest
interval recorded here was for a P. vivax case. P. vivax (and P.
ovale and P. malariae) tend to have longer incubation periods
than P. falciparum.6
Discussion
In 2005, there were 44 cases of malaria notified in Ireland.
Although malaria has been notifiable for many years, it is
likely that there has been under-notification and some of the
current increase undoubtedly reflects improved reporting
consequent to the Infectious Diseases (Amendment) (No 3)
Regulations  (S.I. 707 of 2003). 7
The majority of cases in 2005 were associated with travel in
Africa (91% of those for whom country of infection
information was available), parts of West Africa having some
of the most intense malaria transmission in the world.
Although in 2005, holidaymakers and business travellers
formed only a small proportion of the cases reported,
between 2001 and 2004 as many as 36% of malaria cases in
Ireland specified holiday or business as their reason for travel.8
The Health Protection Agency (HPA) in the UK has issued a
number of advisories over the last couple of years, after
several deaths and cases of severe malaria were reported in
holidaymakers returning from The Gambia. Many cases had
either failed to take any prophylaxis or had taken inadequate
or inappropriate prophylaxis.
Increasing numbers of Irish residents were born or raised in
countries endemic for malaria. In 2005, visiting family in
country of origin was the most common reason given by
cases for travel to an endemic region. In the UK, half of
malaria cases occur in minority ethnic groups who have
settled in the UK, that were visiting family and relations
overseas when they acquired malaria.6 Individuals in endemic
regions build up immunity to malaria that fades rapidly while
living in a malaria-free region like Ireland, and may wrongly
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assume that they are still immune to the disease.
Failure to take appropriate prophylaxis and failure to take
sensible protection measure against biting mospuitos are key
factors in acquiring malaria. Only one malaria case in Ireland
in 2005 reported full compliance with their prescribed course
of prophylaxis. The remaining cases either failed to take any
malaria prophylaxis prior to exposure or failed to continue
prophylaxis for the required time period. It is important that
travellers to endemic areas are made aware of the need to be
properly compliant with their antimalarial medication and
anti-mosquito measures, and the potential health
consequences of non- or partial compliance.
The HPA Advisory Committee on Malaria Prevention (ACMP)
has published guidelines (and updates) on prevention of
malaria.9 Four steps remain essential to prevent malaria in
travellers:
Awareness: know about the risk of malaria
Bites by mosquitoes: prevent or avoid
Compliance with appropriate chemoprophylaxis.
Diagnose breakthrough malaria swiftly and obtain treatment
promptly.
It is important that travellers to endemic areas are aware that
preventive measures are not 100% effective, and that they
should seek treatment promptly if they suffer symptoms
suggestive of malaria within a year following their return,
informing their physician of their travel history.
The guidelines of the HPA Advisory Committee on Malaria
Prevention in travellers have also stated the need for
balancing the risk of malaria and the risk of adverse reactions
to anti-malarials. This depends upon place to be visited,
duration of the visit, degree of exposure, level of drug
resistance and the type of traveller.9
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Surveillance of Infectious Disease
Outbreaks in Ireland, 2005
Key points
• 175 infectious disease outbreaks, of which 161 were
gastroenteric/ infectious intestinal disease (IID)
outbreaks were notified in 2005, which was a decrease
on 2004
• The IID outbreaks were responsible for at least 2591
cases of illness
• Viral gastroenteritis caused by norovirus (NV) continues
to the most common cause of IID outbreaks (60% of IID
outbreaks confirmed/suspected NV)
• The majority of IID outbreaks (61%) were reported to
have occurred in healthcare settings
Introduction
The principal objective of the national outbreak surveillance
system is to gain information on the epidemiology of all
outbreaks of infectious disease in Ireland.
More specific objectives include measuring the burden of
illness caused by outbreaks, identifying high-risk groups in the
population and estimating the workload involved in the
management of outbreaks. The information gathered can be
used to inform public health professionals on the causes and
factors contributing to outbreaks, to target prevention
strategies and to monitor the effectiveness of prevention
programmes.
Outbreak definition
An outbreak of infection or foodborne illness may be defined as
two or more linked cases of the same illness or the situation
where the observed number of cases exceeds the expected
number, or a single case of disease caused by a significant
pathogen. Outbreaks may be confined to some of the members
of one family or may be more widespread and involve cases
either locally, nationally or internationally.
Methods 
Since 1st January 2004, outbreaks or “unusual clusters of
changing patterns of illness” became notifiable under the
Amendment to the Infectious Diseases Regulations.1 (see
outbreak definition in box above). Since that date, medical
practitioners and clinical directors of diagnostic laboratories
are required to notify to the medical officer of health any
unusual clusters or changing patterns of illness, and individual
cases thereof, that may be of public health concern.
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In addition since 1st January 2004, all outbreak data are being
entered into the CIDR system database (either directly by the
HSE-region, if that region has gone live onto CIDR) or
indirectly by staff in HPSC.
Results
During 2005, 175 outbreaks of infectious disease were
reported to HPSC, of which 161 were gastrointestinal/
infectious intestinal disease (IID) outbreaks. The IID outbreaks
were responsible for at least 2591 people becoming ill, and
there were 205 reported hospitalisations. The regional
distribution of all outbreaks of infectious disease, and those
specifically IID are detailed in table 1. The highest number of
outbreaks was reported from the HSE-ER region (n=65),
although the highest outbreak rate was in the HSE-S
(7.3/100,000). The lowest rate was reported from the HSE-W
(1.8/100,000).
Causative Pathogen
The breakdown of IID and non-IID outbreaks by pathogen are
outlined in Tables 2 and 3 respectively. The overall numbers of
IID outbreaks reported, decreased compared with 2004.
Continuing the trend observed in previous years, the IID
outbreaks in 2005 have been dominated by norovirus/ suspect
viral outbreaks, accounting for 60% of all IID outbreaks
reported in 2005 (Figure 1). The largest single outbreak
reported in 2005 was a norovirus outbreak in a hospital
involving 187 people.
After norovirus, the next most commonly reported outbreaks
were EHEC, Salmonella enterica, Campylobacter and
Cryptosporidium.
There were 20 outbreaks of EHEC (19 VTEC) reported in 2005,
four general and 16 family outbreaks. The largest VTEC
outbreak involved a significant investigation and occurred at a
private house/crèche in the HSE-MW. Nine cases were ill and
18 cases in total were confirmed positive for E. coli (VTEC)
O157 (VT 2 positive) infection. Two cases with Haemolytic
Uraemic Syndrome were hospitalised. Cases ranged in age
from ten months to sixty-two years. Results from a case-
control study indicated that potential exposure to drinking
water from a vulnerable local private group water scheme was
a risk1.
Seventeen outbreaks of S. enterica were reported in 2005,
affecting a total of 52 people and resulting in 12
hospitalisations. There were three general and 14 family
outbreaks. Three outbreaks were travel related with the Czech
Republic, Tunisia and Spain cited as the countries of infection.
The number of outbreaks reported that were attributable to
Campylobacter rose from one in 2004 to eight in 2005. All
eight outbreaks were family outbreaks, and the suspected
mode of transmission recorded was foodborne (5), person-to-
person (2) and unknown (1).
There were six outbreaks of cryptosporidiosis in 2005: four
general and two family outbreaks. The largest outbreak
reported was a community outbreak affecting 31 people in the
Carlow town area. The mode of transmission was suspected as
waterborne although only low levels of cryptosporidium were
found in the town water supplies. A boil water notice was
issued and subsequently lifted when sampling confirmed that
the town supply was free from cryptosporidium.2
Table 1.  All outbreaks of ID, number of IID outbreaks and total numbers ill in IID outbreaks 
reported by health board (2005).
HSE Area No. Outbreaks Outbreak rate per  No. ill in all No. of IID 
  100,000 pop outbreaks outbreaks
HSE-E 65 4.6 1534 61
HSE-M 10 4.4 117 9
HSE-MW 7 2.1 35 7
HSE-NE 13 3.8 125 12
HSE-NW 11 5 148 10
HSE-SE 31 7.3 477 31
HSE-S 31 5.3 255 25
HSE-W 7 1.8 57 6
Total 175 2.8 2748 161 Year
N
um
be
r o
f o
ut
br
ea
ks
Norovirus/suspect viral
 
Figure 1. Number of outbreaks by year and by pathogen, 1998-2005
(Data prior to July 2001 provided by FSAI)
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Fourteen outbreaks of non-IID/gastroenteric diseases were
notified in 2005. Table 3 outlines the pathogens implicated
and numbers ill. Further details on the non-IID outbreaks are
available in the individual disease chapters. It is hoped that
surveillance data on these outbreaks will improve in the
coming years.
Mode of Transmission
Similar to previous years, person-to-person spread is the
mode of transmission reported for the majority of outbreaks
of IID in 2005 (table 4). Most of these outbreaks were due to
norovirus/ suspect viral. Like 2004, the foodborne route was
the second most frequently suspected mode of transmission
and was identified in over 12 outbreaks in 2005. For many
outbreaks more than one mode of transmission was
suspected.
Location
As in previous years, the commonest location in which
outbreaks occurred in 2005 was healthcare settings (table 5).
61% of all reported IID outbreaks occurred in these settings.
Nine outbreaks were associated with foreign travel in 2005
compared to only one travel associated outbreak in 2004.
Salmonella accounted for three of these outbreaks followed by
Norovirus (2), EHEC (2), Cryptosporidium (1) and Shigella (1).
Seasonal distribution
When the IID outbreaks in 2005 are analysed by month of
onset of illness of first case, it is seen that the majority of
outbreaks occurred in the first 4 months of the year (Figure
2). This peak is attributable to the number of Norovirus
outbreaks that occurred at this time. Norovirus was previously
known as “Winter Vomiting” disease due to the increase in
outbreaks that would occur during winter months.
Discussion
In 2005, all outbreaks of infectious diseases became notifiable
for the first time, under the new Infectious Diseases
Legislation.3 There was an decrease in the overall number of
outbreaks reported nationally in 2005, with 161 outbreaks of
IID notified, compared to 169 in 2004.
As observed in recent years, viral gastroenteritis, principally
caused by norovirus, accounted for the majority of outbreaks
reported in 2005 (60% of IID outbreaks confirmed/suspected
NV). Detailed molecular detection and typing of norovirus
isolates was introduced by the National Virus Reference
Laboratory (NVRL) in 2003, which has enabled us to study in
much greater detail the molecular epidemiology of strains
causing outbreaks. This data is routinely submitted to the
European network ‘Divine-net’, which is an extension of the
previous network entitled “Foodborne Viruses in Europe”.4
Divine-net aims to merge epidemiological and virological data
on outbreaks of viral gastroenteritis, including norovirus,
across Europe.
In 2005 travel associated outbreaks were a significant feature.
In total nine outbreaks were travel associated, including a
large norovirus outbreak on a cruise ship that affected 95
individuals.
An outbreak of shigellosis associated with travel to Egypt was
identified in June 2005 involving over half the passengers on a
flight from Luxor, in Egypt. The Egyptian authorities were
Table 2.  Pathogens associated with IID outbreaks notified in 2005
Disease Number of outbreaks Number ill
Noroviral Infection 61 1891
Suspected Norovirus 32 297
EHEC 20 53
Salmonella 17 52
Campylobacter 8 17
Unknown 8 119
Cryptosporidium 6 49
Norovirus & C. difficile 3 32
C. difficile 2 20
Shigellosis 2 44
Giardiasis 1 3
Rotavirus 1 14
Total 161 2591
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Figure 2.  Seasonal distribution of IID outbreaks, 2005.
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alerted and appropriate measures were put in place.
Subsequent investigations could not conclusively identify the
source of infection.5
In October 2005 Health Protection Scotland identified an
international outbreak of S. Goldcoast infection in tourists
returning from Majorca. An alert through Enter-Net and the
European Commission’s Early Warning and Response System
(EWRS) led to an international response with active case
finding. In total 148 cases were identified in 10 different
countries – including six cases in Ireland. Despite extensive
investigations the source of infection was not identified. The
outbreak was declared over on the 1st December 2005.
Outbreak data has been entered into the CIDR system since
the beginning of 2004, therefore real time data on outbreaks
is available to all CIDR users nationally as they go-live on the
system. With the continued national roll-out of CIDR, it is
hoped enhanced surveillance data on all outbreaks of
infectious disease will be even more timely and complete as
users enter their own outbreak data.
This will enable epidemiological, microbiological and
environmental data relating to the outbreak to be shared
locally and nationally, and should greatly assist in the
management and control of outbreaks, as well as allowing
analysis of the national data to inform future public health
policies.
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Table 3.  Non–IID outbreaks notified in 2005
Disease Number of outbreaks Number ill
Mumps 6 39
HiB 1 2
Influenza A 1 42
Influenza B 1 33
Legionellosis 1 NK
Tuberculosis 1 8
Probable Varicella 1 9
Scabies 1 4
Suspected streptococcal infection 1 20
Total 14 157
Table 5.  IID Outbreaks by location, 2005.  
Location Number of IID Outbreaks  
Hospital 59
Residential Institution 40
Private House 38
Travel Related 9
Community outbreak 4
Hotel 3
Not Specified 3
Other 3
Creche 1
Public House 1
Total 161
Table 4.  Principal mode of transmission reported in outbreaks of IID (2005).
Primary Mode of Transmission  Number of IID Outbreaks
Person-to-person 106
Unknown 20
Foodborne 12
Not Specified 8
P-P and Animal 3
P-P and FB 3
P-P and WB 3
FB and Animal 2
FB and Airborne 1
FB and WB 1
P-P and Airborne 1
Waterborne 1
Total 161
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Key Points
• In 2005, the incidence rate of human salmonellosis
decreased (8.9/105) compared to 2004 (10.6/105) from
analysis of the clinical notification data
• The highest incidence rate was observed in children
under 5 years of age
• After S. Enteritidis (n=145) and S. Typhimurium (n=85),
the next most common serotypes were S. Agona (n=10),
and S. Virchow (n=9)
• 21% of cases were reported to be associated with travel
outside of Ireland in 2005
Introduction
Salmonellosis is one of the most common zoonotic diseases
in humans in Ireland and worldwide. At present, over 2,460
serotypes of Salmonella have been identified. Two serotypes,
however, S. enterica serotype Enteritidis and S. enterica
serotype Typhimurium have accounted for the majority of
cases of human salmonellosis in recent years.
Salmonellosis presents clinically as an acute enterocolitis, with
sudden onset of headache, abdominal pain, diarrhoea, nausea
and occasionally vomiting. Fever is almost always present.
Dehydration, especially amongst vulnerable populations such
as infants, the immunocompromised and the elderly, may be
severe. S. Typhi and S. Paratyphi can cause enteric fever, a
severe systemic life threatening condition, but this is very rare
in Ireland and mainly travel-associated.
Salmonella is a zoonoses and a wide range of domestic and
wild animals, as well as humans can act as the reservoir for
this pathogen. Prevention, surveillance and control of
Salmonella infections is of major public health importance.
Methods
The National Salmonella Reference Laboratory (NSRL) was
established in 2000 in the Department of Medical
Microbiology, University College Hospital, Galway. This
laboratory accepts S. enterica isolates from all clinical and
food laboratories for serotyping, phage typing and
antimicrobial sensitivity testing.
This report reviews data available from the National
Salmonella Reference Laboratory (NSRL) and weekly events of
Salmonella in Ireland, 2005
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salmonellosis extracted from the CIDR system for the year
2004. These data enable us to provide an overview of the
epidemiology and burden of disease caused by Salmonella
infections in Ireland today.
Results
Demographic information
There were 357 clinical isolates of S. enterica referred to NSRL
in 2005. The male: female ratio was 0.9:1. The age groups
and sex of those affected are shown in table 1. The highest
number of cases was seen in children under five years of age.
When age-specific incidence rates were calculated (Figure 1),
the burden of illness in this age group was even more evident.
Seasonality
Analysis of the number of salmonellosis events notified to
HPSC by week in 2005, revealed peaks in incidence from mid-
August to early October. Seasonal peaks are typically seen
each year at this time.
Serotyping, phage typing and antibiotic susceptibility
results from NSRL
Serotyping
The breakdown of Salmonella serotypes by health board is
shown in table 2. It should be noted however that for the
NSRL data, health board location refers to the location of the
clinical laboratory that the isolate was originally sent to, and
may not always correspond with the geographic location of
the case.
As has been the trend in recent years, the predominant
serotype causing human illness in 2005 was S. Enteritidis
(n=145), followed by S. Typhimurium (n=85). Table 3 shows
the changing shift in the more common serotypes in the past
number of years. In 2005, after S. Enteritidis and S.
Typhimurium, the next most commonly isolated serotypes
were S. Agona (n=10), S. Virchow (n=9), S. Hadar (n=8) and S.
Dublin (n=5). There were 5 cases of S. Typhi detected in 
Phage typing
The predominant phage types of S. Typhimurium and S.
Enteritidis are summarised in Tables 4 and 5. The commonest
phage type of S. Typhimurium reported in 2005 was DT104
(44%), followed by DT104b (15%). In previous years (1998-
2003) PT4 was the predominant phage type of S. Enteritidis,
but this trend changed in 2004 with PT1 replacing PT4 as the
main phage type detected. This trend has continued in 2005
with PT1 accounting for 30% of the isolates. This is followed
by PT14b (15%), PT8 (14%) and PT4 (13%).
Travel-association
75 out of 357 isolates (21%) reported to NSRL in 2005 were
found to be associated with travel outside of Ireland. The
most commonly reported countries were Spain (n=7), Nigeria
(n=7), Thailand (n=6), Majorca (n=6) and Tunisia (n=5).
Antimicrobial resistance
The antimicrobial susceptibility patterns of the most
commonly isolated serotypes in 2005 are presented in table
6. Analysis of the 2005 AMR data again demonstrated high
levels of resistance among S. Typhimurium, particularly DT104
isolates.
Table 1. Analysis of clinical isolates of S. enterica (n=357) referred to NSRL,
(2005) by age-group and gender.
Age group (years)  No. of isolates (%)  Male  Female  Unknown
0-4 75 (21) 28 37 10
5-9 19 (5) 10 7 2
10-14 22 (6) 9 13 0
15-19 18 (5) 7 9 2
20-24 29 (8) 16 13 0
25-34 59 (17) 16 40 3
35-44 35 (10) 19 14 2
45-54 31 (9) 20 10 1
55-64 23 (6) 9 13 1
65+ 37 (10) 20 17 0
Unknown 9 (3) 6 3 0
Total 357 160 176 21
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Figure 1.  Age-specific incidence rate of human salmonellosis in Ireland, 2005.
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Table 2.  Serotypes of Salmonella enterica by health board, 2005.
Serotype  HSE-ER HSE-M HSE-MW HSE-NE HSE-NW HSE-SE HSE-S HSE-W Total
Agona 2 0 0 1 1 6 0 0 10
Anatum 3 0 1 0 0 0 0 0 4
Arechavaleta 2 0 0 0 0 0 0 0 2
Blockley 0 1 0 0 0 0 1 2 4
Braenderup 1 0 0 0 0 0 0 0 1
Bredeney 1 0 1 0 0 1 0 0 3
Bukavu 1 0 0 0 0 0 0 0 1
Concord 0 0 1 0 0 0 0 0 1
Corvallis 1 0 0 0 0 1 0 0 2
Cotham 0 0 0 0 0 0 0 1 1
Dublin 0 0 1 0 0 0 2 2 5
Enteritidis 55 8 8 11 11 15 27 10 145
Give 1 0 0 0 0 0 0 1 2
Goldcoast 1 0 1 2 1 0 0 2 7
Hadar 4 0 1 0 0 1 2 0 8
Indiana 1 0 0 1 0 0 0 0 2
Infantis 2 0 0 0 0 1 0 0 3
Isangi 0 0 0 0 0 1 0 0 1
Java 1 0 1 0 0 0 0 5 7
Javiana 1 0 0 0 1 0 0 0 2
Kedougou 0 0 0 0 0 1 0 0 1
Kentucky 1 1 0 1 0 0 0 1 4
Limete 1 0 0 0 0 0 0 0 1
Livingstone 1 0 0 0 0 0 0 0 1
Mikawasima 0 1 0 0 0 0 0 0 1
Minnesota 0 0 0 0 0 1 0 0 1
Newport 4 0 0 0 1 0 0 0 5
Oranienburg 1 0 0 0 1 0 0 0 2
Paratyphi A 1 0 0 0 0 0 0 0 1
Rissen 1 0 0 0 0 0 0 0 1
Saintpaul 1 0 0 0 0 0 0 1 2
Sandiego 1 0 0 0 0 0 0 1 2
Schwarzengrund 0 0 0 0 0 0 1 0 1
Senftenberg 1 0 0 0 0 0 0 0 1
Stanley 3 0 0 0 0 1 1 1 6
Stanleyville 2 0 0 0 0 0 1 0 3
Telelkebir 2 0 0 0 0 0 0 0 2
Tennessee 1 0 0 0 0 0 0 0 1
Thompson 0 0 0 0 0 0 1 0 1
Typhi 3 1 0 0 0 0 1 0 5
Typhimurium 26 9 3 7 5 19 11 5 85
Uganda 1 0 0 1 0 0 0 0 2
Unnamed 2 1 1 1 0 0 1 1 7
Virchow 5 1 0 0 0 0 2 1 9
Worthington 0 0 0 0 0 1 0 0 1
Total 135 23 19 25 21 49 51 34 357
CIR 9.6 10.2 5.6 7.2 9.5 11.6 8.8 8.9 9.1
CIR: Crude incidence rate per 100,000 population
* 1 case of S. Enteritidis was known to be resident in UK
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Figure 2. Number of salmonellosis notifications by week, 2005 (data from CIDR).  
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Clinical notification data
Salmonellosis is a notifiable disease. Medical practitioners
have a statutory obligation to report all suspected cases.
There were 349 cases notified to HPSC through the weekly
notification system in 2005, giving a crude incidence rate of
8.9 per 100,000 population.
Outbreaks
In 2005, there were 17 outbreaks of S. enterica notified to
HPSC; 3 general and 14 family outbreaks, affecting a total of
52 people. Three of the outbreaks were travel related with
Spain, Tunisia and the Czech Republic cited as the countries of
infection. The largest outbreak was a community outbreak
caused by S. Agona that affected 6 people and resulted in 5
hospitalisations.
Discussion 
Salmonella enterica continues to be an extremely significant
cause of gastroenteritis in Ireland, despite a decrease in the
rate of infections due to salmonellosis in 2005 (8.9/105)
compared to 2004 (10.6/105). The highest incidence was
reported in the South East health board region. A similar
incidence rate was reported in Northern Ireland (10.43/105)
[CDSC-NI, 25/08/06 – personal communication], while higher
rates were seen in England and Wales1,2 (22.7/105) [calculated
from provisional data 28/09/06] and Scotland3 (22.3/105).
Similar trends regarding the epidemiology of this pathogen
were noted in 2005 as in previous years. Males and females
were equally affected. All age-groups were affected but the
highest incidence was noted in children less than five years of
age. It is likely that more specimens are submitted for testing
from this age-group, so this should be borne in mind when
interpreting these data.
Analysis of serotyping revealed that there were 44 different
serotypes identified in 2005. S. Enteritidis and S. Typhimurium
were the causative serotypes identified in 65% of cases. The
proportion of cases attributable to S. Typhimurium continues
to decrease with S. Enteritidis and other serotypes increasing
in their relative importance. The emergence of more unusual
serotypes could be attributable to the increase in the number
of cases that are associated with foreign travel (21% in 2005).
In addition a significant number of travel-associated typhoid
cases are reported each year. Five cases were reported in
2005, one associated with travel to India and two with travel
to Pakistan. It is important that travellers are made aware of
the measures that can be taken to reduce the risk of
developing food-/ water-borne illness whilst abroad and
especially that typhoid vaccination is given when travelling to
endemic countries.
In previous years (1998-2003) PT4 was the predominant
phage type of S. Enteritidis, but this trend has changed since
2004 with non-PT4 phage types being detected more and
more. In particular the incidence of PT14b and PT8 has
increased in recent years, accounting for 3% and 5%
respectively of the total phage types detected in 2003 and
increasing to 15% and 14% respectively in 2005. This shift in
phage type has been observed in many countries in Europe in
recent years and could be attributable to factors such as
increased travel, global food trade and animal vaccinations.4,5 
The typing of all human Salmonella cases by the NSRL
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Figure 3. Crude rate of Salmonellosis in Ireland per 100,000 population, 1982-2005 (CIDR)
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Table 3. Serotypes of S. enterica referred to NSRL (2000-2005) (%).
Serotype 2000 2001 2002 2003 2004 2005
S. Enteritidis 239 (36) 248 (46) 165 (40) 205 (42) 173 (41) 145 (41)
S. Typhimurium 284 (43) 165 (30) 140 (34) 135 (28) 125 (30) 85 (24)
S. Agona 6 (1) 2 (0.4) 5 (1) 5 (1) 2 (0.5) 10 (3)
S. Virchow 9 (1) 16 (3) 10 (2) 10 (2) 10 (2) 9 (3)
S. Hadar 11 (2) 4 (1) 6 (1) 21 (4) 4 (1) 8 (2)
S. Dublin 12 (2) 12 (2) 9 (2) 5 (1) 4 (1) 5 (1)
S. Kentucky 15 (2) 4 (1) 1 (0.2) 10 (2) 7 (2) 4 (1)
S. Bredeney 24 (4) 11 (2) 2 (0.5) 3 (1) 11 (3) 3 (1)
All others 65 (10) 81 (15) 78 (19) 92 (19) 83 (20) 88 (25)
Total 665 543 416 486 419 357
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continues to be an extremely powerful discriminatory tool
particularly for cluster/ outbreak detection and especially for
the two most common serovars S. Enteritidis and S.
Typhimurium. In addition the submission of Irish data to
international networks such as Enter-net allows the collation
and analysis of serotyping, phage typing and AMR data across
international borders and not only allows international
outbreaks to be identified but also allows such emerging
trends to be identified, monitored and explained.
In September 2005 the NSRL reported an unusual cluster of
four human cases of S. Agona with a distinctive antibiogram
(AS resistant). By November six cases had been identified, five
from the HSE-S and one with an epidemiological link to the
HSE-S. In addition the NSRL had identified a non-human
(poultry) isolate from a poultry plant in the South-East.
Despite extensive epidemiological, environmental and
microbiological investigations no common source was found.
As no further cases were reported, the outbreak was 
declared over.
In October 2005 an international outbreak of S. Goldcoast
infection in tourists returning from Majorca was identified by
Health Protection Scotland. An alert through Enter-Net and
the European Commission’s Early Warning and Response
system (EWRS) led to an international response with active
case finding. In total 148 cases were identified in 10 different
countries – including six cases in Ireland. Despite extensive
trawling, no testable hypothesis about foods, outlets, or other
potential sources of infection could be generated. The
outbreak was declared over on the 1st December 2005.
Finally analysis of the 2005 AMR data (antimicrobial
resistance) of the various Salmonella serovars demonstrated
high levels of resistance among S. Typhimurium isolates,
particularly DT104 isolates. The emergence of MDR (multi-
drug resistant) S. Typhimurium and DT104 is well documented
and constitutes an increasing global public health problem. 6
Table 4. Phage types of S. Typhimurium in 
human isolates (2005) 
Phage type No. of isolates (%)
DT104 37 (44)
DT104b 13 (15)
DT193 5 (6)
DT12 3 (4)
DT208 1 (1)
U310 1 (1)
Other 12 (14)
No type 13 (15)
Total 85
Table 5. Phage types of S. Enteritidis in 
human isolates (2005)
Phage type No. of isolates (%)
PT1 44 (30)
PT14b 22 (15)
PT8 20 (14)
PT4 19 (13)
PT21 12 (8)
PT24var 4 (3)
PT6a 3 (2)
PT6 3 (2)
Other 13 (9)
No type 5 (3)
Total 145
Total 145
Table 6. Antimicrobial susceptibilities of human Salmonella enterica serotypes isolated in 
Ireland in 2005.
        % Resistance
Serotype (Number)   Amp  Chl  Strep  Sulph  Tet  Trim  Nal
Enteritidis (145) 5 0 0 2 3 2 30
Typhimurium (85) 73 64 72 75 79 8 9
Agona (10) 40 0 40 0 0 0 10
Virchow (9) 22 0 0 44 33 44 89
Hadar (8) 75 0 100 0 100 0 88
Stanley (6) 67 50 33 50 67 17 0
Typhi (5) 20 20 20 20 20 20 40
Kentucky (4) 25 0 25 50 50 0 50
Bredeney (3) 0 0 0 0 0 0 0
Amp = Ampicillin, Chl = Chloramphenicol, Strep = Streptomycin, Sulph = Sulphonamide,
Tet = Tetracycline, Trim = Trimethoprim, Nal = Naladixic acid
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Campylobacteriosis in Ireland,
2005
Key Points
• Campylobacter remains the commonest cause of
gastroenteritis of bacterial aetiology in Ireland
• In 2005, there were 1803 cases of campylobacteriosis
notified (CIR 46.0/105) which is the highest number of
cases reported since 1999 (2085 cases)
• The highest burden of illness was in children under 5
years of age
• In 2005, the highest incidence rate was reported from
the Midlands health board region (69.2/ 105)
Background
Campylobacteriosis is the commonest reported bacterial
cause of infectious intestinal disease in Ireland. Two species
account for the majority of infections: C. jejuni and C. coli.
Illness is characterised by severe diarrhoea and abdominal
pain. Symptoms may subside after a number of days or may
persist for weeks. Rarely, more severe sequelae may develop
such as reactive arthritis, Reiter’s syndrome, or HUS and
approximately 1 in every 1000 cases leads to a severe
neurological disorder called Guillain-Barré Syndrome (GBS).
Undercooked meat especially poultry is often associated with
illness as is unpasteurised milk and untreated water. The
majority of infections, however, remain largely unexplained by
recognised risk factors for disease.
Methods
Human campylobacter infection became a statutorily
notifiable disease for the first time in January 2004 under the
Amendment to the Infectious Diseases Regulations.1
Data for this report were extracted and analysed from the
CIDR system.
Results
Incidence
In total, 1803 notifications of human campylobacteriosis were
notified in 2005 in Ireland. This gives a crude incidence rate
(CIR) of 46 cases per 100,000 population (table 1). This
compared with a CIR of 43.7 cases per 100,000 in 2004. The
annual number of cases by year since 1999 is shown in Figure 1.
Age standardised rates were calculated to allow comparisons
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to be made between health board regions without the
confounding effects of age (Figure 2). In 2005, the highest
incidence was reported from the Midlands region followed by
the South Eastern region. The lowest rate was reported from
the North Eastern region.
Seasonal distribution
Analysis of the data by week of notification is shown in Figure
3. A peak in cases is evident in week 25 and 26.
Age
When the distribution of cases for each age group is
examined, it is evident that by far the highest burden of
illness is seen in children less than five years (Figure 4). This
was also noted in previous years and is a well-reported
feature of campylobacteriosis.
Gender distribution
Females accounted for 53.7 percent of all cases notified
(males 45.8%; unknown 0.6%) (table 2). However the variance
in gender distribution that has been noted since 1999 was
again evident when the data was adjusted for age and sex. In
almost all age - groups there is a predominance of male cases
(figure 5).
Outbreak data
There were eight family outbreaks of campylobacteriosis
notified in 2005, affecting a total of 17 people. The suspected
mode of transmission recorded was foodborne (5), person-to-
person (2) and unknown (1).
Discussion
In 2004, human campylobacter infections became statutorily
notifiable for the first time under the Amendment to the
Infectious Diseases Regulations.1
Therefore since 2004, the data on campylobacteriosis has
been collated directly from the notifiable disease data on
CIDR and not as part of the Zoonoses Directive data
collection (as had been the case since 1999).
Analysis of the 2005 data reveals that campylobacteriosis still
remains the most common cause of bacterial gastroenteric
infection in Ireland - with over five times the number of
salmonellosis cases reported in 2005.
The crude incidence rate (CIR) of campylobacteriosis
increased in Ireland in 2005 (46.0 cases/100,000 persons)
compared to 2004 (43.7/100,000). This was in fact the
highest rate reported in Ireland since the year 1999. In most
regions, an increase was seen in 2005, especially in the HSE-M
and HSE-MW regions, however the CIR for the Western region
decreased from 63.1/105 in 2004 to 51/105 in 2005.
For the same period, higher rates were noted for Northern
Ireland (51.6/100,000) [CDSC-NI, 25/08/06 – personal
communication], England and Wales2,3 (91.8/100,000)
[calculated from provisional data, 28/09/06]  and Scotland4
(90.2/100,000).
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Figure 1.  Annual number of cases of campylobacteriosis in Ireland, 1999-2005 
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Table 1: Number of cases and CIR per 100,000 population of human campylobacteriosis in 
Ireland by health board, 2005.
Health Board No. of cases CIR - (incl. 95% C.I.)
HSE-ER 612 43.7 [40.2 - 47.2]
HSE-M 156 69.2 [58.3 - 80.1]
HSE-MW 140 41.2 [34.4 - 48.0]
HSE-NE 113 32.8 [26.8 - 38.8]
HSE-NW 87 39.3 [31.3 - 47.5]
HSE-SE 230 54.3 [47.3 - 61.3]
HSE-S 271 46.7 [41.1 - 52.3]
HSE-W 194 51.0 [43.8 - 58.2]
Total 1803 46.0 [43.9 - 48.1]
E M MW NE NW SE S W
Figure 2: Age standardised incidence rates (ASIR) of human campylobacteriosis in Ireland, 
compared to crude incidence rates (CIR) in each health board, 2005.
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Table 2. Gender distribution of campylobacter cases by health board region, 2005.
 Female Male  Unknown Total
HSE-ER 332 276 4 612
HSE-M 87 68 1 156
HSE-MW 78 62 0 140
HSE-NE 68 45 0 113
HSE-NW 48 38 1 87
HSE-SE 118 111 1 230
HSE-S 132 138 1 271
HSE-W 105 87 2 194
Total 968 825 10 1803
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As has been noted consistently since 1999, some interesting
epidemiologic features of this pathogen have emerged in
recent years. In particular, the higher incidence rate in young
children and the bias towards male cases in almost all age
groups.
The risk factors associated with Campylobacteriosis remain
poorly understood and this area has been identified as a key
research need in Ireland by an expert group at the conference
Campylobacter Surveillance and Research in Ireland – The Way
Ahead?” which was held in UCD in June 2005.
Already significant strides have been made to expand our
understanding of the complex epidemiology of this infection.
An all-Ireland case-control study carried out by the HSE-ER
region in the ROI and in all four Health and Social Services
Boards (HSSB) in NI was completed in 2005. Findings from
the study reveal that eating chicken, and lettuce, and eating
out in restaurants/ takeaways are major risk factors for
campylobacteriosis in Ireland, North and South.5
A three-year study, “The Sentinel surveillance of
Campylobacter in Ireland”, funded by safefood, commenced
in 2005. This project will involve the collection of detailed
clinical and microbiological information on cases of
Campylobacter infection in order to generate hypotheses as
to potential risk factors for infection. Food, animal and human
sources of Campylobacter will be targeted. This project will
bring together the Public Health Medical Practitioners,
Clinical/Food Laboratory Personnel, Veterinary Health
Specialists and Food Safety research expertise to address the
growing issue of campylobacteriosis in Ireland.6
As the most common cause of bacterial gastroenteritis in
Ireland, Campylobacter continues to be significant public
health issue, both in terms of personal suffering and economic
costs. Through continued surveillance and targeted research
our understanding of this disease will improve and more
effective prevention and control strategies may be developed.
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Figure 3: Total cases of campylobacteriosis events by week, 2005 (data from CIDR)
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Figure 4:  Age specific incidence rates for campylobacteriosis in Ireland, 2005
(data from CIDR)
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Rotavirus in Ireland, 2005
Key Points
• Rotavirus remains one of the most common causes of
acute infectious gastroenteritis in Ireland
• In 2005, there were 2251 cases of rotavirus notified (CIR
57.5/105) 
• The highest burden of illness was in children under 2
years of age
• In 2005, the highest incidence rate was reported from
the Western health board region (99.4/ 105)
Background
Rotavirus is the most common cause of acute gastroenteritis
in children worldwide and a frequent cause of diarrhoea
associated deaths in developing countries. In developed
countries, mortality due to rotavirus is low, however the
morbidity and economic costs associated with infection are
significant.1 
Illness is characterised by sudden onset diarrhoea and
vomiting, often with mild fever. Occasionally there is blood in
stools. Symptoms usually last for only a few days but in
severe cases hospitalisation may be required due to
dehydration. Transmission is usually person-to-person, mainly
via the faecal-oral route. Children less than two years of age
are most susceptible to infection, although cases are often
seen in elderly and immunocompromised adults - particularly
in institutional settings. Transmission can be rapid, through
person-to-person contact, airborne droplets, or contact with
contaminated objects such as toys.
Methods
Acute infectious gastroenteritis became a statutorily notifiable
disease for the first time in January 2004 under the
Amendment to the Infectious Diseases Regulations.1
Only cases of rotavirus and gastroenteritis unspecified are
notifiable under this disease category. Prior to 2004
gastroenteritis was only notifiable when contracted by
children less than two years of age. Data for this report were
extracted and analysed from the CIDR system.
Table 2:  Age specific incidence rates for rotavirus in Ireland, 2005 .
Age Group (Years) Number of cases ASIR
0-4 2172 782.3
5-9 25 9.5
10-14 5 1.8
15-19 2 0.6
20-24 1 0.3
25-34 2 0.3
35-44 0 0.0
45-54 1 0.2
55-64 2 0.6
65+ 22 5.0
Unknown 19 -
Total 2251 57.5
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Results
Incidence
There were 2404 notifications of Acute Infectious
Gastroenteritis (AIG) in 2005. Rotavirus was the causative
organism identified in 2251 (93%) of these giving a crude
incidence rate (CIR) of 57.5 cases per 100,000 population
(table 1). This represents an increase compared to 2004,
when 1600 cases of rotavirus were notified (CIR 40.8 cases
per 100,000). The incidence rates increased across all health
boards relative to 2004 values, except in the Southern Region
where a decrease was observed (Figure 1). The highest
incidence rate was in the Western Region with a CIR of 99.4
per 100,000 population.
Seasonal distribution
Analysis of the data by week of notification is shown in Figure
2. Most cases were notified in the first half of the year with a
peak incidence during week 17. A later peak was also observed
during week 33, however this was attributable to the bulk
uploading of notifications for April, May, June and August for
the WHB region.
Age
When the distribution of cases for each age group is
examined, it is evident that the highest burden of illness is
seen in children less than five years (table 2). A further
breakdown of these figures revealed that the majority (n =
2026) of infections occurred in children less the two years of
age. There has been a continuous increase in the number of
cases affecting this age group over recent years (Figure 3). As
rotavirus became notifiable in 2004 it is possible that figures
for previous years underestimate the true burden of infection
and this should be borne in mind when analyzing these data
Gender distribution
No significant gender bias was noted in 2005 with a male:
female ratio of 1.11: 1. This is similar to the ratio observed in
2004 (1.18: 1) 
Outbreak data
There was only one outbreak of rotavirus notified in 2005.
This general outbreak occurred in the Eastern region in a
residential institution. A total of 14 people became ill and the
suspected mode of transmission was person-to-person spread.
Discussion
In 2004, rotavirus infections became statutorily notifiable for
the first time under the disease category Acute Infectious
Gastroenteritis (Amendment to the Infectious Diseases
Regulations).1 Prior to 2004 only gastroenteritis cases in
children under two years of age were notifiable.
The crude incidence rate (CIR) of rotavirus increased in Ireland
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Figure 1: Crude incidence rate per 100,000 population for rotavirus by health board in 
Ireland, 2004 to 2005.
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Table 1: Number of cases and CIR per 100,000 population of rotavirus in Ireland by health 
board, 2005.
Health Board No. of cases CIR 
HSE-E 658 47.0
HSE-M 176 78.1
HSE-MW 92 27.1
HSE-NE 162 47.0
HSE-NW 167 75.4
HSE-SE 283 66.8
HSE-S 335 57.7
HSE-W 378 99.4
Total 2251 57.5
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in 2005 (57.5 cases/100,000 persons) compared to 2004
(40.8/100,000). In most regions, an increase was seen in
2005, especially in the WHB region. For the same period,
lower rates were noted for England and Wales2,3
(26.8/100,000) [calculated from provisional data 28/09/06]
and Scotland4 (31.5/100,000). However rotavirus is not
statutorily notifiable in the UK and so meaningful
comparisons cannot be made.
Analysis of the data presented here shows that children less
than two years of age are most at risk. This was also noted in
2004 and is a well-reported feature of the illness worldwide.
Seasonal peaks in winter/spring, as observed here, are also a
common feature of rotavirus infections in temperate climates.
The morbidity and associated medical costs associated with
rotavirus infections is considerable, the extent of which was
highlighted in an Irish study published in 2003.5 The study
monitored hospital admissions, treatments and costs of
rotavirus infections in two paediatric hospitals, over a 2-year
period. Results revealed that one percent of all hospital
admissions were for community-acquired rotavirus. Of these
cases, 87% required intravenous rehydration and 13% were
rehydrated orally. The minimum cost per case was 728.40.
This represents a significant burden on healthcare resources in
Ireland.
It is a widely accepted theory that every child will have a
rotavirus infection within the first five years of life.2 These
early rotavirus infections induce long-lasting immunity and
are the reason infections are uncommon in adulthood. This
acquired immunity has prompted much research into the
development of an effective vaccine in recent decades and is
a high priority for international agencies such as WHO and
the Global Alliance for Vaccine and Immunisations.
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Figure 3: Number of cases of rotavirus in children less than two by year, 2001 to 2005  
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Figure 2: Total number of rotavirus events by week, 2005 (data from CIDR)
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Sexually Transmitted Infections 
in Ireland, 2004
Key Points
• There were 10,695* sexually transmitted diseases (STIs)
notified in Ireland in 2004. This represents an increase of
12.1% when compared to 2003 (n=9,538);
• The three most commonly notified STIs in 2004 were
ano-genital warts (n=4,174), Chlamydia trachomatis
(n=2,803) and non-specific urethritis (n=2,746);
• Notifications of ano-genital warts increased by 4.8%;
Chlamydia trachomatis increased by 24.1% and non-
specific urethritis by 17.8%;
• Notifications of infectious hepatitis B and syphilis
decreased by 24.1% and 38.7% respectively;
• Notifications of gonorrhoea increased by 45.2%.
*On 1st January 2004, Infectious Diseases Amendment S.I. No.
707 of 2003 established a revised list of STIs in which
candidiasis, molluscum contagiosum and pediculosis pubis are
no longer classed as notifiable diseases.
Introduction
Sexually transmitted infections (STIs) give rise to illness,
infertility and death. Estimates from the World Health
Organisation (WHO) indicate that there are some 340 million
new cases of syphilis, gonorrhoea, chlamydia and
trichomoniasis in men and women aged 15–49 years around
the world, each year.1 STIs increase the risk of sexual
transmission of HIV.
Early detection and treatment of STIs is important in order to
protect the health of the population. The Health Protection
Surveillance Centre (HPSC) is responsible for the ongoing,
systematic collection, collation and analysis of data relating to
trends in the notification of STIs in Ireland. This analysis is
intended to inform public health action as well as informing
the development of clinical and laboratory services around
the country.
Following amendments to the Infectious Diseases Regulations
(Infectious Diseases (Amendment) (No. 3) Regulations 2003,
S.I. No. 707 of 2003), the list of notifiable STIs was revised in
January 2004 to include the following 11 infections:
• Ano-genital warts;
• Chancroid;
• Chlamydia trachomatis;
• Genital herpes simplex;
• Gonorrhoea;
• Granuloma inguinale;
• Infectious hepatitis B;
• Lymphogranuloma venereum;
• Non-specific urethritis;
• Syphilis, and;
• Trichomoniasis.
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Candidiasis, molluscum contagiosum and pediculosis pubis are
no longer classified as notifiable STIs.
This report is a summary of the key findings noted from the
2004 data returns, a detailed comprehensive report relating to
STI notifications in 2004 is available on the HPSC website.2 
The incidence of STIs in Ireland continues to rise. Notifications
increased by 12.1% in 2004 compared to 2003, this is despite
the exclusion of notifications for candidiasis, molluscum
contagiosum and pediculosis pubis.
Notifications for syphilis decreased by 38.7%. This is
attributable to control measures introduced in response to an
outbreak of syphilis that took place in Dublin between 2000
and 2002. This enhanced syphilis data is briefly summarized in
this chapter, but has been reported more comprehensively
elsewhere.3
STI surveillance in Ireland is largely based on notifications
received from STI clinics. However, in response to changes in
the Infectious Diseases Regulations, there was a notable
increase in the number of notifications received from
diagnostic laboratories in 2004. This is a welcome
development as it helps to strengthen disease surveillance.
Notifications are also received from primary care.
Despite changes to the legislation, STI surveillance in Ireland
has a number of limitations. This was the subject of an
extensive study undertaken by the HPSC in the course of
2004 and 2005. The report and its recommendations can be
found on the HPSC website.4
Methods
Clinicians and laboratories notify their respective Department
of Public Health of probable and confirmed cases of an STI. It
is important to note that the current Infectious Diseases
Regulations oblige both medical practitioners and clinical
directors of diagnostic laboratories to notify the relevant
Medical Officer of Health. Therefore, all clinicians regardless of
setting have a statutory obligation to report probable and
confirmed cases of a sexually transmitted infection.
Notifications are anonymised prior to reporting to the
Medical Officer of Health. Data are then collated, aggregated
and analysed at a local and regional level by individual
Departments of Public Health, as well as nationally by the
HPSC. Analyses are reported quarterly and annually.
This report predates recent organizational changes in the
Health Service. Therefore, this document relates to eight HSE
regions
• HSE-ER
• HSE-M
• HSE-MW
• HSE-NE
• HSE-NW
• HSE-SE
• HSE-S
• HSE-W
STI surveillance statistics relate to annual data from 1989 and
quarterly data from 1995. The data are analysed and
presented by disease, quarter year, HSE region, age group and
gender. Rates per 100,000 population for the years 1989 to
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1993 are based on the 1991 population census; rates for the
years 1994 to 1999 are based on the 1996 population census
and rates for the years 2000 to 2004 are based on the 2002
population census. It should be noted that cases of infectious
hepatitis B may also be reported through the weekly
infectious disease report published by HPSC and although
they are identified in STI clinics, they may not have been
acquired through sexual contact.
Results
Notified STIs between 1989 and 2004
During 2004, 10,695 STI notifications were recorded
compared to 9,538 in 2003 (12.1% increase (table 1)). STI
notifications have risen consistently each year since 1994. The
incidence of sexually transmitted infections has risen by
313.3% between 1994 and 2004 (figure 1).
Since the last annual report, gonorrhoea notifications have
increased by 45.2%. Notifications of C. trachomatis, non-
specific urethritis, genital herpes simplex and ano-genital
warts have also increased (table 1).
Notifications of syphilis and infectious hepatitis B decreased,
syphilis by 38.7% and infectious hepatitis B by 24.1%. The
cumulative rate per 100,000 population for all STIs
notifications increased from 243.5 per 100,000 in 2003 to
273 per 100,000 population in 2004. Table 2 outlines annual
notification by infection and year. The general upward trends
in the most common STI notifications are illustrated in figures
2-8.
Notified STIs by HSE region, 2004
The majority of STI notifications during 2004 were from the
HSE-ER (47.2%). Four HSE regions (ER, MW, S and W)
accounted for 87.4% of all notifications (table 3).
Notified STIs by age group and gender, 2004
STIs in males accounted for 51% of all notifications, 36.4%
were females. Data relating to gender was not reported in
12.5% of cases (table 4). The majority of cases of gonorrhoea
(86.7%), infectious hepatitis B (81.2%), non-specific urethritis
(79.9%), syphilis (72.9%) and ano-genital warts (34.8%) were
seen in males. The majority of notifications of trichomoniasis
(91.7%), genital herpes simplex (66.4%) and C. trachomatis
(53.2%) were seen in females (table 4).
In 2004, 11% (n=1,174) of notified cases of STIs were aged 0
to 19 years, 55.9% (n=5,983) were 20 to 29 years, 15.3%
(n=1,632) were 30 to 39 years, and 5.5% (n=591) were aged
40 years of age or older. The age of cases was not reported in
12.3% of notifications (n=1,315). Those aged 20-29 years
accounted for the largest number of notifications  (table 5).
Disease-specific trends
Ano-genital warts
Ano-genital warts, the clinically visible manifestations of
infection with human papilloma virus (HPV), were the most
commonly notified STI in Ireland in 2004, accounting for 39%
of all notifications. In 2004 ano-gential wart notifications
(n=4,174, rate=106.6 per 100,000 population) increased by
4.8%, compared to 2003 (figure 2). The number of cases
averaged over 1,000 cases per quarter. In 2004, males
accounted for 34.8% of cases and females for 34.6% of cases
Table 1: Numbers of current notifiable sexually transmitted infections, 2004 and 2003.
Sexually Transmitted Infection  2004 2003 Increase  % Increase
Ano-Genital Warts 4174 3981 193 4.8
Chancroid 1 0 1 0
Chlamydia Trachomatis 2803 2258 545 24.1
Genital Herpes Simplex 411 375 36 9.6
Gonorrhoea 270 186 84 45.2
Granuloma Inguinale 1 0 1 0
Infectious Hepatitis B 85 112 -27 -24.1
Lymphogranuloma Venereum 0 0 0 0
Non-Specific Urethritis 2746 2332 414 17.8
Syphilis 144 235 -91 -38.7
Trichomoniasis 60 59 1 1.7
Total 10695 9538 1157 12.1
Table 2: Numbers of current notifiable sexually transmitted infections, 1989 to 2004.
Sexually Transmitted Infection 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004
Ano-Genital Warts 505 917 1089 1066 1432 1532 1972 2286 2514 2886 3049 3735 3993 3932 3981 4174
Chancroid 2 0 0 2 0 2 3 1 1 0 1 16 1 1 0 1
Chlamydia Trachomatis 174 215 164 192 315 133 245 364 462 646 869 1343 1649 1922 2258 2803
Genital Herpes Simplex 78 123 109 125 124 173 198 181 211 243 275 269 331 358 375 411
Gonorrhoea 27 90 73 51 24 98 91 83 98 125 175 290 349 214 186 270
Granuloma Inguinale 0 0 0 0 6 0 0 1 1 0 1 0 0 0 0 1
Infectious Hepatitis B 0 0 0 0 0 0 4 2 0 0 2 15 39 57 112 85
Lymphogranuloma venereum 0 0 0 0 0 0 0 0 5 1 2 0 0 1 0 0
Non-Specific Urethritis 600 738 549 585 756 610 781 823 1034 1083 1265 1726 1634 2025 2332 2746
Syphilis 12 19 20 20 8 11 11 17 16 15 6 46 279 303 235 144
 Trichomoniasis 51 86 163 41 57 29 60 71 94 38 47 78 64 73 59 60
 Total 1449 2188 2167 2082 2722 2588 3365 3829 4436 5037 5692 7518 8339 8886 9538 10695
HPSC Annual Report 2005 43
(gender was not reported for 30.6% cases). Those aged 0-19
years accounted for 8.8% of the total, 44.9% of cases were
aged 20-29 years, 11.8% were aged 30-39 years and 3.8%
were aged 40 years or older. Information relating to age group
was reported in 30.7% of cases.
It is estimated that many more people without warts have
subclinical disease or latent infection with HPV. Most visible
ano-genital warts are benign and caused by HPV types 6 and
11. Infection with some other HPV types, especially 16, 18, 31
and 45 may lead to the development of invasive cervical
cancer and other cancers of the ano-genital tract.5
Chancroid
Chancroid is an uncommon infecton. Since 1989, and with the
exception of 2000 (when 16 cases were notified), the number
of notification has ranged between 0 and 3.
Chlamydia trachomatis
The number of C. trachomatis notifications has increased
steadily since 1995 (figure 3). There were 2,803 cases (71.6
per 100,000 population) notified in 2004. Notifications in the
fourth quarter of 2004 were the highest recorded in any one
quarter. C. trachomatis accounted for 26.2% of all STI
notifications in 2004. In addition to a true underlying increase
in the number of people infected, this increase reflects
increased testing and the use of highly sensitive and specific
DNA amplification techniques (NAATS). The numbers reported
are likely to represent a substantial underestimate of the true
burden of disease as C. trachomatis infection is asymptomatic
in at least 70% of women and 50% of men.6
Males accounted for 45.1% of cases, females 53.2% (gender
was not reported in 1.7% cases). Those aged 0-19 years
accounted for 14.1%, those aged 20-29 years, 69.8%, 12.5%
were aged 30-39 years and 2.9% were aged 40 years or older.
Age data were not reported for 0.8% of cases.
The STI subcommittee of Scientific Advisory Committee (SAC)
of the HPSC has recently highlighted the need for chlamydia
screening in Ireland and strongly recommended that the
feasibility, acceptability, likely uptake and effectiveness of
screening in various settings in Ireland be examined as a
matter of priority.7
Genital herpes simplex
Genital herpes simplex notifications increased by 9.6% since
2003 (figure 4). A total of 411 cases were reported (10.5 per
100,000 population). There was a decrease in notifications in
Q2 (n=86) and a rise during Q4 (n=117). Males accounted for
32.8% of the total and females 64.4%. Gender was not
reported in 0.7% cases. Those aged 0-19 years accounted for
10.7% of cases, while 55% of cases were aged 20-29 years,
22.9% were aged 30-39 years and 10.2% were aged 40 years
or older. Age was not reported in 1.2% of cases.
Gonorrhoea
The peak in gonorrhoea notifications observed in 2001
coincided with an outbreak of syphilis amongst Men who
have Sex with Men (MSM). Gonococcal infections tend to be
concentrated in core risk groups, such as MSM. This may be
reflected in the 2004 data, in that 86.7% of notifications were
male, and 11.1% were female.
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Figure 1. All currently notifiable STIs combined by year and by gender,between 1995 
and 2004.
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Ano-genital warts by year and by gender,between 1995 and 2004.
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Figure 3. Trachomatis by year and by gender,between 1995 and 2004.
0
1000
2000
3000
1995 1996 1997 1998 1999 2000 2001 2002 2003 2004
Male Female Total
HPSC Annual Report 200544
There were 270 cases of gonorrhoea notifications in 2004
(figure 5) (6.9 per 100,000 population). This reflects a rise of
45.2% in the number of reported cases compared to 2003.
Those aged 0-19 years accounted for 6.3% of cases, 58.9% of
cases were aged 20-29 years, 23.7% were aged 30-39 years
and 11.1% were aged 40 years or older.
It should be noted that the reported numbers of gonorrhoea,
like chlamydia, are likely to represent an underestimate of the
true incidence of infection, as gonorrhoea can be
asymptomatic in up to 86% of women and 55% of men.8
Granuloma inguinale
Granuloma inguinale is a rarely reported infection in Ireland.
The number of cases of granuloma inguinale has ranged from
0 to 6 cases per year, between 1989 and 2004.
Infectious Hepatitis B
Between 1989 and 1999, infectious hepatitis B cases reported
through the STI quarterly notification system ranged from 0
to 4 cases per year. Notifications increased from two cases in
1999 to 112 in 2003, the highest yearly total on record
(figure 6). A large proportion of this rise is attributable to
increased screening and testing. In 2004, 85 notifications were
received (2.2 per 100,000 population), a decrease of 24.1%
compared to 2003. Males accounted for 81.2% of
notifications, and females 15.3% (gender was not reported in
3.5% cases). The number of male cases increased by 4.5%,
female cases decreased by 71.7% in 2004, compared to 2003.
Those aged 0-19 years accounted for 11.8% of notifications,
40% of cases were 20-29, 32.9% were 30-39 and 15.3% were
aged 40 years or older.
Lymphogranuloma venereum
No cases of lymphogranuloma venereum (LGV) were notified
during 2004. Notifications of LGV have ranged between 0 and
5 cases per year, between 1989 and 2004.
Non-specific urethritis 
In 2004, 2,746 cases of non-specific urethritis were notified
(figure 7) (70.1 per 100,000 population). Males accounted for
79.9% of cases, and females 20% (gender was not reported
0.1% cases). This represents a 20.4% rise in male notifications
and an 8.1% rise in female notifications compared to 2003.
Those aged 0-19 years accounted for 12.1% of notifications,
60.4% of cases were aged 20-29 years, 19.3% were aged 30-
39 years and 8.0% were aged 40 years or older. Non-specific
urethritis accounted for 25.7% of all STI notifications in 2004.
Syphilis
Between 1989 and 1999 the mean number of annual
notifications was 14.1 (figure 8). Notifications peaked in 2002
with 303 cases reported. Syphilis has remained endemic since.
In the course of 2004, 144 cases were notified (3.7 per
100,000 population). This represents a decrease of 38.7%
compared to 2003. Males accounted for 72.9% of
notifications and females 26.4% (gender was not reported
0.7% cases). This represents a 23.4% decline among men and
a decline of 60.8% among women, compared to 2003. Of
those cases notified, 2.8% were aged 0-19 years, 34.7% of
Table 3: Notified sexually transmitted infections by HSE region, 2004 and percentage change compared to 2003.
Sexually Transmitted Infection HSE-ER HSE-M HSE-MW HSE-NE HSE-NW HSE-SE HSE-S HSE-W Total
Ano-Genital Warts 1813 0 526 1 217 393 698 526 4174
Chancroid 0 0 0 0 0 0 0 1 1
Chlamydia Trachomatis 1563 39 208 36 78 159 380 340 2803
Genital Herpes Simplex 248 0 27 0 2 14 51 69 411
Gonorrhoea 189 1 8 1 6 12 29 24 270
Granuloma Inguinale 0 0 1 0 0 0 0 0 1
Infectious Hepatitis B 57 0 10 1 8 0 3 6 85
Lymphogranuloma Venereum 0 0 0 0 0 0 0 0 0
Non-Specific Urethritis 1058 0 908 0 163 183 331 103 2746
Syphilis 97 1 8 2 1 4 20 11 144
Trichomoniasis 25 9 1 5 1 4 12 3 60
 5050 50 1697 46 476 769 1524 1083 10695
Total 47.2% 0.5% 15.9% 0.4% 4.6% 7.2% 14.2% 10.1% 100%
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cases were aged 20-29 years, 37.5% were aged 30-39 years
and 23.6% were aged 40 years or older. Age was not reported
in 1.4% of cases. Routine syphilis surveillance was enhanced
in 2000 in response to the rise in notifications (see section on
enhanced syphilis surveillance below for further details).
Enhanced surveillance of syphilis, 2004
Due to the complex nature of syphilis surveillance, this
section relates only to enhanced surveillance reporting.
Enhanced Surveillance was established in the year 2000 and
modified somewhat in 2004. A total of 104 cases of syphilis
were reported during 2004. Amendments to the Infectious
Diseases Regulations resulted in a large number of
notifications from laboratory sources during 2004 (n=199),
due to the lack of enhanced surveillance data on these
notifications; few are included in this analysis.
Reflecting the distribution of the population and provision of
clinical services, 99% of cases (n=103) were reported by the
HSE-ER. With regard to stage of illness at the time of
diagnosis, of the 104 cases reported, 72.1% (n=75) cases
were early* syphilis and 13.5% (n=14) were late† syphilis
cases. Men accounted for 79.8% (n=83/104) of diagnoses and
women 20.2% (n=21/104). MSM accounted for 57.7%
(n=60/104) of cases: 93.3% (n=56) were homosexual and
6.7% (n=4) were bisexual. Of particular concern is the
proportion of cases attributed to heterosexual contacts -
38.5% (n=40), of whom 55% were male and 45% female.
Sexual orientation was unaccounted for in 3.8% (n=4) of
cases. HIV positivity was reported in 16.3% (n=17/104) of
cases, 11 of whom were early syphilis cases, two were late
syphilis cases and staging was unknown in four cases. A
concurrent STI was reported in 15.4% of cases; 68.8% were
early syphilis cases and 12.5% were late syphilis. HIV was not
diagnosed as a concurrent infection. Of those women (n=8)
who were diagnosed through antenatal screening, most were
diagnosed with early syphilis.
*Early (infectious) syphilis cases refer to primary, secondary and early latent
syphilis cases.
†Late syphilis cases refer to late latent and tertiary syphilis cases.
Trichomoniasis
Trichomoniasis notifications fluctuated significantly between
1989 and 2004. The highest number of cases on record
occurred in 1991 when 163 notifications were made (4.6 per
100,000 population). The average number of notifications for
all years between 1989 and 2004, excluding 1991, was 60.5.
During 2004, 60 cases (1.5 per 100,000 population) were
notified. This represents an increase of 1.7% compared to
2003. Five percent of cases notified were male and 91.7%
were female. The number of male cases decreased by 70%
and the number of female cases increased by 12.2%,
compared to 2003. Notifications among those aged 0-19
years account for 6.7% of the total number of cases, 38.3% of
cases were aged 20-29 years, 31.7% were aged 30-39 years
and 23.3% were aged 40 years or older.
Discussion
The incidence of sexually transmitted infections in Ireland
continues to rise. The upward trend reflects changing social
values and lifestyles choices. The figures suggest that more
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Figure 4. Genital herpes simplex by year and by gender, between 1995 and 2004.
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Figure 6. Infectious hepatitis B by year and by gender, between 1995 and 2004.
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Gonorrhoea by year and by gender, between 1995 and 2004.
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people are being tested and treated for sexually transmitted
infections than ever before. Yet clearly more needs to be done
to prevent infection and limit the harm that results. This
requires relevant, timely and accurate information. The
methods currently used to generate this information have a
number of limitations. Chief among those is the absence of
disaggregated and detailed demographic data. Due to the lack
of demographic, clinical and risk factor data, it is not possible
to characterize those individuals most at risk, nor it is possible
to plan, structure or target sexual health services to meet the
needs of the population.
The Sexually Transmitted Infections subcommittee for the
Scientific Advisory Committee of the HPSC recently reviewed
the adequacy of STI surveillance in this country.4 Their report
makes a number of important recommendations, not least is
the call for a national Sexual Health Strategy. Such a strategy
is necessary to provide a framework for the future
development of prevention, diagnostic and treatment services
such that they are fair, equitable and that they meet the
needs of the population in an effective and acceptable
manner.
There is an established body of evidence from the United
Kingdom to suggest that sexual ill health is not equally
distributed among the population. In the UK, the highest
burden of illness is borne by women, gay men, teenagers,
young adults and those from minority ethnic backgrounds.
There is a strong link between social deprivation and the
incidence of STIs.9 STI surveillance in Ireland suggests that
similar trends are evolving in this country. However,
weaknesses in current systems hamper our ability to quantify
the inequity and evaluate the effectiveness of control
measures, including prevention and treatment. More work in
this area is required.
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Table 4: Notified sexually transmitted infections by gender, 2004.
Sexually Transmitted Infection  Male Female Gender UK1 Total
Ano-Genital Warts 1454 1445 1275 4174
Chancroid 0 1 0 1
Chlamydia Trachomatis 1264 1492 47 2803
Genital Herpes Simplex 135 273 3 411
Gonorrhoea 234 30 6 270
Granuloma Inguinale 1 0 0 1
Infectious Hepatitis B 69 13 3 85
Lymphogranuloma Venereum 0 0 0 0
Non-Specific Urethritis 2193 550 3 2746
Syphilis 105 38 1 144
Trichomoniasis 3 55 2 60
Total 5458 3897 1340 10695
% 51% 36.4% 12.5% 100%
1UK=Unknown.
Table 5: Notified sexually transmitted infections by age group (years), 2004.
Sexually Transmitted Infection  0-19 20-29 30-39 40+ Age UK1 Total
Ano-Genital Warts 367 1875 492 159 1281 4174
Chancroid 0 1 0 0 0 1
Chlamydia Trachomatis 395 1955 350 80 23 2803
Genital Herpes Simplex 44 226 94 42 5 411
Gonorrhoea 17 159 64 30 0 270
Granuloma Inguinale 0 1 0 0 0 1
Infectious Hepatitis B 10 34 28 13 0 85
Lymphogranuloma Venereum 0 0 0 0 0 0
Non-Specific Urethritis 333 1659 531 219 4 2746
Syphilis 4 50 54 34 2 144
Trichomoniasis 4 23 19 14 0 60
Total 1174 5983 1632 591 1315 10695
% 11.0 55.9 15.3 5.5 12.3 100
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Key Points
• During 2005, there were 318 newly diagnosed cases of
HIV infection, a 10% decrease on the number of cases
diagnosed in 2004 (356 cases)
• The cumulative total of HIV infections reported in
Ireland to the end of December 2005 is 4,082
• Of the 318 cases, 159 were among heterosexuals, 66
among IDUs and 57 among MSM. Incomplete data were
received for 28 (8.8%) of the newly diagnosed cases
• Of the 318 cases, 128 were born in Ireland, 116 were
born in sub-Saharan Africa and 15 were born in other
countries in western Europe. Information on geographic
origin is unavailable for 42 of the newly diagnosed cases
• Twenty seven of the 318 cases newly diagnosed with
HIV in 2005 were late diagnoses, i.e. they were
diagnosed with AIDS at the time of HIV diagnosis
• A total of 876 AIDS cases and 431 deaths among
HIV/AIDS cases have been reported to the HPSC up to
the end of December 2005
Introduction
During 2005, an estimated 4.1 million people worldwide
became newly infected with HIV and an estimated 2.8 million
lost their lives to AIDS.1 HIV infection remains a disease of
major public health importance in the WHO European region,
with increasing numbers of people living with HIV.2
Timely and complete HIV surveillance data are essential to
accurately monitor trends in the epidemic. Data on HIV and
AIDS in Ireland are obtained from the national HIV case based
reporting system, a voluntary anonymised surveillance
system. Neither HIV nor AIDS are statutorily notifiable at
present in Ireland.
Materials and Methods
HIV and AIDS surveillance in Ireland is voluntary and
anonymous and operates in cooperation with laboratories,
clinicians and departments of public health. For every newly
diagnosed HIV infection, a HIV/AIDS surveillance report form
is sent by the laboratory which confirms the diagnosis, to the
treating clinician. Forms are completed by the clinician and
forwarded to the appropriate department of public health
which in turn forwards them to the HPSC where national
figures are collated. Analysis of HIV data is carried out by the
HPSC every six months and a report is published on the HPSC
website. Clinicians are also asked to report all cases of AIDS
and deaths among HIV/AIDS patients to the HPSC using the
HIV/AIDS surveillance report form. A summary of the HIV and
AIDS data are forwarded twice yearly to the European Centre
for the Epidemiological Monitoring of AIDS (EuroHIV).
HIVand AIDS in Ireland, 2005
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Results
Newly diagnosed HIV infections
During 2005, a total of 318 HIV infections were newly
diagnosed, compared to 356 cases in 2004 and 399 cases in
2003. The rate of HIV infection in 2005 was 81 per million
population. The cumulative total number of HIV infections
reported up to the end of December 2004 was 4,082.
Probable route of transmission
Table 1 shows newly diagnosed HIV infections in 2004 and
2005 by probable route of transmission. The cumulative total
of cases by probable route of transmission is also provided.
Figure 1 shows trends in newly diagnosed cases from 1994 to
2005 by probable route of transmission for the three most
frequent routes, namely, heterosexual contact (HC), men who
have sex with men (MSM) and injecting drug users (IDUs).
Information on risk group was unavailable for 28 (8.8%) of
the cases newly diagnosed in 2005.
Heterosexual contact
There were 159 heterosexually acquired cases diagnosed
during 2005. This compares to 178 cases in 2004 and 223
cases in 2003. Of the 159 heterosexual cases, there were 91
females and 68 males and the mean age was 33.4 years. Of
the 159 cases acquired through heterosexual contact, 101
were born in sub-Saharan Africa (SSA) and 32 were born in
Ireland. Seventeen (10.7%) of the 159 heterosexual cases
diagnosed in 2005 were diagnosed late, i.e. diagnosed with
AIDS at the time of HIV diagnosis.
Men who have sex with men
There were 57 new diagnoses among MSM during 2005, a
decrease from the number diagnosed in 2004 (64 cases) and
2003 (75 cases). The mean age at HIV diagnosis in MSM in
2005 was 37.1 years. Of the 57 cases diagnosed in 2005, 37
(64.9%) were born in Ireland and seven (12.3%) in western
Europe. Five (8.8%) of the 57 cases in MSM were diagnosed
late.
Injecting drug use
There were 66 new diagnoses among IDUs during 2005,
compared to 71 in 2004 and 49 in 2003. Of the 66 cases, 37
were male, 29 were female and the mean age at HIV
diagnosis was 30.5 years. Fifty five (83.3%) were born in
Ireland. Four (6.2%) of the 66 cases in IDUs were diagnosed
late.
Mother to child transmission
There were three cases of mother to child transmission (MCT)
diagnosed in children in 2005. Two children were born in SSA
and one was born in Ireland. In this case, the mother was
presumed to have been infected in SSA. In all three cases, the
mother was diagnosed after the birth of the child. In addition,
there were 105 babies born to a HIV infected mother during
2005, 90 are not infected and 15 remain of indeterminate
status (i.e. do not meet the criteria for HIV infection and are
<18 months at time of test).
Sex and Age distribution
Of the 318 cases newly diagnosed in 2005, 181 (56.9%) were
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Figure 1: Newly diagnosed HIV infections in Ireland among heterosexuals, 
MSM and IDUs (1994 to 2005) 
0
300
450
400
150
250
100
200
50
350
1994 1998 2001 2002 2003 2004 20051997 200019961995 1999
Total Heterosexual MSM IDU
Table 1: HIV infected patients in Ireland by probable route of transmission
(up to end December 2005) 
Probable route of transmission 2005 Cumulative Total (to end 
  Dec. 2005)
IDU 66 1270
Heterosexual 159 1487
MSM 57 885
Haemophiliac - 106
Children (including MCT) 3 85
Transfusion Recipient 4 11
Other 1 93
Unknown 28 145
Total 318 4082
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male and 136 (42.8%) were female, giving a male to female
ratio of 1.3:1. Gender was unknown for one case. Among
females, the most frequent route of transmission was
heterosexual contact, which accounted for 67% of newly
diagnosed infections. Among males, the most frequent routes
of transmission were heterosexual contact (38%) and sex
between men (31%). Of the 136 females who were diagnosed
with HIV infection in 2005, 33 were reported to be pregnant
at HIV diagnosis. Information relating to pregnancy status was
not provided for 17 of the female cases.
Most of the newly diagnosed cases (74.5%) were aged
between 20 and 40 years. The mean age at HIV diagnosis was
33.4 years. The mean age at HIV diagnosis was 29.7 years in
females and 36.2 years in males, a difference of 6.5 years.
Geographic origin
Analysis of 2005 cases by geographic origin is presented in
figure 2. Classification by geographic origin is as used by
EuroHIV and is based on country of birth. Of the 318 cases
diagnosed in 2005, 128 were born in Ireland, 116 in SSA, 15 in
western Europe, seven in central and eastern Europe and five
in south and south east Asia. Information on geographic origin
is unavailable for 42 of the newly diagnosed cases.
Area of residence
Of the 318 cases newly diagnosed in 2005, 209 were resident
in the Eastern Region (i.e. Dublin, Kildare and Wicklow) and 63
were resident elsewhere in the country at the time of HIV
diagnosis. Information on area of residence is unavailable for
46 of the 318 cases. By risk group, 83.3% of IDUs, 73.7% of
MSM and 67.7% of heterosexuals were resident in the Eastern
region at HIV diagnosis.
Stage of infection
Information on stage of infection at time of HIV diagnosis
was available for 267 of the newly diagnosed cases. Of the
267 cases, 179 were asymptomatic at HIV diagnosis and 27
were diagnosed with AIDS at the time of HIV diagnosis. Of
the 27 late diagnoses, 17 were among heterosexuals, five
among MSM and four among IDUs. The probable route of
transmission was unknown for one case.
AIDS cases and deaths among HIV/AIDS cases
A total of 876 AIDS cases, including 190 cases (21.7%) in
females, were reported to the end of 2005. Of the 876 AIDS
cases, 390 (44.5%) were reported to have died. The total
number of deaths in HIV infected individuals (with or without
an AIDS diagnosis) reported to the end of 2005 was 431.
Figure 3 shows the number of AIDS cases and deaths reported
among AIDS cases by year of diagnosis and year of death
(includes all cases reported up to the end of December 2005).
AIDS cases are analysed by year of diagnosis as recommended
by NASC.3 It is important to note that there is significant
underreporting and late reporting of AIDS cases and deaths
among HIV and AIDS cases. It is likely that further reports
particularly relating to recent years, will be received and the
number of cases of AIDS and deaths will be revised upwards
for some years, in particular for the later years.
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Figure 3: AIDS cases and HIV/AIDS related deaths, 1983 to 2005 
(reported up to June 2006)
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Figure 2: Newly diagnosed HIV infections in Ireland by probable route of transmission and 
geographic origin (2005)
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Discussion
Between 1998 and 2003, there was a dramatic increase in the
number of newly diagnosed HIV infections in Ireland, from
120 cases in 1998 to 399 cases in 2003 (a 3.3 fold increase).
This decreased to 356 cases in 2004 and 318 cases in 2005.
While these data indicate a downward trend, it is important
to note that these data do not represent HIV incidence. The
data include individuals who were infected in previous years
and depend on uptake of HIV testing. Available data on HIV
infection in the EU show that the number of new HIV
diagnoses increased from 14,028 in 2001 to 17,281 in 2004
(in 20 countries where complete data was available).4 In
addition, the ongoing increase in annual notifications of STIs
in Ireland (from 2,588 in 1994 to 10,695 in 2004) is of
concern as the presence of an STI is known to facilitate the
transmission and acquisition of HIV.5,6
The drop in the number of newly diagnosed HIV cases is due
predominantly to a decrease in the number of heterosexually
acquired cases, from a peak of 232 in 2002 to 159 in 2005.
This is largely due to a drop in heterosexually acquired cases
in persons born in SSA, from 177 cases in 2002 to 101 in
2005. This may reflect the recent decrease in the number of
asylum seeker applications (from 11,634 in 2002 to 4,323 in
2005), with possibly fewer cases being detected through the
asylum seeker screening program. However, it is important to
remember that people coming to Ireland from SSA do not
form a homogeneous group and include students, immigrant
workers, refugees, economic migrants, asylum seekers and
others. The number of heterosexually acquired cases in
persons born in Ireland remained steady between 2002 and
2005 with an average of 30 cases per year. Currently,
heterosexual contact is the most frequently reported mode of
transmission in most countries in western Europe with the
number of cases in this transmission group almost doubling
between 2001 and 2004 (from 5,968 to 11,126).2 In many
countries, as in Ireland, the majority of these cases were in
persons born in countries with generalised epidemics. This is
not unexpected given the prevalence of HIV in those regions
of the world and reinforces the need to ensure that
prevention and care services are adapted to reach migrant
populations.
There were 57 new diagnoses among MSM during 2005, a
decrease from the number diagnosed in 2004 (64 cases) and
2003 (75 cases). However, MSM continue to be a population
at high risk for HIV infection and worryingly the number of
HIV cases reported among MSM in most western European
countries increased between 2000 and 2004.2
The number of new diagnoses among IDUs decreased in 2005
compared to 2004. There was a considerable jump in the
number of cases in IDUs between 1998 and 1999 (from 26 to
69 cases) with an average number of 60 cases per year since
then. Ongoing transmission of HIV among IDUs highlights the
need for maintaining harm reduction measures in order to
prevent transmission of blood borne viruses among this group.
The detection of HIV infection before or during pregnancy
allows for the provision of appropriate care and treatment for
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the mother and allows for the reduction or even prevention of
mother to child transmission of HIV infection.7 A policy to
recommend and offer routine antenatal HIV testing to all
women was introduced in Ireland in 1999. Since 2002, the
HPSC has collected data on the uptake of the antenatal HIV
test from all maternity hospitals/units in Ireland. Further
information on the antenatal HIV screening programme can
be found on the HPSC website (www.hpsc.ie).
The analysis of AIDS surveillance data and interpretation of
trends is difficult. The usefulness of these data depends on the
extent to which case reporting is complete and it is felt that
there is considerable under-reporting and late reporting of
AIDS cases and deaths among HIV/AIDS cases. The efficacy of
highly active antiretroviral therapy (HAART), which was
introduced in Ireland in 1996, has led to a fall in the number
of patients who develop AIDS-defining conditions and has
improved outcomes for those who do develop such
conditions. Therefore, clinicians may no longer consider it
meaningful to define patients in terms of their disease stage
and consequently may be less likely to report an AIDS
diagnosis. However, it appears that reporting of AIDS cases,
particularly where HIV and AIDS are diagnosed
simultaneously, has improved since the introduction of HIV
case based reporting in 2001.
It is of concern that 27 of the 318 cases newly diagnosed
with HIV in 2005 were late diagnoses, i.e. they were
diagnosed with AIDS at the time of HIV diagnosis. There are
significant benefits associated with diagnosing HIV as early in
the course of infection as possible, both to the individual and
to the community. These individuals who were diagnosed late
do not have the opportunity to avail of treatment and
intervention prior to their AIDS diagnosis.
More detailed HIV and AIDS reports are available on the HPSC
website (http://www.ndsc.ie/A-Z/HepatitisHIVAIDSandSTIs/
HIVandAIDS/Publications/).
Acknowledgements
The HPSC wish to thank all who have contributed to HIV and AIDS
surveillance - the National Virus Reference Laboratory, microbiology
laboratories, the Department of Health and Children, the departments of
public health, consultants in infectious disease/GUM and all other clinicians
involved.
References
1. UNAIDS (2006). 2006 report on the global AIDS epidemic. Geneva
2. EuroHIV. HIV/AIDS Surveillance in Europe. End-year report 2004. Saint-
Maurice: Institut de Veille sanitaire, 2005. No 71.
3. AIDS strategy 2000. National AIDS strategy committee. Department of
Health and Children. Available at  http://www.dohc.ie/publications/
aids_strategy_2000.html
4. Nardone A. Transmission of HIV/AIDS in Europe continuing.
Eurosurveillance weekly 2005 10: 1-2.
5. HPSC (2005). Sexually Transmitted Infections 2004, Annual Summary
Report.
6. Fleming DT, Wasserheit JN. From epidemiologic synergy to public health
policy and practice: the contribution of other sexually transmitted diseases to
sexual transmission of HIV infection. Sex Transm Infect 1999; 48: 773-777.
7. Connor EM et al. Reduction of maternal-infant transmission of human
immunodeficiency virus type 1 with zidovudine treatment. N Engl J Med.
1994; 331(18): 1173-1180.
HPSC Annual Report 200552
Viral Hepatitis in Ireland, 2005
Key Points
• Hepatitis A incidence remained low, with 56 cases
notified in 2005
• The number of hepatitis B notifications continued to
increase with 905 cases reported in 2005, compared to
724 cases in 2004
• Where acute/chronic hepatitis B status was known,
90.5% (n=705) of cases were reported as chronic and
9.5% (n=74) were reported as acute
• Increases were also seen in hepatitis C notifications,
with 1,439 cases reported, compared to 1,136 in 2004.
The majority of cases occurred in young adults
• Baseline data collection for the national database for
people infected with hepatitis C though administration
of blood and blood products has been completed. The
first annual report will be produced in early 2007
Viral Hepatitis - Type A
Introduction
Hepatitis A is an acute, usually self-limiting disease of the
liver caused by the hepatitis A virus (HAV). It is transmitted by
person-to-person contact, primarily via the faecal-oral route
and is associated with poor hygiene and sanitation and water
that is contaminated with human faecal matter.1 
In developed countries, hepatitis A is most commonly seen
among travellers to endemic countries, injecting drug users
(IDU), men who have sex with men (MSM) and household or
sexual contacts of known cases. Sporadic food and waterborne
outbreaks and outbreaks in crèches also occur. The median
incubation period for hepatitis A is 30 days and infection can
usually be transmitted from one to three weeks prior to onset
of illness to approximately one week after the appearance of
jaundice. Prolonged viral excretion, for up to six months, can
occasionally occur. Clinical severity tends to increase with age
and adults can experience severe illness lasting several
months. Symptoms include sudden onset of fever, fatigue, loss
of appetite, nausea and abdominal pain. Jaundice usually
occurs within a few days of onset of symptoms.1,2 
A safe and effective vaccine is available for hepatitis A. In
Ireland, vaccination is recommended for individuals in high-
risk groups such as travellers to high endemicity countries,
patients with chronic liver disease, individuals at occupational
risk, close contacts of infected persons, individuals with
haemophilia and recipients of plasma-derived clotting factors.3
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Materials and Methods
Hepatitis A is a notifiable disease under the Infectious
Diseases Regulations 1981. Aggregate data on notifications
are available from 1982 and disaggregate data are available
since mid-2000. An amendment to the regulations
implemented on 1st January 2004 (S.I. 707 of 2003)
introduced case definitions and mandatory laboratory
reporting.4
Results
Hepatitis A incidence remained relatively low in 2005, with 56
cases notified to HPSC. This corresponds to an age-
standardised incidence rate (ASIR) of 1.4/100,000 population
and represents an increase of 19% compared to the number
of notifications received in 2004 (n=47) (figure 1). Forty-
eight cases were reported as confirmed, six were reported as
possible and the case classification was not reported for two
cases. The highest ASIRs were in the HSE-W (2.6/100,000
population, n=10) and HSE-NW (2.2/100,000 population,
n=5) (figure 2). However, a large proportion (70%) of the
HSE-W cases represented late notifications and had onset
dates in 2004. Fifty-seven percent of cases notified in 2005
were female (n=32). Young adults aged between 25 and 44
years (n=25) and adults over the age of 65 years (n=12) were
most affected. (figure 3). Four cases had travelled outside
Ireland within the incubation period of the disease. No
hepatitis A outbreaks were reported to the HPSC in 2005.
Discussion
There is currently no enhanced surveillance system for
hepatitis A in Ireland, but risk factor information is collected in
the context of outbreaks. In 2005, four cases were thought to
be travel-associated. Little or no information on the source of
infection was available for the remainder of the cases.
The age distribution of cases notified in 2005 is different to
that in 2004, when the highest rates were in young children,
followed by young adults. In 2005, high rates were seen in
people aged over 65 years in addition to young adults. High
rates in young adults are expected in countries with low
endemicity as many people are not exposed to hepatitis A in
childhood and hence are not immune. Young adults are more
likely to travel outside of Ireland and eat in restaurants both
on holidays and at home. The cases in the over 65s were not
clustered in time or place and none of them were reported as
being part of an outbreak.
Outside of Ireland, an outbreak among MSM was reported in
Dorset, England and a foodborne outbreak was reported
among Danish travellers returning from a holiday at a Turkish
resort.5,6
Viral Hepatitis – Type B
Introduction
Hepatitis B virus is transmitted by contact with blood or body
fluids of an infected person. The main routes of transmission
worldwide are perinatal, child-child transmission, unsafe
injections and sexual contact. Although only a small
proportion of those infected experience symptoms in the
acute phase, there is a high probability of developing chronic
infection if the infection is acquired in infancy or early
childhood. Approximately 90% of infants infected at birth, 20-
50% of children infected between one and five years of age
Year
N
um
be
r o
f n
ot
ifi
ca
ti
on
s
Figure 1. Number of cases of hepatitis A notified, 1989-2005
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Figure 2. Age-standardised incidence rates of hepatitis A per 100,000 population by HSE area, 2003-2005
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and 1-10% of those infected as older children or adults
develop chronic hepatitis B infections.1, 7
It is estimated that more than 350 million people worldwide
are chronically infected. In Sub-Saharan Africa, South-East Asia
and parts of China over 8% of the population have chronic
hepatitis B infections, most of which were contracted at birth
or through child-to-child contact in household settings.
Chronic infection is associated with an increased risk of
developing liver cirrhosis and/or hepatocellular carcinoma and
an estimated 15-25% of chronically infected people will die
prematurely from these conditions.1,7 The prevalence of
hepatitis B virus infection in Ireland is low (<1%)8, however
infection is more prevalent in certain high-risk populations
such as MSM, IDU9,10, prisoners11 and immigrants from
intermediate- or high-endemicity countries.
Hepatitis B is a vaccine-preventable disease and in 1992 the
WHO recommended that hepatitis B vaccine be included in
routine immunisation programmes in all countries by 1997.7
The current vaccination policy in Ireland is based on targeting
identifiable risk groups for vaccination. These include babies
born to mothers with acute or chronic hepatitis B infections,
patients with chronic renal failure or haemophilia, individuals
at occupational risk, close contacts of infected persons, IDU,
prisoners, homeless people, heterosexuals with multiple
partners and MSM.3  
Materials and Methods
Hepatitis B is a notifiable disease under the Infectious
Diseases Regulations 1981. An amendment to the regulations
implemented on 1st January 2004 (S.I. 707 of 2003)
introduced case definitions and mandatory laboratory
reporting, and differentiated between notifications of acute
hepatitis B and chronic hepatitis B for the first time.4
Departments of Public Health, in conjunction with HPSC,
introduced enhanced surveillance of acute cases of hepatitis B
from January 2005. Some enhanced forms are also received
for chronic cases.
Results
The increase in hepatitis B notifications seen in recent years
continued in 2005, with 905 cases notified. This represents a
25% increase compared to 2004 (figure 4). The national age-
standardised notification rate was 23/100,000 population,
with the highest rates reported by the HSE-E (32.6/100,000
population, n=491) and the HSE-W (25.7/100,000 population,
n=91) (figure 5). Case classification was reported for 821
cases, with 95% (n=777) of cases reported as confirmed and
5% (n=44) reported as probable.
Eighty-six percent of notifications (n=779) contained
information on acute/chronic status. Where status was known,
90.5% of cases were reported as chronic (n=705) and 9.5%
were reported as acute (n=74).
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Figure 3: Age- and sex-specific incidence rates of hepatitis A per 100,000 population, 2005
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Figure 4. Number of cases of hepatitis B notified, 1990-2005 
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The age and sex breakdown for acute and chronic cases
differed substantially and is presented separately in figures 6a
and 6b. Seventy-six percent of acute cases notified in 2005
were male (n=56) and 24% (n=18) were female. Over 60%
(63.5%, n=47) were aged between 20 and 44 years. However,
adults of all ages were affected and 26% (n=19) of acute
hepatitis B cases were aged 45 years or older. There was also a
higher proportion of male (53%, n=372) chronic cases than
female (41%, n=292), but the difference was not as marked
(sex was unknown for 6%). Young adults were predominantly
affected, with 82% (n=578) of chronic cases aged between 20
and 44 years. The age distribution for male chronic cases was
slightly older than that for females.
Risk factor information and region of birth also differed
between acute and chronic cases. Enhanced surveillance forms
were received for 49 of the 74 acute cases and no risk factor
was identified for 13 (26.5%) of these. The main risk factors
identified for acute hepatitis B related to sexual exposure.
Where enhanced data were received, 6.1% (n=3) of cases
were associated with sexual contact with a known case of
hepatitis B, 24.5% (n=12) of cases were MSM and a further
20% (n=10) were associated with possible sexual exposure
(sexual orientation not identified). The cases with known or
suspected sexual exposure ranged in age from 19 to 70 years
and were mostly males (80%). Where reason for testing was
identified (n=41), 73% (n=30) of acute cases were tested
because they were symptomatic and 15% (n=6) were tested
because they were MSM or went for STI screening. Where
country of birth was known (59%, n=44), 75% (n=33) were
born in Ireland.
Limited enhanced data and risk factor information were
available for chronic cases, but where information was
available, 139 out of 183 cases (76%) were identified as
either asylum seekers or as having been born in a country
where hepatitis B is endemic (hepatitis B surface antigen
prevalence of 2% or higher). Where region of birth was
identified (n=144), 52.1% (n=75) of chronic cases were born
in Sub-Saharan Africa, 13.2% (n=19) were born in East
Asia/The Pacific, 9.7% (n=14) were born in Central Europe
and 7.6% (n=11) were born in Western Europe (10 in Ireland).
The most common countries of birth were Nigeria (20.8%),
China (11.8%) and Somalia (10.4%). Where the reason for
testing was reported (n=116), 66% (n=76) of chronic cases
were identified through asylum seeker screening and 9%
(n=10) were identified through antenatal screening.
Discussion
Statutory notifications of hepatitis B have increased every
year since 1999 and the epidemiology of hepatitis B in Ireland
is changing. This is due in part to the changes in immigration
patterns to Ireland associated with economic development.
The number of asylum seeker applications increased from
1,179 in 1996 to a peak of 11,634 in 2002, and decreased to
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Figure 5. Age-standardised incidence rates of hepatitis B per 100,000 population by HSE area, 2005
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Figure 6a. Age-and sex-specific incidence rates of acute hepatitis B per 100,000 population, 2005
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4,323 in 2005.12 The most common nationalities of asylum
seekers in 2005 were Nigerian (34%), Somalian (9%) and
Romanian (9%). All of these countries have either
intermediate or high hepatitis B surface antigen prevalence.
The number of work permits issued by the Department of
Enterprise, Trade and Employment has also increased
substantially in recent years, with 4,328 new permits issued in
1999 and 29,594 in 2002.13 The number has decreased since
then and 7,354 new permits were issued in 2005. The most
common countries of origin in 2005 were the Philippines,
India and South Africa, all of which have either intermediate
or high hepatitis B endemicity. Limited information is
available on the actual risk factors for cases with chronic
infections but it is likely that a large proportion of infections
were acquired at birth or in early childhood where individuals
were born in countries with endemic hepatitis B.
The number of acute hepatitis B notifications also increased
in 2005, with most cases occurring in Irish nationals. Sexual
acquisition remained the dominant likely source of infection.
The current immunisation policy in Ireland is based on
targeting identifiable risk groups for vaccination. MSM and
individuals who change sexual partner frequently are included
as risk groups in the immunisation guidelines. However, there
may be problems identifying people at risk. Most sexually
acquired acute cases were tested for hepatitis B because they
were symptomatic. Many people at risk may not attend STI
clinics or discuss their sexual behaviour with their GPs and
may never have been offered hepatitis B vaccination. The
number of sexually-acquired acute cases in people aged over
35 years increased by 70% in 2005 compared to 2004 and
people who fall outside of the expected demographic for
sexually transmitted infections may be less likely to be offered
vaccination.
A proportion of the increases seen in recent years are likely to
be attributable to improvements in case identification and
notification with the introduction of mandatory laboratory
reporting and screening programmes such as voluntary health
screening for asylum seekers and antenatal screening in many
maternity hospitals.
Hepatitis B data have improved significantly with the
introduction of case definitions, differentiation between acute
and chronic hepatitis B and enhanced surveillance for
hepatitis B. Further improvements are anticipated with the
planned addition of the enhanced surveillance questions to
CIDR by the end of 2006.
Viral Hepatitis-Type C
Introduction
Hepatitis C virus (HCV) was first identified in 1989. It was
previously known as non-A non-B hepatitis and was known to
be the cause of most transfusion-associated hepatitis. The
WHO estimates that about 170 million people worldwide are
currently infected with HCV. 1,14
HCV is transmitted primarily via exposure to contaminated
blood or blood products and the main causes of infection are
sharing infected needles or other drug paraphernalia and the
receipt of unscreened blood or blood products. Occupational
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Figure 6b. Age- and sex-specific incidence rates of chronic hepatitis B per 100,000 population, 2005
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exposure to infected blood, mother-to-baby and sexual
transmission also occur but are less common. In developed
countries, it is estimated that 90% of people with chronic
hepatitis C are current or former injecting drug users or have
received unscreened blood or blood products.1,14
Over 90% of cases are asymptomatic in the acute phase of
the disease but between 50 and 80% progress to chronic
infection. Of those chronically infected about 10-20%
develop cirrhosis and between 1 and 5% develop
hepatocellular carcinoma over a period of 20-30 years. There
is currently no vaccine available for hepatitis C. 1,14
Materials and Methods
Hepatitis C became a notifiable disease under the Infectious
Diseases Amendment Regulations introduced on the 1st
January 2004 (S.I. 707 of 2003).4 Previously hepatitis C could
be notified under the category “viral hepatitis, type
unspecified”, but was not a notifiable disease in its own right.
Since the HPSC started collecting disaggregate data in mid-
2000, many of the notifications of viral hepatitis type
unspecified have included information on the causative agent
and most of these were hepatitis C.
Results
The number of cases of hepatitis C remained high in 2005
with 1,439 cases notified to the HPSC, compared to 1,136 in
2004 (figure 7). This corresponds to an ASIR of 36/100,000
population. Over 70% of all cases were reported by the HSE-
E, giving an ASIR of 69/100,000 population (n=1063) (figure
8). Sixty-four percent (n=918) of cases were male and 35%
(n=503) were female (sex was unknown for 1% (n=18)).
Young adults of both sexes were most affected, with 80%
(n=1,154) of cases aged between 20 and 44 years. The age
breakdown of males and females was very similar (figure 9).
Discussion
Prior to 2004, there was very little routine information
available to describe the epidemiology of hepatitis C in
Ireland. The 2004 and 2005 data indicate that the incidence
of hepatitis C is high and that the geographic distribution is
skewed towards the HSE-E.
There is currently no enhanced surveillance system for
hepatitis C. However, studies in Irish settings and anecdotal
evidence indicate that new cases of hepatitis C are mainly
occurring in injecting drug users and are strongly associated
with sharing syringes or other drug paraphernalia.9,10,11 A cross-
sectional study of blood-borne infections in clients attending
addiction treatment centres in the HSE-E found that 66% had
antibodies to hepatitis C virus, and a national study of
individuals entering prisons found that 72% of IDU had
hepatitis C antibodies.10,11 The skewed geographic distribution
and the predominance of males and young adults of both
sexes, in the notification data, are likely to be a reflection of
this.
Additional information, particularly risk factor data, is
essential for identifying populations at risk and for planning
public health strategies for hepatitis C prevention and future
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Figure 8. Age-standardised incidence rates of hepatitis C per 100,000 population by HSE area, 2004 & 2005
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Figure 7. Number of notifications of hepatitis (type unspecified) 1990-2003, and
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health service provision. It is hoped that the proposed
introduction of enhanced surveillance for hepatitis C, and the
availability of this on CIDR, will result in improvements in the
hepatitis C data.
National Hepatitis C Database
A national database of people infected with hepatitis C
through the administration of blood or blood products has
been set up by HPSC in association with the eight designated
hepatology units. This project was recommended by the
Consultative Council on Hepatitis C 15 and is supported
financially by the Department of Health and Children.
The objectives of the database are:
• To follow the natural history of infection in this group of
people
• To evaluate the impact of various host factors on the
progression of the disease
• To evaluate the outcomes of treatment
• To monitor the uptake of services
• To provide information for the planning and evaluation of
health services
• To serve as a resource for future research into hepatitis C
Any person who has contracted hepatitis C infection through
the administration of blood or blood products within the
State is eligible to be included in the database. It is estimated
that over 1,700 persons have been infected with hepatitis C in
this way. These include women infected through anti-D
immune globulin, persons with haemophilia, recipients of
blood transfusion and persons who received treatment for
renal disease.
Data collection commenced at the end of 2004 and is based
on data contained in the medical records of patients who
have attended any of the eight designated hepatology units.
Baseline data collection has been completed and the first
annual report will be published in early 2007.
Follow-up information will be collected annually thereafter.
Only patients who have given written consent are included in
the database and the database does not contain names or
addresses. Ethical approval for the database has been received
from the ethics committees of the eight hospitals. Patient
support groups are represented on the Steering Committee,
which oversees the project. There will be an annual call for
research based on the data contained in the database and this
process will also be overseen by the Steering Committee.
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Figure 9. Age- and sex-specific incidence rates of hepatitis C per 100,000 population, 2005
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Infectious Disease Notifications in
Ireland, 2005
Key Points
• There were 11,228 notifications reported through the
weekly infectious disease notification system in 2005
• Infectious disease notifications in 2005 increased by
20% compared to 2004, i.e. 1,892 additional
notifications in 2005
• Acute infectious gastroenteritis and mumps
notifications predominantly accounted for this increase
• A rise in notifications due to cryptosporidiosis, hepatitis
B, hepatitis C and influenza also contributed to the
increase
Introduction 
Infectious diseases that are at the present time statutorily
notifiable in Ireland are specified in the Infectious Diseases
(Amendment) (No.3) Regulations 2003 (S.I. No. 707 of 2003)
which came into effect on the 1st January 2004. As before
clinicians and now laboratory directors are legally obliged to
notify. The amendment legislation also introduced the use of
case definitions for infectious diseases for the first time in
Ireland and specified that unusual clusters or changing
patterns of illness that may be of public health concern must
be reported.
Under the legislation, as soon as a medical practitioner
becomes aware of, or suspects that, a person is suffering from,
or is a carrier of, an infectious disease specified in the
regulations, or as soon as a clinical director of a diagnostic
laboratory identifies an infectious disease specified in the
regulations, he/she is required to provide a written or
electronic notification to a Medical Officer of Health in the
relevant HSE Area. For a subset of diseases that have serious
public health implications, medical practitioners/laboratory
directors are required to give immediate preliminary
notification (e.g. by phone) to the Medical Officer.1 These
notifications provide the basis for disease control and
surveillance in Ireland.
The medical officers in the HSE Areas investigate the notified
cases as appropriate. Case investigation, depending on the
disease, may include: 1) collecting more detailed data on the
case including possible risk factors for the disease 2) obtaining
a specimen for laboratory testing if not already obtained by
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the medical practitioner 3) contact tracing i.e. identifying
persons who may have been in contact with the patient
during the time the patient was infected or during the time
the patient was infectious or had the same exposure as the
patient (e.g. ingested the same infected food or water).
Contact tracing identifies exposed individuals who may be
susceptible to the disease; prophylaxis or vaccination may be
administered to these individuals (if appropriate and
depending on the disease in question). The purpose of case
investigation is to stop further spread of disease after a case
is identified and to prevent the disease from occurring again.
The HSE Areas either enter the notifications directly into the
Computerised Infectious Disease Reporting (CIDR) system to
which HPSC has real-time access or they forward the
notification data to HPSC on a weekly basis where these data
are inputted to CIDR. At HPSC a weekly infectious disease
report on national data is produced from CIDR. This report is
distributed to those involved in the control and surveillance of
infectious disease in Ireland. An abbreviated version of this
report is also available on the HPSC website.
Surveillance at a national level allows infectious disease trends
to be monitored, provides information about the need for, and
impact of, infectious disease prevention and control
programmes, guides infectious disease policy development
and allows Ireland to meet international reporting
requirements such as providing infectious disease data to EU
disease specific networks and to the World Health
Organisation (WHO).
A summary of the 2005 infectious disease data reported
through the weekly infectious disease notification system is
presented in this report.
Materials and Methods
HPSC and four of the HSE Areas namely HSE-M, HSE-NE,
HSE-SE and HSE-S commenced using the CIDR system during
2005. (CIDR is described in a separate chapter in this
document). The HSE Areas using CIDR enter infectious
disease notifications directly onto CIDR. HPSC can view these
data using the Business Objects reporting tool on CIDR
(except for patient name and address). For HSE Areas not
using CIDR during 2005, Medical Officers in the HSE Areas
provided case based data to the Director of HPSC by the
Wednesday of each week, on infectious diseases notified to
them during the previous week, using an agreed dataset.2 At
HPSC, this data was inputted to a Microsoft Access database
and then migrated to the CIDR system on the Thursday
evening of each week. Following year-end, extensive data
cleaning and validation was undertaken by HPSC in
conjunction with the HSE Areas. Duplicate notifications were
identified and removed, case classifications were reviewed,
inconsistencies in the data identified and inaccuracies
corrected and notifications were updated with more complete
information if available.
Data for this report were extracted from CIDR on the 5th
September 2006. These figures may differ from those
published previously, due to ongoing updating of notification
data on CIDR. Data analysis was performed using Business
Objects and Microsoft Excel. Case classifications were
assigned to notifications as per the Case Definitions for
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Table 1. Number of notifiable infectious diseases by HSE Area in 2005, total numbers notified in 2005 and 2004 and the comparison between total numbers in 2004 and 2005
Infectious disease HSE-E HSE-M HSE-MW HSE-NE HSE-NW HSE-SE HSE-S HSE-W Total 2005 Total 2004 Increase/
           Decrease
Acute anterior poliomyelitis 0 0 0 0 0 0 0 0 0 0 0
Acute infectious gastroenteritis 717 212 94 167 167 295 364 388 2404 1899 505
Anthrax 0 0 0 0 0 0 0 0 0 0 0
Bacillus cereus food-borne infection/intoxication 0 0 0 0 0 0 0 0 0 1 -1
Bacterial meningitis (not otherwise specified) 11 1 2 2 2 6 4 2 30 36 -6
Botulism 0 0 0 0 0 0 0 0 0 0 0
Brucellosis 1 3 46 1 0 1 0 1 53 60 -7
Campylobacter infection 612 156 140 113 87 230 271 194 1803 1711 92
Cholera 0 0 0 0 0 0 0 0 0 0 0
Clostridium perfringens (type A) food-borne disease * * * * * * * * 1 5 -4
Creutzfeldt Jakob disease * * * * * * * * 4 4 0
Creutzfeldt Jakob disease (new variant) * * * * * * * * 2 0 2
Cryptosporidiosis 38 36 56 62 43 99 105 131 570 431 139
Diphtheria 0 0 0 0 0 0 0 0 0 0 0
Echinococcosis 0 0 0 0 0 0 0 0 0 0 0
Enterohaemorrhagic Escherichia coli 35 16 27 7 7 17 10 15 134 67 67
Giardiasis 27 1 1 2 7 6 5 8 57 53 4
Haemophilus influenzae disease (invasive) 15 3 1 5 0 2 2 6 34 38 -4
Hepatitis A (acute) 18 0 6 4 5 8 5 10 56 47 9
Hepatitis B (acute and chronic) 491 43 45 58 30 62 85 91 905 723 182
Hepatitis C 1062 46 53 48 13 62 63 91 1438 1136 302
Influenza 82 39 117 2 11 15 31 21 318 79 239
Legionellosis 5 0 1 1 0 1 1 0 9 4 5
Leptospirosis 2 1 2 0 4 2 2 2 15 15 0
Listeriosis 2 3 1 2 0 0 1 3 12 11 1
Malaria 12 5 1 10 2 2 10 2 44 27 17
Measles 52 8 6 9 4 7 1 6 93 330 -237
Meningococcal disease 64 21 16 18 11 19 36 18 203 198 5
Mumps 225 55 104 82 174 29 125 289 1083 423 660
Noroviral infection 474 46 107 146 47 52 104 81 1057 1126 -69
Paratyphoid 0 0 0 0 0 0 0 0 0 4 -4
Pertussis 28 2 13 15 3 2 6 14 83 92 -9
Plague 0 0 0 0 0 0 0 0 0 0 0
Q fever 0 0 4 1 0 0 1 4 10 7 3
Rabies 0 0 0 0 0 0 0 0 0 0 0
Rubella 11 0 2 1 1 1 1 0 17 49 -32
Salmonellosis 118 22 19 31 22 51 48 38 349 417 -68
Severe Acute Respiratory Syndrome (SARS) 0 0 0 0 0 0 0 0 0 0 0
Shigellosis 13 5 5 0 0 4 8 1 36 57 -21
Smallpox 0 0 0 0 0 0 0 0 0 0 0
Staphylococcal food poisoning 6 0 0 0 0 0 0 0 6 3 3
Streptococcus group A infection (invasive) 19 1 3 3 3 1 1 18 49 35 14
Streptococcus pneumoniae infection (invasive) 106 7 34 28 4 32 9 37 257 175 82
Tetanus 0 0 0 0 0 0 0 0 0 1 -1
Toxoplasmosis 18 5 2 1 3 9 1 8 47 33 14
Trichinosis 0 0 0 0 0 0 0 0 0 0 0
Tularemia 0 0 0 0 0 0 0 0 0 0 0
Typhoid 3 1 0 0 0 0 0 1 5 5 0
Typhus 0 0 0 0 0 0 0 0 0 0 0
Viral encephalitis 0 0 0 0 2 1 0 3 6 5 1
Viral haemorrhagic fevers 0 0 0 0 0 0 0 0 0 0 0
Viral meningitis 13 3 3 1 1 6 1 7 35 23 12
Yellow fever 0 0 0 0 0 0 0 0 0 0 0
Yersiniosis * * * * * * * * 3 6 -3
*Data not reported to HSE Area level when total figures for Ireland less than five cases      
The EARSS, STI and TB data are not included in this report.  Data on these diseases can be found in separate chapters in this document   
 The 2004 figures shown here may differ from those published previously, due to ongoing updating of notification data on CIDR     
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Table 2. Number of notifiable infectious diseases by age group (years) in 2005    
Infectious disease 0-4  5-9 10-14 15-19  20-24  25-34  35-44  45-54  55-64  65+  Unknown Total
Acute infectious gastroenteritis 2238 32 8 5 8 14 12 6 10 50 21 2404
Bacterial meningitis (not otherwise specified) 13 1 2 3 2 2 2 2 1 2 0 30
Brucellosis 0 0 0 0 0 2 8 16 15 12 0 53
Campylobacter infection 455 124 64 92 154 271 178 151 124 183 7 1803
Clostridium perfringens (type A) food-borne disease 0 0 0 0 0 0 0 0 0 1 0 1
Creutzfeldt Jakob disease 0 0 0 0 0 0 0 0 1 3 0 4
nv Creutzfeldt Jakob disease 0 0 0 0 1 0 0 0 1 0 0 2
Cryptosporidiosis 351 74 29 14 21 34 14 13 4 14 2 570
Enterohaemorrhagic Escherichia coli 55 14 8 7 8 4 16 7 5 10 0 134
Giardiasis 12 2 1 4 4 14 8 8 2 2 0 57
Haemophilus influenzae disease (invasive) 16 2 1 2 0 0 3 2 1 7 0 34
Hepatitis A (acute) 1 1 3 3 2 13 12 4 5 12 0 56
Hepatitis B (acute and chronic) 9 6 5 54 142 391 196 55 27 16 4 905
Hepatitis C 22 8 4 22 190 626 337 155 36 23 15 1438
Influenza 56 42 24 11 12 42 42 23 20 44 2 318
Legionellosis 0 0 0 0 0 0 4 2 1 2 0 9
Leptospirosis 0 0 2 1 2 0 1 3 4 2 0 15
Listeriosis 0 0 0 0 0 0 0 2 2 8 0 12
Malaria 5 3 2 1 5 16 5 5 1 0 1 44
Measles 76 10 3 1 0 0 0 0 0 0 3 93
Meningococcal disease 128 15 12 19 8 3 3 2 8 4 1 203
Mumps 49 87 108 323 302 135 32 22 8 5 12 1083
Noroviral infection 49 5 3 10 16 32 34 54 97 738 19 1057
Pertussis 61 9 5 2 0 0 2 3 0 0 1 83
Q fever 0 1 0 0 0 3 4 1 1 0 0 10
Rubella 16 0 0 0 1 0 0 0 0 0 0 17
Salmonellosis 83 17 19 19 32 53 33 33 24 36 0 349
Shigellosis 3 0 0 1 3 15 9 0 4 1 0 36
Staphylococcal food poisoning 0 0 0 0 0 1 1 1 0 3 0 6
Streptococcus group A infection (invasive) 4 2 2 3 2 5 5 3 7 15 1 49
Streptococcus pneumoniae infection (invasive) 50 8 1 1 6 15 23 22 30 99 2 257
Toxoplasmosis 3 2 1 3 6 16 8 5 2 1 0 47
Typhoid 0 0 1 0 0 2 1 0 1 0 0 5
Viral encephalitis 2 0 0 0 0 2 0 0 0 2 0 6
Viral meningitis 11 5 4 3 3 3 4 1 0 0 1 35
Yersiniosis 2 0 0 0 0 0 1 0 0 0 0 3
Total 3770 470 312 604 930 1714 998 601 442 1295 92 11228
The EARSS, STI and TB data are not included in this report.  Data on these diseases can be found in separate chapters in this document
Notifiable Diseases booklet.3 Incidence rates were calculated
using population data taken from the 2002 census.
Notifiable infectious diseases that were reported through the
weekly infectious disease notification system in 2005 are
presented in this chapter. Therefore, three of the European
Antimicrobial Resistance Surveillance System (EARSS) diseases
(enterococcal bacteraemia, Escherichia coli infection (invasive)
and Staphylococcus aureus bacteraemia), all sexually
transmitted infections (STIs) and tuberculosis (TB) are
excluded. Reports on the EARSS, STI and TB data are included
as separate chapters within this document. A report on
infectious disease outbreaks is also included elsewhere in this
document.
Results
Notifiable infectious diseases
The breakdown of infectious diseases notified in 2005 by HSE
Area, age group, sex and case classification are presented in
tables 1 – 4, respectively. Please note that notifiable diseases
with no cases in 2005 are not presented in tables 2 - 4.
There were 11,228 infectious disease notifications reported to
HPSC during 2005, representing a 20% increase in
notifications compared to 2004 (n=9,336). Acute infectious
gastroenteritis, cryptosporidiosis, hepatitis B, hepatitis C,
influenza and mumps mainly accounted for this increase
(table 1).
Of the 11,228 infectious disease notifications gastrointestinal
diseases accounted for 57.8% of notifications, bloodborne
diseases for 20.9%, vaccine preventable diseases for 11.7%,
respiratory and direct contact diseases for 7.7%, vector borne
and zoonotic diseases for 1.5%, other viral diseases (includes
viral encephalitis, viral haemorrhagic fevers and viral
meningitis) for 0.4% and transmissible spongiform
encephalopathies (Creutzfeldt Jakob disease and new variant
Creutzfeldt Jakob disease) for less than 0.1% of the
notifications (figure 1).
Case classification was assigned for 98% of the notifications in
2005 compared to 81% in 2004. During 2005, 88% were
classified as confirmed, three percent as probable, six percent as
possible, while two percent had no case classification assigned
(table 4).
No cases of acute anterior poliomyelitis, anthrax, Bacillus
cereus food-borne infection/intoxication, botulism, cholera,
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diphtheria, echinococcosis, paratyphoid, plague, rabies, SARS,
smallpox, tetanus, trichinosis, tularemia, typhus, viral
haemorrhagic fevers or yellow fever were notified 
during 2005.
As comprehensive reports on campylobacter infection,
cryptosporidiosis, Enterohaemorrhagic Escherichia coli,
Haemophilus influenzae disease (invasive), hepatitis A (acute),
hepatitis B (acute and chronic), hepatitis C, malaria, measles,
meningococcal disease and bacterial meningitis (not
otherwise specified), mumps, salmonellosis, Streptococcus
group A infection (invasive), Streptococcus pneumoniae
infection (invasive) are presented in separate chapters
elsewhere in this document, these diseases are not discussed
in any further detail here.
Acute infectious gastroenteritis
During 2005, 2,404 cases (61.4/100,000) of acute infectious
gastroenteritis were notified. This is an increase of
approximately 27% compared to 2004 when 1,899 cases 
(48.5/100,000) were notified. In 2005, of the 2,404
notifications 94% (n=2,251) were due to rotavirus while in
2004 of the 1,899 notifications, 84% (n=1,600) were due to
rotavirus. This represents a 41% increase in the number of
rotavirus specified under acute infectious gastroenteritis in
2005 compared to 2004. Rotavirus is discussed further in a
separate chapter in this document.
Brucellosis
During 2005, 53 cases of brucellosis were notified compared
to 60 notifications in 2004. Case classification was provided
for 52 of the notifications; seven were classified as confirmed
while 45 were classified as probable. The number of
notifications in 2005 and 2004 appears to be a significant
increase on the previous ten years when on average there
were 11 notifications each year. However, it is important to
bear in mind that cases are now being notified by laboratories
that would previously have gone unreported and the
notifications classified as probable may be a reflection of past
infection rather than acute infection as many of the
laboratory reports were based on an isolated high titre result.
Forty-nine of the cases (92%) in 2005 were male while four
(8%) were female. The cases ranged in aged from 30 years to
83 years (mean age, 55 years; median age, 55 years).
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Figure 2.  Influenza notifications by week and month of notification in 2005 
Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
Influenza A Influenza B Influenza not typed Organism not reported
1 3 5 7 9 11 13 15 17 19 21 23 25 27 29 31 33 35 37 39 41 43 45 47 49 51
Figure 1.  Infectious disease notifications in 2005 by disease category
(Please note the EARSS, STI and TB data are not included in these figures).
Gastrointestinal Vectorborne and zoonotic
Bloodborne Other viral
Vaccine preventable Transmissable spongiform
encephalopathiesRespiratory and direct contact
57.83%
20.87%
11.67%
1.51%
0.05%
0.37% 7.71%
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Table 3. Number of notifiable infectious diseases by sex in 2005
Infectious disease    Male Female  Unknown  Total
Acute infectious gastroenteritis 1227 1125 52 2404
Bacterial meningitis (not otherwise specified) 18 12 0 30
Brucellosis 49 4 0 53
Campylobacter infection 968 825 10 1803
Clostridium perfringens (type A) food-borne disease 0 1 0 1
Creutzfeldt Jakob disease 1 3 0 4
nv Creutzfeldt Jakob disease 1 1 0 2
Cryptosporidiosis 309 259 2 570
Enterohaemorrhagic Escherichia coli 62 71 1 134
Giardiasis 32 24 1 57
Haemophilus influenzae disease (invasive) 15 19 0 34
Hepatitis A (acute) 24 32 0 56
Hepatitis B (acute and chronic) 480 373 52 905
Hepatitis C 918 502 18 1438
Influenza 154 163 1 318
Legionellosis 8 1 0 9
Leptospirosis 14 1 0 15
Listeriosis 6 6 0 12
Malaria 21 21 2 44
Measles 52 40 1 93
Meningococcal disease 113 90 0 203
Mumps 620 457 6 1083
Noroviral infection 445 609 3 1057
Pertussis 43 40 0 83
Q fever 9 1 0 10
Rubella 8 9 0 17
Salmonellosis 168 179 2 349
Shigellosis 14 21 1 36
Staphylococcal food poisoning 4 2 0 6
Streptococcus group A infection (invasive) 25 24 0 49
Streptococcus pneumoniae infection (invasive) 149 108 0 257
Toxoplasmosis 18 28 1 47
Typhoid 3 2 0 5
Viral encephalitis 3 3 0 6
Viral meningitis 25 10 0 35
Yersiniosis 1 2 0 3
Total 6007 5068 153 11228
The EARSS, STI and TB data are not included in this report.  Data on these diseases can be found in separate chapters in this document 
Clostridium perfringens (type A) food-borne disease
One case of Clostridium perfringens (type A) food-borne
disease was notified during 2005 compared to five cases in
2004. The case in 2005 was aged greater than 65 years.
Creutzfeldt Jakob disease 
In 2005, four cases of classical Creutzfeldt Jakob disease (CJD)
were notified. This is identical to 2004 when four cases were
also notified. All four cases in 2005 were aged greater than
55 years and three cases occurred in females.
nv Creutzfeldt Jakob disease
Two cases of new variant Creutzfeldt Jakob disease (nvCJD)
were notified during 2005. One case was in the age group
20-24 years while the second case was in the age group 55-
64 years. Only one other case of nvCJD was notified since
nvCJD became notifiable in 1997; this case was notified
in 1999.
Giardiasis
Fifty-seven cases of giardiasis were notified in 2005, giving a
notification rate of 1.5 per 100,000 total population. This is
similar to 2004 when 53 cases were notified. In 2005, the
cases ranged in age from 7 months to 74 years (mean age, 28
years; median age, 29 years). Twenty-four of the cases were
female, 32 were male while gender was unreported for one
case. Case classification was reported for 53 notifications; all
53 were classified as confirmed.
Influenza
Three hundred and eighteen cases of influenza were notified
in 2005, giving a notification rate of 8.1 per 100,000
population. This is a four-fold increase compared to 2004
when 79 cases of influenza were notified. Over a third
(n=116) of influenza notifications were in February (Weeks 5-
8) of 2005 with 21% (n=66) in Week 5 of 2005 (figure 2).
Twenty-one of the 116 influenza notifications in February had
onset dates reported, of these 15 had onset dates in late
2004. The peak in notifications during Week 17 was due to a
school outbreak of influenza that occurred in the HSE-M
during Week 16.
Of the 318 influenza notifications during 2005, 216 were
reported as influenza A virus, 65 as influenza B virus while
organism details were not reported for the remaining 37
notifications. Thirty-four cases were classified as possible
while the remaining 284 were classified as confirmed.
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Based on data obtained through the influenza sentinel
surveillance system, a report on influenza activity during the
2005/2006 season is included elsewhere in this document
while a report on influenza activity during the 2004/2005
season in available on the HPSC website.4  
Legionellosis
Nine cases of legionnaires’ disease were notified in 2005. All
nine cases were aged greater than 35 years. Eight of the
cases were male and one was female. Seven of the cases
were classified as confirmed while two were classified as
probable. There was one death. Of the nine cases, two were
community-acquired, two were hospital-acquired, and five
were travel-associated. Countries of travel included France,
Spain and Turkey. A case of legionnaires’ disease is defined as
travel-associated if the patient spent one or more nights away
from their home in accommodation used for commercial or
leisure purposes e.g. hotels, holiday apartments etc. in the 10
days before the onset of illness. Travel-associated cases may
involve travel within Ireland or travel abroad. All travel-
associated cases in 2005 were notified to the European
Working Group for Legionella Infections (EWGLI) surveillance
scheme. The aim of this surveillance scheme is to detect
cases of travel-associated legionnaires’ disease and thereby
rapidly identify outbreaks and implement control measures.5
Leptospirosis
Fifteen cases of leptospirosis were notified in 2005 identical
to 2004 when 15 cases were also notified. All except one of
the cases in 2005 were male (93%) and all cases were aged
between 14 and 76 years (mean age, 43 years; median age, 51
years). Risk exposures reported included occupational
exposure through farming activities (n=4), outdoor
recreational contact with water (n=2) and exposure in or
around the home/garden (n=2). There was also one case that
reported accidental exposure to pond water. The species
implicated was reported as Leptospira interrogans hardjo for
two cases; species was not reported for the remaining 13
cases.
Listeriosis 
Twelve cases of listeriosis were notified in 2005 compared to
Table 4. Number of notifiable infectious diseases by case classification in 2005   
Infectious disease Confirmed Probable Possible Not Specified Total
Acute infectious gastroenteritis 2251 151 0 2 2404
Bacterial meningitis (not otherwise specified) 8 5 17 0 30
Brucellosis 7 45 0 1 53
Campylobacter infection 1794 1 0 8 1803
Clostridium perfringens (type A) food-borne disease 1 0 0 0 1
Creutzfeldt Jakob disease 4 0 0 0 4
nv Creutzfeldt Jakob disease 2 0 0 0 2
Cryptosporidiosis 565 0 0 5 570
Enterohaemorrhagic Escherichia coli 134 0 0 0 134
Giardiasis 53 0 0 4 57
Haemophilus influenzae disease (invasive) 34 0 0 0 34
Hepatitis A (acute) 48 0 6 2 56
Hepatitis B (acute and chronic) 777 44 0 84 905
Hepatitis C 1432 0 0 6 1438
Influenza 284 0 34 0 318
Legionellosis 7 2 0 0 9
Leptospirosis 14 0 0 1 15
Listeriosis 11 0 0 1 12
Malaria 43 0 0 1 44
Measles 11 0 76 6 93
Meningococcal disease* 180 7 16 0 203
Mumps 436 85 488 74 1083
Noroviral infection 1037 16 0 4 1057
Pertussis 33 6 30 14 83
Q fever 2 4 0 4 10
Rubella 0 0 15 2 17
Salmonellosis 344 1 0 4 349
Shigellosis 36 0 0 0 36
Staphylococcal food poisoning 6 0 0 0 6
Streptococcus group A infection (invasive) 47 0 0 2 49
Streptococcus pneumoniae infection (invasive) 251 1 4 1 257
Toxoplasmosis 47 0 0 0 47
Typhoid 5 0 0 0 5
Viral encephalitis 6 0 0 0 6
Viral meningitis 8 23 0 4 35
Yersiniosis 3 0 0 0 3
Total 9921 391 686 230 11228
*As per the case definitions, meningococcal disease notifications are classified as definite, presumed and possible. For convenience they are reported in this table as confirmed, probable 
and possible, respectively.
The EARSS, STI and TB data are not included in this report.  Data on these diseases can be found in separate chapters in this document   
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11 in 2004. The cases in 2005 ranged in age from 48 years to
83 years (mean age, 68 years; median, 71 years) and 50%
were male. Ten cases were reported either as elderly (>64
years) or as suffering from an underlying illness that
predisposed them to listeriosis. No information on risk factors
was available for the remaining two cases but one was aged
over 55 years. No pregnancy-associated or neonatal cases
were reported. Clinical presentations included septicaemia
(n=5), meningitis (n=1) and peritonitis (n=1); no clinical
information was provided for the remaining five cases.
Noroviral infection
There were 1,057 noroviral infection notifications during
2005, giving a notification rate of 27.0 per 100,000
population. In 2004, there were 1,126 noroviral notifications.
In 2005, the majority (n=738, 70%) of notifications and the
highest age specific rates (169.3/100,000) were in those aged
greater than 64 years. Gender was reported for 1,054 cases,
of these 609 cases (58%) were female and 445 (42%) were
male.
Pertussis
There were 83 (2.1/100,000) pertussis notifications in 2005
compared to 92 in 2004. The majority (90%) of cases in 2005
were aged less than 15 years with 73% of cases in the age
group 0-4 years. Forty-three cases were male while 40 were
female. Thirty-three cases (40%) were classified as confirmed,
six (7%) as probable, 30 (36%) classified as possible and 14
(17%) had no case classification assigned. There is no
enhanced surveillance system in place for pertussis so
additional information, such as detailed vaccination history of
the cases is not available.
Q Fever
Ten cases of Q fever were notified during 2005 compared to
seven in 2004. In 2005, nine cases occurred in males and one
in a female. The cases ranged in age from six years to 55
years (mean age, 36 years; median age, 36 years). Case
classification was provided for six notifications; two were
classified as confirmed and four as probable.
Rubella
During 2005, 17 rubella cases were notified compared to 49
in 2004 and 59 in 2003. Case classification was provided for
15 of the rubella notifications; all 15 were classified as
possible. Sixteen of the cases (94%) notified in 2005 were 
aged less than four years. Eight cases were male and nine
were female.
Shigellosis
Thirty-six cases (0.9/100,000) of shigellosis were notified in
2005 compared to 57 in 2004 and 36 in 2003. The majority
of cases (89%) in 2005 occurred in those aged 20 years or
older. Of the 36 cases notified, 22 were due to Shigella
sonnei, 12 due to Shigella flexneri while species was not
reported for the remainder. All 36 cases were classified as
confirmed. Twenty-one cases were female, 14 were male
while gender was not reported for one case.
Staphylococcal food poisoning
Six cases of staphylococcal food poisoning were notified
during 2005 compared to three in 2004. The cases in 2005
ranged in age from 28 to 93 years. All six cases were
classified as confirmed.
Toxoplasmosis
During 2005, 47 cases of toxoplasmosis were notified
compared to 33 in 2004. Three of the cases in 2005 were
reported as congenital cases, the first congenital cases
reported since the condition became notifiable in 2004.
Congenital cases are identified through a pilot toxoplasmosis
screening program which commenced in July 2005, and is co-
ordinated at the Rotunda Hospital in conjunction with the
National Newborn Screening Laboratory.
The remaining 44 cases ranged in age from 5 years to 93
years (mean age, 33 years; median, 29 years). Of the 44 cases
twenty-five were female, 18 male while gender was not
reported for one case.
Typhoid
Five cases of typhoid were notified during 2005 identical to
2004 when five cases were also notified. The cases in 2005
ranged in age from 10 to 55 years (mean age, 33 years;
median age, 33 years). Three of the cases were male and two
were female. The countries of infection were India (n=1),
Nigeria (n=1), Pakistan (n=1) and not reported (n=2). All five
cases were classified as confirmed.
Viral encephalitis
Six cases of viral encephalitis were notified in 2005, similar to
five cases in 2004. All six cases in 2005 were classified as
confirmed. Herpes simplex virus was reported as the
causative organism for two cases; the causative organism was
not reported for the remainder.
Viral meningitis
In 2005, 35 (0.9/100,000) cases of viral meningitis were
notified compared to 23 in 2004 and 39 cases in 2003. Sixty-
six percent (n=23) of cases in 2005 occurred in those aged
less than 20 years with over 30% (n=11) in the age group 0-4
years. The majority of viral meningitis notifications in 2005
were male (n=25). Of the 35 notifications, eight were
classified as confirmed, twenty-three as probable while case
classification was not specified for the remainder. The
causative organisms were reported as Coxsackievirus A (n=1),
Coxsackievirus B (n=1) while the causative organisms were
not reported for the remainder.
Yersiniosis
Three cases of yersiniosis were notified during 2005 compared
to six in 2004. All three cases in 2005 were classified as
confirmed. Two of the cases were less than one year of age.
Discussion
Overall, the number of notifications in 2005 reported to HPSC
through the weekly infectious disease notification system
(n=11,228) increased by 20% compared to 2004 (n=9,336).
These figures exclude the EARSS organisms (S. pneumoniae is
an exception and should be reported through both systems),
STI and TB data that are presented as separate chapters in
this document. A small subset of notifiable diseases
contributed to most of this increase in 2005 compared to
2004. Cryptosporidiosis notifications increased by 32%, acute
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infectious gastroenteritis and hepatitis C notifications by 27%
and hepatitis B notifications by 25% compared to 2004.
There was a 2.6-fold increase in mumps notifications during
2005 (n=1,083) compared to 2004 (n=423). This was due to
an outbreak that started towards the end of 2004 and
continued in 2005. The mumps outbreak is discussed further
in a separate chapter in this document.
Influenza notifications increased four-fold in 2005 (n=318)
compared to 2004 (n=79). Notifications peaked in February
2005 when a third of all the cases were notified. However,
this peak was probably due to a delay in notifying rather than
any true peak in influenza activity at that time in 2005. This
observation is supported by the fact that of the 21
notifications in February 2005 with onset dates reported (out
of a total of 116) 15 had onset dates in late 2004 and
furthermore the influenza sentinel surveillance system
observed an increase in influenza-like illness towards the end
of 2004 with a peak in the first week of 2005 and not in
February 2005, which coincides with the onset/occurrence
date of the late notifications.
Gastrointestinal illnesses account for over half of the
notifications reported through the weekly infectious disease
reporting system in 2005, with blood-borne, vaccine
preventable and respiratory and direct contact diseases
accounting for most of the remainder. However, in addition
to the 11,228 infectious disease notifications presented in this
chapter for 2005, there were also 3,784 reports of EARSS
organisms and 461 TB notifications (provisional figure). A
final figure for STI notifications in 2005 is not yet available,
however, more than likely it will be of similar magnitude to
2004, when 10,695 cases were notified. These figures indicate
the burden of disease due to the notifiable infectious diseases
in Ireland, with STIs contributing to a substantial proportion
of that burden.
The amendment, S.I. No. 707 of 2003 that came into effect in
January 2004 introduced the use of case definitions for
infectious diseases for the first time in Ireland. Case
definitions allow more effective analysis and interpretation of
notification data. Case classification was assigned for 98% of
the notifications in 2005. This is a considerable improvement
compared to 2004 when case classifications were assigned for
81% of notifications. Standard operating procedures for the
HSE Areas using CIDR during 2005 may have played an
important role in the improvement in assigning case
classifications to notification data during 2005. For those
using CIDR, data entry, data cleaning and data validation
checks are approached by all users in a relatively standardised
way, thereby, helping to improve the quality of the
notification data and the efficiency with which data 
are managed.
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Computerised Infectious 
Disease Reporting System (CIDR)
Key Points
• CIDR is the new national shared information system
used to manage the surveillance and control of
infectious diseases in Ireland.
• CIDR national roll-out commenced in early 2005 and is
now being used in six of the eight HSE areas (covering
80% of the population).
• All information in CIDR is held in a single shared
national information repository. As a web-based system
(built using modern internet technologies) CIDR allows
the rapid reporting and appropriate sharing of clinical
and laboratory information among CIDR users.
• CIDR has been found to be a robust and secure system
that can be adapted to meet the changing surveillance
needs in Ireland 
• CIDR has been awarded the IS17799 accreditation for
information security management. HPSC, including CIDR,
is the first public sector body in Ireland to be awarded
this accreditation.
• HPSC uses CIDR for the routine collation and analysis of
infectious disease notifications.
Computerised Infectious Disease Reporting System (CIDR)
Computerised Infectious Disease Reporting (CIDR) is the new
national shared information system used to manage the
surveillance and control of infectious diseases in Ireland.
CIDR national roll-out commenced in early January 2005 and
is now being used in six of the eight HSE areas (covering 80%
of the population).
All information in CIDR is held in a single shared national
information repository. As a web-based system (built using
modern internet technologies) CIDR allows the rapid reporting
and appropriate sharing of clinical and laboratory information
among CIDR users.
CIDR has been found to be a robust and secure system that
can be adapted to meet the changing surveillance needs in
Ireland. CIDR has been awarded the IS17799 accreditation for
information security management. HPSC, including CIDR, is
the first public sector body in Ireland to be awarded this
accreditation. HPSC uses CIDR for the routine collation and
analysis of infectious disease notifications.
Background 
Computerised Infectious Disease Reporting (CIDR) system was
developed by the HPSC in collaboration with its partners; the
DoHC, the HSE areas, the FSAI and the FSPB. CIDR utilises
modern internet-based technologies. CIDR is now providing
an integrated and standardised electronic surveillance system
to collect, collate, analyse and disseminate good quality
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laboratory-based and clinical notification data on
communicable disease in a timely manner in Ireland.
CIDR allows:
• The provision of timely and comprehensive information to
facilitate public health action in individual cases of infectious
disease
• The generation of standard reports on the incidence and
burden of infectious diseases nationally, regionally, and
locally
• Evaluation of the effectiveness of prevention and control
programmes nationally, regionally and locally 
CIDR System 
CIDR was designed in 2002, and development and testing of
the system took place between 2003-2004. CIDR was
successfully piloted in 2004 in HSE North East and reference
laboratories, following which national implementation was
recommended by CIDR Board.
The CIDR system uses the latest .NET development
environment with SQL Server 2000 as the backend database
and makes extensive use of XML technology, in line with the
inter-operability requirements of e-government initiatives.
Ensuring that information within CIDR is stored and accessed
appropriately is key to CIDR. A number of data security
protection systems are in place; access to the system is
provided via the Government Virtual Private Network (G-
VPN); the core system is firewall-protected; information is
encrypted before being transferred from local PCs to the core
system; and access to the system is limited to authorised
users (username, password and user authentication required
by unique RSA key fobs). CIDR was accredited with the
IS17799 in February 2005.
CIDR users in public health departments and clinical
microbiology laboratories enter and retrieve infectious disease
information from CIDR via standard browser software on their
personal computers. No additional software is required.
CIDR reporting
The information collected and stored by CIDR is available for
analysis utilising a report writing / business intelligence
application called ‘Business Objects’. This software enables
information to be retrieved from complex relational databases
in a user-friendly fashion yet leaves the underlying data safe.
In Business Objects there is a set of reports that are available
to all users (Corporate Documents). All users can run these
reports, however the data and the level of detail returned will
depend on the user’s access rights. Business Objects can also
be used to create reports.
CIDR implementation in 2005 
CIDR Project Board recommended national CIDR roll-out in
November 2004. In early 2005, CIDR roll-out implementation
began in a phased manner.
Table 1. CIDR implementation in Public Health Departments and Hospital laboratories
HSE area Public Health implementation  Hospital Laboratory implementation(by date and laboratory site)
Reference laboratories  May 2004 NVRL, NMRL, NSRL, MRSA†
HSE North East May 2004 May 2004 Our Lady of Lourdes, Drogheda; Navan; Cavan-Monaghan; Dundalk
HSE-Midlands April 2005 April 2005 Mullingar/Tullamore/Port Laois 
HSE South July 2005 January 2006  Mercy Hospital 
HSE South East October 2005 October 2005 Waterford Regional Hospital 
HSE North West February 2006 Not yet implemented
HSE East June 2006 June 2006 St. James’ Hospital 
HSE Mid-west Not yet implemented Not yet implemented
HSE West Not yet implemented Not yet implemented
* Pilot implementation in May 2004, CIDR “go-live” from February 2005 
† National Virus Reference laboratory (NVRL); National Meningococcal Reference laboratory (NMRL); National MRSA reference laboratory (NMRSAL); National Salmonella Reference 
Laboratory (NSRL).
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Rolling CIDR out nationally has required an on-going and
close collaboration between the different HSE directorates
(Population Health, National Hospitals Office and National
Information and Communication Technology Office
Directorate), HSE areas (Departments of Public Health,
regional hospital microbiology laboratories, and IT staff) and
the national CIDR team.
CIDR implementation in Departments of Public Health
and laboratories
By the end of 2005 CIDR was implemented in four HSE areas,
another two HSE areas implemented CIDR in the first six
months of 2006. Laboratories have implemented CIDR in
tandem with, or closely following, regional public health
department implementation where possible. However, in
some areas laboratories have not been able to implement
CIDR simultaneously (table 1). However, with time, additional
laboratories are implementing CIDR, thus facilitating the
notification process of notifiable infectious diseases.
CIDR implementation in laboratories has required close liaison
between CIDR team, and the relevant laboratory personnel.
Prior to implementation all laboratories review and document
their current business processes in relation to infectious
disease notification, and also document the expected practice
when each laboratory participates in CIDR.
Laboratory notifications are entered in to CIDR via manual
entry or via a data extract from the relevant Laboratory
Information Management System (LIMS). The CIDR design is
open and flexible enough to accept data from systems other
than LIMS e.g. MS Access databases.
CIDR Disaster Recovery / Business Continuity
The core CIDR system is physically located within the
premises of HPSC. Data is backed up daily and stored securely
off-site. As part of a business continuity plan, in the event of
unanticipated loss of equipment or access to that equipment,
a disaster recovery / business continuity solution was
developed, in conjunction with Fujitsu. This Business
Continuity solution replicates data via the Government VPN
to a Disaster Recovery CIDR environment hosted off-site. The
Disaster Recovery system has been tried and tested on a
number of occasions and has demonstrated that this solution
can support business continuity in the event of the main
system being down.
CIDR training 
There are now more than 200 CIDR users across the six HSE
CIDR using sites, HPSC and reference laboratories. All CIDR
users must complete data protection training prior to CIDR
application training. There is separate training for public health
and laboratory CIDR users, relevant to their needs. Additional
advanced CIDR training is provided to high-level public health
CIDR users. CIDR training is provided in HPSC and is delivered
by HPSC staff who are trained for this purpose.
Supporting CIDR users
CIDR helpdesk
CIDR helpdesk is manned by designated HPSC/CIDR helpdesk
staff. The helpdesk is available during normal working hours
and can be accessed via email or telephone. All calls are
logged and are dealt with by CIDR operations or technical
staff.
Figure 1. CIDR national implementation progress by HSE area  (July 2006)
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CIDR user group
As part of good information governance a national CIDR user
group was convened in December 2005. This group meets
quarterly. The CIDR user group members represent the
nominated public health and laboratory CIDR users from each
of the HSE CIDR using areas. These meetings provide CIDR
users with a forum to compare and discuss various aspects of
CIDR.
CIDR user group members review updates and upgrades to
the CIDR system and feed in questions and suggestions on
CIDR operation. Suggestions come from CIDR users locally,
through the CIDR helpdesk, or from CIDR team. At these
meetings CIDR team highlights any issues that have arisen in
the last quarter and presents solutions and recommendations
for standardisation of data and business processes to the
CIDR user group. The views of the user group will be taken
into account in any updates or upgrades of the CIDR system.
CIDR user group members feedback to their regional CIDR
users via their local CIDR user groups.
CIDR communications
CIDR newsletter is distributed bi-or tri-monthly to all CIDR
users and is available on the HPSC website. Additional
information on CIDR (Frequently asked Questions, News,
Training, Presentations and Committees) is available on the
HPSC website at http://www.ndsc.ie/hpsc/CIDR/.
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Measles in Ireland, 2005
Key Points
• There were 93 measles notifications in 2005
• The crude incidence rate of measles per 100,000
population in 2005 was 2.4 compared to 8.4 in 2004 and
14.6 in 2003 
• Of the 93 measles notifications 12% were classified as
confirmed, 82% were classified as possible and six
percent had no case classification assigned
Introduction
Measles is an acute viral infectious disease characterised by
high fever, cough, conjunctivitis, runny nose and rash.
Complications of measles include otitis media, pneumonia,
croup, diarrhoea and encephalitis. Measles results in death in
approximately one to two cases per 1,000 population. In
Ireland, three measles deaths were reported during 2000. Two
of these deaths were as a result of pneumonia complicating
measles and one was due to post-measles encephalitis.
Measles is highly contagious but can be prevented by
vaccination. Measles vaccine in Ireland is currently available
as part of the combined measles-mumps-rubella (MMR)
vaccine. More than 99% of individuals who receive two MMR
doses (provided the first dose is given after their first
birthday) develop immunity to measles. Two doses of MMR
are required to ensure protection, as two to five percent of
children fail to respond to one dose of MMR. In Ireland,
vaccination with the first dose of MMR (MMR1) is
recommended at twelve to fifteen months of age and the
second dose (MMR2) at four to five years of age.
The number of measles notifications, in Ireland, by year since
1948 is shown in figure 1. The highest number of
notifications was in 1959, with 15,134 cases reported. In the
1970s an average of 2,327 cases of measles were notified
each year with an average of seven deaths every year from
measles. In 1985 there were nearly 10,000 measles
notifications, this was the same year a measles vaccine was
HPSC Annual Report 2005 75
first introduced into Ireland. By 1991 the number of measles
notifications had dropped to 135.
Since 2000 measles is notified weekly to HPSC. HPSC
routinely publishes a national measles report that is
distributed to those involved in measles control and
surveillance in Ireland. HPSC also forwards the measles
notification data to the EU measles surveillance network
EUVAC.NET and to the World Health Organisation (WHO) on
a monthly basis.
This review summarises the 2005 measles notification data.
Materials and Methods
During 2005, for HSE Areas using the CIDR system, measles
notifications were inputted directly on CIDR at regional level.
HPSC can view this data using the Business Objects reporting
tool on CIDR (except for patient name and address). For HSE
Areas not using CIDR, anonymous notifications were sent to
HPSC and these data were inputted on CIDR by HPSC.
Measles data presented in this report were taken from the
CIDR system on the 19th September 2006. These figures may
differ from those published previously, due to ongoing
updating of notification data in CIDR.
Case classifications are assigned to measles notifications as
per the Case Definitions for Notifiable Diseases.1 Analysis of
measles data was carried out using Business Objects and
Microsoft Excel. Incidence rates were calculated based on
population data taken from the 2002 census.
Results
Incidence
A total of 93 measles cases were notified during 2005, giving
a crude incidence rate of 2.4 per 100,000 population. In
contrast, the crude incidence rate was 8.4 per 100,000 in
2004 and 14.6 per 100,000 in 2003. The annual number of
notifications in 2005 is the lowest since 1948 when measles
was specified as a notifiable disease under the Health Act,
1947 (figure 1).
The breakdown of measles cases by HSE Area and the crude
incidence rates by HSE Area during 2005 are presented in
table 1. The highest number of notifications was in the HSE-E
(n=52, 56%) followed by the HSE-NE (n=9, 10%). The
highest crude incidence rate in 2005 was in the HSE-E
(3.7/100,000) followed by the HSE-M (3.5/100,000).
There were on average two notifications each week during
2005. No outbreaks of measles were notified during 2005.
Case classification 
Case classification was provided for 94% (n=87) of measles
notifications in 2005. Of the 93 notifications in 2005, 11
(12%) were classified as confirmed, 76 (82%) as possible
while case classification was not provided for six (6%)
notifications. All 11 notifications classified as confirmed were
laboratory confirmed.
Age and sex distribution
A breakdown of measles notifications by age group and the
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Figure 1.  Annual number (log scale) of measles notifications in Ireland 1948-2005 and year of 
introduction of measles and MMR vaccine.  (A measles and rubella campaign for primary
school-age children was conducted in 1995).
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age specific incidence rates per 100,000 population in 2005
are presented in table 2. All measles notifications, where age
was reported, were aged less than 20 years. The highest
number of notifications (n=41, 44%) in 2005 was in those
aged 1-2 years followed by those aged less than one year
(n=27, 29%) and those aged 5-9 years (n=10, 11%). The
highest incidence rates in 2005 were in those aged less than
one year (49.5/100,000) and 1-2 years (36.7 /100,000). Of
the 93 measles notifications, 52 were male, 40 were female,
while sex was not reported for one notification.
Laboratory data
Laboratory results were provided to HPSC for 24 (24/93, 26%)
measles notifications. Eleven of these were laboratory positive
for measles while 13 were negative for measles (table 3).
Oral fluid specimens should be obtained between one and five
weeks following the appearance of the rash. Samples
obtained less than one week after rash onset may lead to a
false negative result. Of the 13 laboratory negative measles
cases, 12 had oral fluid specimens sent for laboratory testing.
Four of these negative oral fluid specimens were taken less
than seven days after onset while five had no specimen date
reported. The remaining negative oral fluid specimens were
taken greater than one week following onset.
As measles vaccine induces a positive measles IgM response a
positive IgM test cannot be used to confirm the diagnosis of
measles in individuals who received measles vaccine six to 45
days before rash onset. Of the 11 laboratory positive measles
notifications two had received at least one dose of vaccine.
The date of vaccination in relation to onset of disease was not
provided for one of these while the second case was
vaccinated two years prior to onset.
Vaccination data
Vaccination status was reported for 59 (63%) of the 93
notifications. Thirty-six cases (36/59, 61%) were
unvaccinated. Seventeen percent (6/36) of those
unvaccinated were aged greater than 15 months and
therefore, were potentially eligible for vaccination with MMR1
(assuming there were no contraindications to vaccination).
Five cases (5/59, 8%) were vaccinated with MMR1 only. All
five cases were aged less than six years. Of the five cases
vaccinated with MMR1; one received the vaccine less than 18
days prior to onset suggesting the possibility they may have
been incubating measles at the time of vaccination; three
were vaccinated greater than six months prior to onset; the
date of vaccination in relation to disease onset was not
reported for one case. An additional 12 cases received at least
one dose of MMR. The MMR1 vaccination dates were reported
for six of these notifications; all six were vaccinated greater
than three months prior to onset.
Six cases received MMR2. The dates of vaccination were only
reported for three of the six cases. None of these cases were
reported as laboratory confirmed; therefore, none of these six
        
Table 2.  Number of measles notifications by age group and age specific incidence rate per 
100,000 population (ASIR) in 2005   
Age group (years)   Number ASIR
<1  27 49.5
1-2  41 36.7
3-4  8 7.2
5-9  10 3.8
10-14  3 1.1
15-19  1 0.3
20-24  0 0.0
25+  0 0.0
Unknown  3 -
Total   93 2.4
        
Table 1.  Number of measles notifications and crude incidence rates (CIR) per 100,000 
population by HSE Area in 2005      
HSE Area     Number CIR
HSE-E  52 3.7
HSE-M  8 3.5
HSE-MW  6 1.8
HSE-NE  9 2.6
HSE-NW  4 1.8
HSE-SE  7 1.7
HSE-S  1 0.2
HSE-W  6 1.6
Total   93 2.4
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cases are known to be, or can be, classified as vaccine failures
based on the data provided.
Hospitalisation data & complications of measles
Information on hospitalisation status was available for 38
cases (38/93, 41%). Five cases were hospitalised representing
13% (n=5/38) of all cases with known hospitalisation status
(table 4). The length of hospital stay was only reported for
two notifications, with the length of stay ranging from seven
to nine days. The hospitalised cases ranged in age from 8 to
18 months.
Three of the hospitalised cases were unvaccinated; all three
were aged less than 15 months. One hospitalised case, aged
18 months, had received one dose of MMR (date of
vaccination was not provided). Vaccination status was not
provided for the remaining hospitalised case.
Information on measles associated complications was
reported for 10 (10/93, 11%) notifications. One case was
reported to have a lower respiratory tract infection. The nine
remaining cases were reported to have no complications. No
measles deaths were reported among the 93 measles
notifications. However, the Central Statistics Office reported
one measles death in 2005 in a case in the age group
25-34 years.
Discussion
During 2005, there were only 93 measles notifications in
Ireland. This is a 3.5-fold decrease compared to 2004 (n=330)
and a six-fold decrease compared to 2003 (n=572) and is the
lowest number of measles notifications recorded since 1948
when measles was specified as a notifiable disease under the
Health Act, 1947 (figure 1). The WHO has targeted 2010 for
eliminating measles and reducing the incidence of congenital
rubella infection to less than one case of congenital rubella
syndrome per 100,000 live births in the WHO European
Region. In order to achieve measles elimination in Ireland it is
essential that all suspected measles cases are notified.
Strengthening of measles surveillance will be a critical
component in the control and elimination of this disease.
Measles surveillance is required to detect cases and to
understand the reasons for the occurrence of this disease so
that appropriate and timely control measures can be
implemented.
Measles can be difficult to diagnose clinically. It is important
that follow-up laboratory information is provided for accurate
surveillance. For elimination it is also essential that all
suspected cases have specimens sent for laboratory testing.
Of the 93 measles notifications in 2005, 74% (n=69/93)
either had no specimen sent for laboratory testing or had no
laboratory results reported. Laboratory testing is a very
important part of measles surveillance. Good surveillance and
laboratory data provide evidence, where there is low
incidence, that the absence of notifications is attributable to
the absence of disease rather than to inadequate detection
and reporting.
Table 3. Measles laboratory test results (n=24).
                             Laboratory Result 
Specimen type Positive Negative Total
Oral fluid sample 4 12 * 16
Serum sample 6 1 † 7
Oral fluid and serum samples 1 0 1
Total 11 13 24 ‡
* specimen date in relation to onset date not reported for 5 cases, and for 4 cases the 
specimen was taken <7 days after onset 
 †specimen taken <7 days after onset 
‡laboratory results were only provided for 24 of the 93 notifications 
Table 4.  Number of measles notifications in Ireland by age group and hospitalisation status during 2005       
Age group (years) Hospitalised Not hospitalised Not reported/unknown Total
<1 3 10 14 27
1-2 2 17 22 41
3-4 0 1 7 8
5-9 0 5 5 10
10-14 0 0 3 3
15-19 0 0 1 1
20-24 0 0 0 0
25+ 0 0 0 0
Unknown 0 0 3 3
Total 5 33 55 93
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For Ireland to achieve the WHO target, of measles elimination
and preventing congenital rubella infection, it is also essential
that all rubella and congenital rubella cases are notified. It is
again important to have follow-up laboratory information as
rubella can also be difficult to diagnose clinically and often
measles and rubella are clinically indistinguishable. During
2005 only 17 rubella cases were notified; 15 of these were
classified as possible while two had no case classification
assigned. This low number suggests rubella is underreported
in Ireland. (Rubella data are described in the infectious
disease chapter in this document.)
The incompleteness of measles surveillance data provided to
HPSC continues to be a major limitation. For example,
vaccination status was not provided for over a third of
notifications. Also, for a number of cases, where vaccination
status was provided, the date of vaccination in relation to
disease onset was not reported, making interpretation of the
vaccination data difficult. Good vaccination data allow
informed decisions to be made about where vaccination
coverage should be improved. To prevent outbreaks occurring
it is important to monitor what populations are unvaccinated.
As measles surveillance and data quality are improved so to
will the ability to control and prevent measles cases thereby
aiding elimination of measles in Ireland.
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Mumps in Ireland, 2004-2005
Key Points
• A national mumps outbreak that commenced in
November 2004 continued during 2005
• The outbreak was predominantly in those born before
1988, particularly those born between 1983 and 1986,
who were not scheduled to receive two MMR doses
during childhood as MMR was first introduced in 1988
• An outbreak control team was convened in November
2004 and control measures implemented
• As outbreaks were reported in a number of third level
colleges all new entrants, in autumn 2005, were
recommended MMR vaccine (if not previously 
vaccinated with two doses) 
Introduction
Mumps is an acute viral infectious disease characterised by
fever and swelling of one or more salivary glands, most
commonly the parotid gland. Mumps infection can present
with other symptoms such as meningitis or pancreatitis.
Mumps infection  may also cause inflammation of the ovaries,
testicles or breast tissue. More serious problems include
encephalitis and deafness, but these are rare.
Mumps virus is spread from person to person through
airborne transmission, by droplet spread, such as from coughs
and sneezes, and through kissing or other direct contact with
saliva of an infected person.
In Ireland, mumps became a notifiable disease in 1988.
Between 1988 and 2003, only clinicians were required to
notify mumps cases. Since January 2004, laboratories are also
required to notify cases identified.1 Between 1988 and 2003
two mumps outbreaks occurred, the first in 1989 with 709
notifications, and the second during 1996/1997 with 707
notifications (figure 1). The number of mumps cases notified
during the inter-epidemic period was low, with approximately
40 cases notified annually.
Mumps infection can be prevented by vaccination. Mumps
vaccine in Ireland is available as part of the combined
measles-mumps-rubella (MMR) vaccine. Vaccination with the
first dose of MMR is recommended at twelve to fifteen
months and the second dose at four to five years.2 Mumps
vaccine was first offered in Ireland in 1988, with the
introduction of the MMR vaccine. In 1992, a second dose of
MMR was recommended for children aged 10 to 14 years. As
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a result of mumps outbreaks in 1996/1997, that
predominantly affected primary school children, the age of
the second dose was lowered to four to five years in 1999.
Materials and Methods
Mumps data, obtained through the weekly infectious disease
notification system, for 2004-2005 are presented here.
During 2004, Medical Officers in the HSE Areas provided case
based data to the Director of HPSC by the Wednesday of each
week, on infectious diseases notified to them during the
previous week, using an agreed dataset.3 These notifications
were inputted on a Microsoft Access database in HPSC. In
2005, HPSC commenced using the CIDR system. Historical
notifiable infectious disease data since 1988 were migrated
from the Microsoft Access system to CIDR. Four of the HSE
Areas also commenced using CIDR during 2005 namely the
HSE-M, HSE-NE, HSE-SE and HSE-S. For HSE Areas live on
CIDR the infectious disease notifications are entered directly
on CIDR at regional level. HPSC can view this data using the
Business Objects reporting tool on CIDR (except for patient
name and address). For HSE Areas not live on CIDR during
2005, Medical Officers in the HSE Areas continued to provide
case based data to the Director of HPSC by the Wednesday of
each week, on infectious diseases notified to them during the
previous week. At HPSC, these data were migrated to the
CIDR system on the Thursday of each week. The figures
presented in this report are based on data on the CIDR
system as of the 5th September 2006. These figures may
differ from those published previously, due to ongoing
updating of notification data in CIDR.
An enhanced surveillance system for mumps was established
during 2004 to capture information on the mumps outbreak.
Enhanced mumps data received at HPSC were entered on a
Microsoft Access database. Please note the final cleaning and
validation of the 2004 and 2005 data on the mumps
enhanced database, with all the Departments of Public Health
in the HSE Areas, was not completed at the time of writing of
this report.
Case classifications were assigned to mumps notifications as
per the Case Definitions for Notifiable Diseases.4
Analysis of mumps data was carried out using Business
Objects, Microsoft Access and Excel. Incidence rates were
calculated based on population data taken from the 2002
census.
Results
Epidemiology
A national mumps outbreak began in Ireland in 2004 and
continued into 2005. In total, there were 423 (10.8/100,000)
mumps notifications during 2004 and 1,083 (27.6/100,000) in
2005. In comparison, 40 (1.0/100,000) cases were notified
during 2003. The increase in mumps notifications commenced
at the beginning of November 2004 (Week 44 2004) peaking
in the second week of November (Week 45 2004) with 81
notifications and again in mid-April (Week 16 2005) with 54
notifications (figure 2). Between Week 44 2004 (early
November) and Week 52 2005 there were 1,433 notifications
with on average 23 mumps notifications each week. In
comparison, there was, on average, less than one mumps
Table 1. Number of mumps notifications and crude incidence rates (CIR) per 100,000 
population by HSE Area, 2003-2005
HSE Area 2003 2004 2005
 Number CIR Number CIR Number CIR
HSE-E 20 1.4 96 6.9 225 16.1
HSE-M 4 1.8 109 48.4 55 24.4
HSE-MW 1 0.3 14 4.1 104 30.6
HSE-NE 4 1.2 13 3.8 82 23.8
HSE-NW 0 0.0 111 50.1 174 78.5
HSE-SE 4 0.9 9 2.1 29 6.8
HSE-S 5 0.9 16 2.8 125 21.5
HSE-W 2 0.5 55 14.5 289 76.0
Total 40 1.0 423 10.8 1083 27.6
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Figure 1. Number of mumps notifications by year and year of introduction of MMR vaccine
in Ireland
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notification each week in 2003. All HSE Areas reported more
cases in 2004/2005 compared to 2003 (table 1). The highest
crude incidence rates were in the HSE-NW and HSE-W during
2005. The outbreak was predominantly among those born
before 1988 and, in particular, in those born between 1983
and 1986 (figure 3); many of this group were in third level
education and were associated with outbreaks in colleges and
universities. Of the 1,433 mumps notifications from Weeks
44 2004 to Week 52 2005; 505 (35%) were classified as
confirmed; 94 (7%) as probable; 554 (39%) as possible. Case
classification was not supplied for 280. Of the 1,433
notifications 809 were male, 616 were female while sex was
not reported for eight notifications.
Mumps notifications declined during 2006. From June 2006
(Week 23) to late August 2006 (Week 35) there were on
average six notifications (provisional data) each week.
Enhanced surveillance system
At the start of the outbreak in 2004 an enhanced surveillance
system was established to collect information on risk factors
for infection and reported vaccination status. This
information helped identify appropriate control strategies to
prevent ongoing transmission and to identify public health
strategies needed. Mumps enhanced data were also used to
determine the morbidity associated with mumps illness.
Enhanced data received at HPSC for 2004/2005 notifications
are reported here. Please note the final cleaning and
validation of these data on the mumps enhanced database,
with all the Departments of Public Health in the HSE Areas,
was not completed at the time of writing of this report.
The most likely place where the case acquired mumps was
reported for 349 notifications; for 67% (n=234/349) of these
mumps notifications university/college was reported as the
place the infection was most likely acquired.
Of the 389 notifications where vaccination status was
reported 28% (n=109/389) were unvaccinated, 43%
(n=166/389) were reported to have received one dose of
MMR (MMR1) and 29% (n=114/389) were reported to have
received two doses of MMR (MMR2). Self reported
vaccination status might be inaccurate. Of the cases reported
to have received MMR1 61% (n=102/166) had no vaccination
dates reported and 89% (n=148/166) had no MMR batch
number reported. Both vaccination dates were only reported
for 39% (n=45/114) of cases reported to have received MMR2
and nine percent (n=4/45) of these were vaccinated with
MMR2 less than 18 days prior to onset of symptoms, this
means they were probably exposed already. Only four
percent (n=5/114) of cases that were reported to have
received two doses of MMR had both MMR batch numbers
reported.
Information on hospitalisation status was available for 467
notifications. Thirty-seven cases were hospitalised,
representing eight percent of all cases with known
hospitalisation status. Reported complications of mumps
included orchitis (18%, n=44/243), pancreatitis (1.16%,
n=4/345), meningitis (1%, n=4/400), deafness (0.76%,
n=3/395), mastitis (0.29%, n=1/349) and encephalitis
(0.25%, n=1/397).
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Figure 2. Number of mumps notifications by week and year, 2004-2005
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Public Health Strategies/Control Measures
At the beginning of the outbreak a national outbreak control
team was convened, bringing together health professionals
from all HSE Areas, DoHC, NVRL and HPSC. This group
agreed on public health strategies (vaccination and
management of cases and close contacts) to control the
outbreak at national and local level. Communication
messages were standardised and control measures were
implemented locally.
Because the outbreak predominantly affected third level
colleges this population was targeted for a MMR vaccination
programme. All students and staff under 25 years of age who
had not received two does of MMR were recommended
vaccination. The vaccine was provided either by public health
services, student health services, or by the student’s own GP.
MMR vaccine was also provided for those at risk in the wider
community through GP practices. Public health messages
during the outbreak urged parents to make sure that their
children were vaccinated with two doses of MMR by six years
of age (i.e. routine vaccination schedule). Vaccine was provided
free of charge by the HSE Areas.
To prevent ongoing transmission of mumps virus and ensure
high levels of immunity among the college students the
mumps outbreak control group also recommended that all
new entrants to third level colleges for the academic year
2005/2006 (less than 25 years of age) should be fully
vaccinated with two doses of MMR prior to commencing the
academic year.
To increase awareness of the outbreak leaflets and
information materials were developed and disseminated
locally and made available on the HPSC Internet site and
other HSE Internet sites. These materials included
information about mumps, MMR vaccination and the control
measures recommended.
Discussion
The number of mumps notifications increased dramatically
during 2004 (n=423) and 2005 (n=1,083) compared to 2003
(n=40). The majority of notifications were in those born
before 1988 and in particular in older teenagers and young
adults born between 1983 and 1986, who were too old to
have been routinely scheduled for two doses of MMR during
childhood. Protection against mumps was first offered in
Ireland in 1988, with the introduction of the MMR vaccine. In
1992, a second dose of MMR was recommended for children
aged 10-14 years. In 1999 the age of the second dose was
lowered to four to five years.
Other countries have also recently reported resurgence in
mumps. During 2004 and 2005, the United Kingdom had an
outbreak of mumps. During 2005, 56,390 (provisional figure)
mumps cases were notified; the majority were in those aged
19-23 years and attending colleges or universities.5 These
cases were too old to be offered two doses of MMR routinely
when it was introduced in the United Kingdom in 1988.
These individuals would have missed the opportunity for
mumps exposure during childhood because high MMR
vaccination coverage in younger children had reduced
circulation of mumps in the United Kingdom.6
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Figure 3.  Mumps notifications (n=1,341) from Week 44 2004 to Week 52 2005 by year of birth and year of introduction of MMR in Ireland
(year of birth not shown for 6 cases born before 1944)
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In the United States an outbreak of mumps began in a college
in Iowa in December 2005 and by May 2006 involved at least
ten additional states.7 The age group most affected was
young adults aged 18-24 years, many of whom were college
students.7 In Iowa, preliminary vaccination data among 1,192
mumps cases indicated six percent were unvaccinated, 12%
had received one dose of MMR vaccine, 51% had received
two doses while vaccination status was unknown for 31% of
cases (the majority of whom were adults).7
In studies in the United States mumps vaccination was shown
to be between 78% and 91% effective.8 However, a recent
report by Harling et al. suggests that the effectiveness of one
dose could be as low as 64%.9 The same study documented
vaccine effectiveness of 88% with two doses.9 As mentioned
above, preliminary data in the mumps outbreak in Iowa
indicated a large proportion of cases had received one or two
doses of MMR. A number of the mumps notifications in
Ireland were also reported to have received one or two doses
of MMR vaccine, however, for the majority of these cases the
vaccination status was not confirmed, as most did not have
complete vaccination dates or vaccination batch numbers
reported. The HSE Area staff experienced great difficulty in
determining the true vaccination status of cases, due to lack
of immunisation records or difficulty accessing immunisation
records. Accurate vaccination status is vital to determine the
efficacy of the vaccine and to inform vaccination policy. This
emphasises the importance, and need, for a national
vaccination registry in Ireland.
Mumps notifications declined during 2006. It is anticipated
that the mumps notifications will continue to decline in 2006.
With MMR1 uptake in those 24 months of age in 2005
approximately 11% below the target uptake of 95% it is vital
that immunisation uptake rates improve if future mumps
outbreaks are to be prevented.
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Immunisation Uptake in Ireland,
2005
Key Points
• Immunisation uptake rates at both 12 and 24 months
improved in 2005
• Uptake of D3, T3, P3, Hib3, Polio3 and MenC3 at 12
months was 85%
• Uptake of D3, T3, P3, Hib3 and Polio3 at 24 months was
90%
• Uptake of MenC3 at 24 months was 89%
• Where data were available uptake of MMR1 at 24
months was 84% 
Introduction
Vaccination is a simple, safe and effective way of protecting
people against harmful infectious diseases that can cause
serious complications and sometimes death. In addition,
vaccination helps reduce the possibility of passing on vaccine-
preventable infections to others in the community. To
effectively control vaccine-preventable diseases and prevent
outbreaks it is recommended that at least 95% of children
complete the childhood immunisation schedule.
The current Irish childhood immunisation schedule
recommends that babies receive one dose of vaccine against
tuberculosis (BCG vaccine) at birth or by one month of age
and three doses of vaccines against diphtheria, pertussis,
tetanus, Haemophilus influenzae type b, poliomyelitis and
meningococcal group C at two, four and six months of age.
Between 12 and 15 months of age children should receive the
first dose of MMR. A booster dose of diphtheria, pertussis,
poliomyelitis and tetanus and the second dose of MMR should
be given at four to five years of age.
Immunisation uptake statistics for 2005 are presented in this
report. These statistics relate to children registered in the
immunisation databases in the HSE Areas. The proportion of
these children who completed the recommended
immunisation schedule by 12 or 24 months of age in 2005 
is reported.
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Materials and Methods
Each HSE Area maintains a childhood immunisation register.
In 2005, each HSE Area provided HPSC with immunisation
uptake data on a quarterly basis. These uptake data related to
all children on the HSE Area databases who reached their first
or second birthday (uptake at 12 and 24 months, respectively)
in that quarter and who had received three doses of vaccine
against diphtheria (D3), pertussis (P3), tetanus (T3), H.
influenzae type b (Hib3), poliomyelitis (Polio3) and
meningococcal group C (MenC3) and one dose of BCG vaccine
(uptake at 12 months only) and one dose of vaccine against
measles, mumps and rubella (MMR1; uptake at 24 months
only). Data on the number of children eligible for
immunisation in each cohort, the number immunised and the
percentage immunised were provided.
HPSC collated and analysed these data in Microsoft Excel and
quarterly reports were produced which are available on the
HPSC website.1 Annual immunisation uptake rates presented
in this report were calculated by collating the quarterly data
provided by the HSE Areas. These statistics, therefore, relate
to children who were 12 and 24 months of age in 2005 i.e.
birth cohorts born between 01/01/2004 & 31/12/2004 and
01/01/2003 & 31/12/2003 and who completed the
immunisation schedule outlined above.
Results
Immunisation uptake rates at 12 months
In 2005, national immunisation uptake rates at 12 months
were 85% for D3, P3, T3, Hib3, Polio3 and MenC3. This was an
improvement of two percent when compared to 2004 (figure
1). Immunisation uptake rates in Ireland have been steadily
rising each year since 2001, when uptake of vaccines was
between 68 and 70% (figure 1). In 2005, uptake of the above
vaccines ranged from 80-81% in the HSE-E to 91% in the
HSE-M (table 1). In 2005, BCG uptake rates were available for
the second time for an entire year. Five of the eight HSE
Areas were in a position to provide figures (representing a
third of the national birth cohort), and uptake was 93%. BCG
uptake ranged from 89% in the HSE-M to 97% in the HSE-SE
(table 1).
Quarterly immunisation uptake rates for D3, P3, T3, Hib3, Polio3
and MenC3 rose in 2005 from 83-84% in Q1-2005 to 87% by
Q4-2005 (figure 2). The highest uptake rate at 12 months
since the collation of these data commenced in Q3-2000 was
reported in Q4-2005 (87%). This is in contrast to the low
that was seen in Q2-2001 when uptake rates were 65 to 67%
(figure 2).
Immunisation uptake rates at 24 months
In 2005, a slight improvement in immunisation uptake rates
at 24 months was seen. National uptake for D3, P3, T3, Hib3
and Polio3 was 90% and 89% for MenC3 (figure 3). Compared
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Figure 1.  Annual immunisation uptake rates at 12 months in Ireland, 2001-2005
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Table 1. Immunisation uptake rates in children 12 months of age in 2005  
  % Uptake at 12 months
 Cohort born between 01/01/2004 – 31/12/2004
HSE Area No. in cohort D3 P3 T3 Hib3 Polio3 MenC3 BCG
HSE-E 22,728 81 81 81 81 81 80 na*
HSE-M 3,963 91 91 91 91 91 91 89
HSE-MW 5,098 87 87 87 87 87 87 93
HSE-NE 6,315 90 90 90 90 90 89 na*
HSE-NW 3,167 90 90 90 90 90 89 90
HSE-SE 6,790 87 87 87 87 87 87 97
HSE-S† 8,631 85 85 85 85 85 85 90‡
HSE-W 5,700 87 87 87 87 87 85 na*
Ireland 62,392§ 85 85 85 85 85 85 93
* Data not available at this time    
† As the denominator/number in cohort varied according to vaccine, most commonly 
used number is presented here.  The number in cohort eligible for BCG vaccine was 1,810 
 ‡ HSE-S: part coverage of neonatal BCG, Kerry only    
§ Number in cohort eligible for BCG vaccine was 20,592    
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with 2004, uptake of these vaccines improved by one percent
(figure 3). Uptake of D3, P3, T3, Hib3, Polio3 and MenC3 ranged
from 86-88% in the HSE-E to 96% in the HSE-M (table 2).
Six of the eight HSE Areas had 90% or greater uptake for all
these vaccines. The target uptake of 95% was reached for D3,
P3, T3, Hib3, Polio3 and MenC3 in the HSE-M during Q1-2005
to Q4-2005 and for D3, P3, T3, Hib3 and Polio3 in the HSE-NW
during Q3-2005.
During 2005 MMR1 uptake was 84% nationally, however, this
figure is incomplete as MMR1 data in Q4-2005 was only
available for seven of the eight HSE Areas. In Q4-2005 MMR1
uptake was 95% in the HSE-M.
Discussion
Childhood vaccinations have made a major contribution to
reducing the incidence of infectious disease in Ireland and in
eliminating diseases such as polio and smallpox. Monitoring
immunisation uptake is necessary to identify under
vaccinated populations and to evaluate the effectiveness of
efforts to increase uptake. Uptake of 95% is recommended to
control and prevent outbreaks of disease such as measles.
National immunisation uptake rates for D3, P3, T3, Hib3, Polio3
and MenC3 at 12 and 24 months increased by two and one
percent, respectively, in 2005 compared to 2004. The 2005
uptake figures for D3, P3, T3, Hib3, Polio3 and MenC3 at both 12
months (85%) and 24 months (89-90%) are the highest
reported since collation of these data commenced in 2000
and 1999, respectively. For all vaccines, with the exception of
MMR1, uptake rates at 24 months were 90% or greater in six
of the eight HSE Areas. In the HSE-M the target uptake rate
of 95% was reached for MMR1 during Q4-2005. This is the
first time any HSE Area reached the target uptake of 95% for
MMR1 since the collation of these statistics commenced in
1999. The target uptake of 95% was also reached at 24
months for D3, P3, T3, Hib3, Polio3 and MenC3 in the HSE-M
during Q1-2005 to Q4-2005, for D3, P3, T3, Hib3 and Polio3 in
the HSE-NW during Q3-2005 and at 12 months for BCG in
the HSE-SE during Q1-2005 to Q4-2005. These continued
improvements in uptake rates are encouraging. However,
further improvements are necessary so that the 95% target
rate is achieved nationally for all vaccines. In 2005, national
uptake rates at 24 months for D3, P3, T3, Hib3, Polio3 and
MenC3 were five to six percent below the target rate while
MMR1 was 11% below the target rate.
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Table 2. Immunisation uptake rates in children 24 months of age in 2005 
        % Uptake at 24 months
                Cohort born between 01/01/2003 – 31/12/2003
HSE Area No. in cohort D3 P3 T3 Hib3 Polio3 MenC3 MMR1
HSE-E 22,224* 88 87 88 87 87 86   78*
HSE-M† 3,837 96 96 96 96 96 96 93
HSE-MW 5,105 90 90 90 90 90 90 86
HSE-NE 6,003 93 92 93 93 93 92 89
HSE-NW 3,233 94 93 94 93 94 92 89
HSE-SE 6,862 91 91 91 91 91 90 86
HSE-S† 8,383 91 91 91 91 91 90 85
HSE-W 5,504 92 91 92 92 92 89 83
Ireland 61,151 90 90 90 90 90 89 84*
*The national MMR
1 
 figure is incomplete, as Q-4 2005 MMR
1
 data was not available for the 
HSE-E.  HSE-E MMR
1
figure is based on data from Q1-2005 to Q3-2005.  The numbers in the 
HSE-E and Ireland cohorts eligible for MMR
1
 vaccine were 16,766 and 55,778, respectively.
† As the denominator/number in cohort varied according to vaccine, most commonly used 
number is presented here.      
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Key Points
• In 2005, 203 cases of meningococcal disease were
notified in Ireland
• Neisseria meningitidis serogroup B accounted for 83% of
these notifications
• There were six meningococcal disease related deaths 
in 2005
• Five of the deaths occurred in children <5years of age
Introduction
Meningococcal disease occurs worldwide. There are
significant variations in the geographical distribution of the
Neisseria meningitidis serogroups that cause disease.
Serogroups B and C are responsible for the majority of
meningococcal disease in developed countries. Serogroup Y
accounts for up to a third of the cases in the United States,
yet it occurs relatively infrequently in most other developed
countries. Meningococcal disease in Africa and Asia can
largely be attributed to serogroup A and in more recent times
serogroup W135.
Since 2001 the incidence of meningococcal disease has been
on the decline in Ireland with rates of 5-6 cases per 100,000
total population occurring of late. This is in contrast with the
epidemic-like rates that occurred towards the end of the last
century when >14 cases per 100,000 total population were
occurring annually.
A major contributory factor in this reduction has been the
introduction of the MenC conjugate vaccine in 2000 to the
routine childhood immunisation schedule at 2, 4 and 6
months and the implementation at the same time of a catch-
up programme for under 23 year olds. Following the
introduction of this vaccine, the incidence of serogroup C has
plummeted from approximately 130 cases (>3/100,000) to
just five cases (0.1/100,000) annually.
In this report the epidemiology of meningococcal disease in
2005 is described. A brief update on other forms of bacterial
meningitis is also presented.
Meningococcal Disease in Ireland,
2005
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Materials and Methods
Meningococcal disease is a notifiable disease in Ireland. From
1982-2003 it was notifiable under bacterial meningitis
(including meningococcal septicaemia). More recently it has
become a notifiable disease in its own right with the
implementation of the Infectious Disease (Amendment) (No.
3) Regulations 2003 (SI No. 707 of 2003) on January 1st
2004.1  
Most forms of bacterial meningitis are now notifiable under
their specific disease pathogen name as listed in the
legislation. For bacterial meningitis pathogens not listed,
these forms of meningitis are notifiable under the disease
termed “bacterial meningitis (not otherwise specified)”. The
case definitions used are described in the HPSC Case
Definitions for Notifiable Diseases booklet.2
Detailed enhanced surveillance of meningococcal disease and
bacterial meningitis has been in place in Ireland since 1997
under the heading of, bacterial meningitis (including
meningococcal septicaemia). All historical case based data on
meningococcal disease and bacterial meningitis notifications
since 1999 are now in the Computerised Infectious Disease
Reporting (CIDR) system. During 2005, for areas using CIDR,
meningococcal disease and bacterial meningitis notifications
were inputted directly at regional level, events created and
enhanced information updated on the system. For areas not
on the system, notifications including the enhanced data
continued to be sent to HPSC and these data were inputted
on CIDR by HPSC.
In 2005 the meningococcal disease notifications on CIDR
were reconciled monthly by HPSC with the Irish
Meningococcal and Meningitis Reference Laboratory (IMMRL)
national database on laboratory confirmed cases.
Approximately once per quarter Departments of Public Health
were requested by HPSC to review the meningococcal disease
and bacterial meningitis events for 2005 to ensure the data
was accurate and complete. Following year-end, final data
cleaning and validation checks on the 2005
notifications/events was undertaken by HPSC in conjunction
with the Departments of Public Health and the IMMRL. Any
updates to these events were made in the CIDR system.
For this report, data analysis was performed using Business
Objects Reporting in CIDR and MS Excel. Incidence rates were
calculated using population data taken from the 2002 Census
of Population as the denominator. The Irish population was
used as the standard population when applying the direct
method of age standardisation. This was undertaken in order
to control for the confounding effect of age so that incidence
rates between HSE areas could be compared.
Data for this report were extracted from CIDR on 6th
September 2006. These figures may differ from those
published previously, due to ongoing updating of notification
data in CIDR.
Results
Total notifications
In 2005, 203 cases of meningococcal disease were notified.
As no imported cases were reported, all cases have been
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included in the analysis for this report. The incidence of
meningococcal disease increased very slightly in 2005
(5.2/100,000 total population) compared with 2004
(5.1/100,000; n=198) but was lower than that reported in
2003 (6.1/100,0000; n=237) and 2002 (6.5/100,0000; n=253)
(figure 1). Ninety-two percent (187/203) of the
meningococcal disease notifications in 2005 were laboratory
confirmed. One hundred and eighty cases were classified as
“definite” of which 100 were confirmed by PCR alone, 71 by
both culture and PCR and nine by culture alone. The
remaining seven laboratory confirmed cases were classified as
“presumed” and were confirmed by serology (n=1),
microscopy (n=5) and culture from a non-sterile site (n=1).
In addition there were 16 cases for which there was no
positive laboratory confirmation, these are classified as
“possible”. The number of meningococcal disease cases by
serogroup and case classification are presented in table 1.
Age and gender distribution
There were 113 (56%) cases of meningococcal disease in
males in 2005 and 90 (44%) in females, giving a male to
female ratio of 1.25:1.0.
In 2005, the meningococcal disease notifications ranged in
age from 1 month – 71 years, with a median age of 2 years.
Age was not reported for one case. Twenty five percent of all
the cases (n=52) occurred in infants <1 year of age, giving an
age specific rate of 95.4 per 100,000. As in previous years the
incidence rate was highest in this age group, followed by the
1-4 year olds, with an age specific rate of 34.1 per 100,000.
Serogroup distribution
Neisseria meningitidis serogroup B accounted for 83% of the
meningococcal disease notifications in 2005, with 169 cases
being notified. The remainder of the notifications were due to
serogroup C (n=5), serogroup W135 (n=3), serogroup Y (n=3),
non-groupable (n=2) and in 21 where no organism was
detected (table 1).
The incidence of serogroup B disease increased very slightly in
2005 compared with 2004, from 4.2 per 100,000 total
population to 4.3 per 100,000 total population. The incidence
of serogroup C disease continues to remain at the same all
time low incidence rate seen since 2003 of 0.1 per 100,000
total population.
Meningococcal disease by HSE area
To control for the confounding effect of age across HSE areas,
direct age standardisation of the 2005 meningococcal disease
data was undertaken. The highest incidence rate was in HSE-
M with 8.6 cases occurring per 100,000 population (95% CI
4.9-12.3/100,000) while the lowest was in HSE-SE where 4.3
cases per 100,000 population arose (95% CI 2.4-6.3/100,000).
Six of the eight HSE areas had incidence rates ranging
between 4.3 and 4.9 per 100,000, while the remaining two
HSE areas had higher rates – 6.4 per 100,000 in HSE-S and
8.6 per 100,000 in HSE-M. None of the rates in the HSE
areas were considered statistically different from the national
rate of 5.2 per 100,000 (95% CI 4.5-5.9/100,000) since the
95% confidence intervals overlapped. The age standardised
and crude incidence rates by HSE area are presented in 
figure 2.
Table 1. Number of meningococcal disease notification by serogroup and case classification, in 2005
Classification Serogroup B Serogroup C Serogroup W135 Serogroup Y Non Groupable No organism Total
Definite 168 4 3 3 2 0 180
Presumed 1 1 0 0 0 5 7
Possible 0 0 0 0 0 16 16
Total 169 5 3 3 2 21 203
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MenC vaccine failures
There was one MenC vaccine failure in 2005, which is a case
of serogroup C meningococcal disease arising in an individual
despite having been fully vaccinated against the disease. This
vaccine failure arose in a two year old child who had received
three doses of MenC as an infant. The child recovered.
No MenC vaccine failures occurred in either 2004 or 2003.
Meningococcal disease deaths
There were six meningococcal disease related deaths in 2005
(5 due to serogroup B and 1 due to serogroup Y). This is a
case fatality ratio of 3% (6 deaths/203 cases). Five of the six
deaths occurred in children <5 years of age, CFR of 3.9%.
Four of these deaths were due to serogroup B disease and one
due to serogroup Y. There was also a serogroup B related
death in a young adult.
In comparison, there were 10 meningococcal disease deaths in
2004, giving a CFR of 5%. This included seven serogroup B
deaths in young children, a serogroup C related death in an
elderly adult and two meningococcal disease deaths where no
organism was detected and were therefore classified as
possible cases.
Other forms of bacterial meningitis
Although not as common as meningococcal disease other
forms of bacterial meningitis can and do occur. In 2005 the
breakdown of these was as follows: 30 cases of bacterial
meningitis (not otherwise specified), Streptococcus
pneumoniae meningitis (n=19), Haemophilus influenzae
meningitis (n=9; 7 type b, 1 type f and 1 non-capsular), TB
meningitis (n=8, provisional figure) and listeria meningitis
(n=1). Separate chapters in this report examine in detail the
epidemiology of S. pneumoniae invasive infections, invasive H.
influenzae disease and tuberculosis.
With regard to bacterial meningitis (not otherwise specified)
notifications in 2005, eight were classified as “confirmed”
which consisted of group B streptococci (n=5), group C
streptococci (n=1), Pseudomonas aeruginosa (n=1) and
Staphylococcus aureus (n=1) meningitis. No organism was
identified for the remaining 22 cases of which five were
classified as “probable” and 17 as “possible”. No deaths were
reported relating to bacterial meningitis (not otherwise
specified) in 2005.
The listeria meningitis case notified under listeriosis occurred
in an elderly adult.
Discussion
In comparison with the late 1990s when Ireland was in the
midst of a meningococcal disease epidemic and incidence
rates in excess of 14 cases per 100,000 were arising annually,
the burden of meningococcal disease in this country has
declined to a third of these rates. In 2005, 5.2 cases per
100,000 total population occurred. As in previous years the
highest morbidity and mortality was in young children in
2005. Sixty three percent of all the cases and 83% of all the
deaths occurred in <5 year olds. Overall, the distribution of
cases by gender shows a slight predominance of disease
among male patients. PCR remains a very important tool in
the laboratory diagnosis of meningococcal disease, with over
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half the laboratory confirmed cases being diagnosed by this
method alone and another 38% confirmed by PCR and
culture methods. Therefore, PCR was involved in diagnosis of
92% of laboratory confirmed cases in 2005.
Significant advances have been made toward the control of
meningococcal disease with the development of
meningococcal conjugate vaccines. The success of the MenC
conjugate vaccine immunisation campaign in Ireland in
reducing the burden of serogroup C disease, has also been
experienced by several European countries who have
undertaken such programmes. This vaccine has proven to be
highly safe and effective. A monovalent serogroup A
conjugate vaccine is currently being developed at an
affordable price, offers hope for the elimination of large
epidemics in African countries. On 14th January 2005, a
tetravalent conjugate vaccine incorporating serogroups A, C, Y,
W135 was licensed in the United States for 11-55 year olds
and is now recommended for the routine immunisation of
adolescents and other high risk groups.
Despite its decline in recent years in Ireland, meningococcal
disease and in particular serogroup B disease continues to be
a serious public health concern. The incidence rate for
serogroup B disease in 2005 was 4.3 cases per 100,000 total
population and although almost half that reported in 1999
(8.1/100,000), a rate of 4 per 100,000 is still high in
comparison to many other developed countries where rates of
1 per 100,000 or less are reported.
Worldwide serogroup B causes about 50% of meningococcal
disease. To date, attempts to obtain an effective and broad-
spectrum vaccine for this serogroup have failed. Since the
development of a conjugate B polysaccharide vaccine has
proven problematic, alternative approaches are now the focus
of intensive research such as vaccines derived from outer
membrane proteins and genome-based vaccine discovery
using reverse vaccinology technology. Effective prevention of
meningococcal disease will not be achievable without the
development of a vaccine against serogroup B disease. Until
then meningococcal disease will continue to contribute
substantially to the burden of morbidity and mortality in
children both in Ireland and globally.
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Invasive Haemophilus influenzae
in Ireland, 2005
Introduction
Haemophilus influenzae and in particular H. influenzae type b
(Hib) causes serious invasive diseases. These infections occur
predominantly in children and the clinical manifestations
include meningitis, septicaemia, epiglottitis and cellulitis.
Invasive disease due to other H. influenzae serotypes or to
non-capsular strains can also occur. Routine use of the Hib
conjugate vaccine has led to a remarkable decline in Hib
disease in both developed and developing countries. Ireland
has been no exception. Following the introduction of the
vaccine to the Irish childhood immunisation schedule in
October 1992, the incidence of Hib disease declined from 2.9
per 100,000 total population in the late 1980s to 0.2 per
100,000 total population by 2000. However, towards the end
of 2004 a rise in the number of Hib cases and vaccine failures
was seen and this continued into 2005.1
Materials and Methods
Since January 1st 2004 with the implementation of the
Infectious Diseases (Amendment) (No. 3) Regulations 2003,
invasive H. influenzae is a notifiable disease, with clinicians and
laboratories legally obliged to notify. Prior to this, data on
invasive H. influenzae cases were obtained through regular
laboratory surveys, bacterial meningitis notifications and
reports from the Health Protection Agency reference
laboratory in the UK. An enhanced surveillance system
commenced in 1999. A case of invasive H. influenzae is
defined as the isolation of the organism or its nucleic acid
from a normally sterile site. Full details of the case definition
are provided in the HPSC Case Definitions booklet.2 
Key Points
• 34 cases of invasive Haemophilus influenzae were
notified in 2005
• 41% of cases occurred in children <5 years of age
• 18 cases of H. influenzae type b (Hib) were notified
• 72% of Hib cases occurred in children <5 years
• 14 true Hib vaccine failures occurred in 2005 compared
to six in 2004
• 92% of Hib cases occurring in children <5years in 2005
were associated with Hib vaccine failures
• A Hib catch-up booster campaign was launched in
November 2005
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Data pertaining to H. influenzae cases prior to 2004 (1996-
2003) are on an MS Access database. H. influenzae
notifications since 2004 are inputted to the Computerised
Infectious Disease Reporting System (CIDR). At least once per
quarter events on CIDR were reconciled by HPSC with reports
from the HPA Haemophilus Reference Unit, relating to Irish
isolates typed there. Departments of Public Health were
requested by HPSC each quarter to review events to date for
2005 to ensure data were accurate and complete. Following
year-end, final data cleaning and validation checks on the
2005 notifications/events were undertaken by HPSC in
conjunction with the Departments of Public Health. Any
updates to these events were made in the CIDR system.
Analysis for this report was performed using Business Objects
Reporting in CIDR and MS Excel. Incidence rates were
calculated using the 2002 Census of Population as the
denominator.
Data for this report were extracted from CIDR on 4th
September 2006. These figures may differ from those
published previously, due to ongoing updating of notification
data in CIDR.
Results
H. influenzae – Cases
In 2005, 34 cases (0.9/100,000) of invasive H. influenzae
disease were notified in Ireland, compared to 38 in 2004
(0.97/100,000). Sixteen of the thirty four cases notified in
2005 were in children <5 years of age, three were in 5-14
year old children and the remainder were in adults (n=15)
(table 1). The highest age specific incidence rates were in the
1-4 year olds (6.3/100,000), followed by the <1 year olds
(3.7/100,000) (table 1). The clinical diagnosis for the 19 cases
that occurred in children were as follows: meningitis (n=8),
septicaemia (n=5), epiglottitis (n=3), cellulitis (n=1), septic
arthritis (n=1) and unknown (n=1).
Over half of the cases in 2005 (n=18) were due to H.
influenzae type b (Hib) disease (table 1). Thirteen (72%) of
the Hib infections occurred in children <5 years and two in 5-
14 year old children. Over the same period in 2004, 18 cases
of invasive Hib were also reported; nine were in children <5
years of age and nine were in adults. In addition to the 18
Hib cases in 2005, cases of invasive H. influenzae disease due
to type f (n=2), non capsular (n=10) and strains that were not
typed (n=4) also occurred (table 1).
H. influenzae – Deaths
Four deaths due to invasive H. influenzae were reported in
2005. Two were due to Hib disease, one occurring in a young
child the other in an elderly adult. The two other deaths were
also in a young child and an elderly adult and were due to
non-capsular strains of H. influenzae.
Hib vaccine failures
A true Hib vaccine failure (TVF) is defined as Hib disease
occurring in an individual despite being fully vaccinated
against the disease. An apparent vaccine failure (AVF) is Hib
disease arising in an individual who had received some but
not all the recommended doses of Hib vaccine and therefore
was incompletely immunised.
There were 14 Hib TVFs and one AVF in 2005. In 2004 and
2003, six and three TVFs occurred respectively (figure 1). The
Table 1.  Number of invasive H. influenzae cases by serotype and age group in 2005
 Type b Type f Non capsular Not typed Total ASIR of Hib ASIR of all H. influenzae
<1 1 0 1 0 2 1.8 3.7
1-4 12 0 2 0 14 5.4 6.3
5-9 1 0 1 0 2 0.4 0.8
10-14 1 0 0 0 1 0.4 0.4
15-19 0 0 0 2 2 0.0 0.6
20-44 0 2 1 0 3 0.0 0.2
45-64 1 0 1 1 3 0.1 0.4
65+ 2 0 4 1 7 0.5 1.6
All ages 18 2 10 4 34 0.5 0.9
ASIR, age specific incidence rate per 100,000
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14 TVFs in 2005 ranged in age from 13 months to 14 years.
The majority (86%; 12/14) arose in children <5 years of age.
Therefore, 92% (12/13) of the Hib cases in 2005 that
occurred in children <5years of age were associated with
TVFs.
Discussion
The number of invasive H. influenzae disease notifications
declined very slightly in 2005 compared with 2004 i.e. down
from 38 to 34 cases. The proportion of cases occurring in
adults declined from 66% in 2004 (25/38) to 44% in 2005
(15/34). Therefore, an increase in the proportion of cases
occurring in children was seen in 2005, accounting for 56% of
the cases. This increase of invasive H. influenzae cases in
children <15 years of can largely be attributed to an increase
in type b cases in 2005, 15 cases occurred compared to 9 in
2004. Associated with this increase in Hib cases in 2005, was
a very substantial rise in Hib vaccine failures, 14 occurring in
total. Prior to 2004 the number of TVFs never exceeded four,
ranging between one and four per year. In 2004, six TVFs
occurred with four of these occurring in the last quarter of
the year. This increase continued on into 2005, with five, and
three TVFs reported in Quarter 1 and Quarter 2, respectively.
The increase in the number of Hib cases in fully vaccinated
children led to concerns that a three-dose infant schedule was
no longer sufficient to maintain long term protection. A
similar situation had emerged in the UK a number of years
previously.3 Therefore, in response to this emerging trend in
Ireland and coupled with the scientific evidence that Hib
vaccine efficacy is higher in those immunised at an older age
(>12 months), than in children vaccinated routinely as
infants,4 the National Immunisation Advisory Committee
recommended that a catch up Hib dose be offered to children
<4 years of age, in order to further protect this age group
from Hib disease.
The catch up campaign was launched by HSE on 21st
November 2005 and ran until May 2006. Defaulters were
followed up over the summer months.
Furthermore, as recommended by the National Immunisation
Advisory Committee, HSE Management Team have now
approved the inclusion of a routine Hib booster in the
childhood immunisation schedule at 12 months of age,
commencing on 18th September 2006.
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Figure 1.  Number of Hib cases in <15 year olds that were associated with and
not associated with a true vaccine failure (TVF), 1998-2005
0
12
6
10
4
8
16
14
2
1998 1999 2000 2001 2002 2003 2004 2005
TVF Non TVF
HPSC Annual Report 200596
Invasive Pneumococcal Disease in
Ireland, 2005
Key points
•   Statutory infectious disease notifications
underestimate the burden of invasive pneumococcal
disease (IPD) in Ireland when compared with European
Antimicrobial Resistance Surveillance System (EARSS)
reports
•   In 2005, 257 cases IPD were notified through the
notification system compared to 175 cases in 2004
•   Through EARSS, 401 IPD isolates were reported in 2005,
almost identical to 2004 (n=400)
•   Both systems demonstrated the same age incidence
trends, with rates highest in the very young and the
very old
Introduction
Streptococcus pneumoniae can cause invasive and non-
invasive disease. Invasive pneumococcal disease (IPD)
includes septicaemia, pneumonia, and meningitis. The most
common non-invasive diseases are otitis media, sinusitis and
bronchitis. IPD tends to be a disease of early childhood and
of older adults. More than 90 serotypes of S. pneumoniae
have been described based on capsular polysaccharide
composition. Although most serotypes have been shown to
cause serious disease, only a few serotypes produce the
majority of infections.
Vaccination is the only available tool to prevent
pneumococcal disease. A 23-valent polysaccharide vaccine
(PPV23) has been available for many years. It has been used
extensively in Ireland, targeted at older children (>2 years)
and adults considered at risk of IPD.1 However, its application
has been limited since it is poorly immunogenic in young
children and therefore, not suitable for inclusion in routine
childhood immunisation schedules. In more recent years a 7-
valent pneumococcal conjugate vaccine (PCV7) has been
licensed for use in many countries, including Ireland. In
Europe, it is estimated that 74.4% of the most commonly
reported serotypes in young children are covered by the
PCV7. This vaccine is recommended for use in Ireland in
infants and young children considered at increased risk of IPD.
Materials and Methods
Invasive S. pneumoniae infection (IPD) was made a notifiable
disease from 1st January 2004 with clinicians and laboratories
legally obliged to notify. The case definition for IPD is
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outlined in the HPSC Case Definitions for Notifiable Diseases
booklet.2
In 2005, the HSE areas using the Computerised Infectious
Diseases Reporting (CIDR) system inputted the notifications
directly. For areas not on the system, notifications were
forwarded weekly to HPSC and from there, inputted to CIDR.
Following year-end, a detailed data cleaning and validation
process was undertaken by HPSC in collaboration with the
Departments of Public Health in the HSE areas. Updates to
notifications/events were made directly on CIDR.
Data relating to IPD are also collated through the European
Antimicrobial Resistance Surveillance System (EARSS) in
Ireland. Details of the EARSS system are described in a
separate chapter within this document.
Incidence rates in this report were calculated using the 2002
Census of Population as the denominator. The Irish
population was used as the standard population in the direct
age standardisation method.
Data for this report was extracted from CIDR on 11th
September 2006. These figures may differ from those
published previously, due to ongoing updating of notification
data on CIDR.
Results
Infectious Disease Notification System
In 2005, 257 cases (6.6/100,000 population) of IPD were
notified through the weekly infectious disease notification
system. This was a 47% increase compared to 2004 when
175 cases were notified (4.5/100,000 population). The
majority of the IPD notifications in 2005 were classified as
confirmed (98%, n=251). The remainder consisted of one
probable, four possible and one case where case classification
was not reported. The overall male to female ratio was 1.4:1.0
(149/108). The age distribution of IPD in 2005 ranged from 1
month to 96 years, for two cases age was not reported. The
incidence rates were highest in the very old, i.e. 85 years of
age and older (45.5/100,000) and the very young, i.e. <1 year
(34.9/100,000) (figure 1). Incidence rates were also high in 1-
2 year olds (22.4/100,000) and in the age groups 65 years
and older, all had incidence rates >16 per 100,000 (figure 1).
For those in the age groups between 3 and 64 years, incidence
rates did not exceed 10 per 100,000 and ranged from 0.3 to
9.1 per 100,000 (figure 1).
When IPD incidence rates were examined by geographical
distribution (HSE area), variation between HSE area was
apparent despite controlling for the confounding effect of age
using direct age standardisation. Incidence rates ranged from
1.5 per 100,000 population in HSE-S to 9.9 per 100,000 in
HSE-MW (figure 2). The HSE-S (1.5/100,000; 95% CI 0.5-2.5),
HSE-NW (1.6/100,000; 95% CI 0.03-3.1) and HSE-M
(3.1/100,000; 95% CI 0.8-5.4) all had incidence rates of IPD
significantly lower than the national rate (6.6/100,000; 95%
CI 5.7-7.3). The remaining five HSE areas all had incidence
rates within the range 7.3 to 9.9 per 100,000 population
(figure 2).
Table 1.  Number of isolates of S. pneumoniae by serotype in 2005 (n=24)
Serotype 1 6B 7F 8 9N 9V 14 15C 19A 23F 33F 38 Total
All ages 4 1 3 1 1 3 5 1 1 2 1 1 24
<5 years 0 1 2 0 1 1 3 1 1 0 1 0 11
PCV7* N Y N N N Y Y N N Y N N -
PPV23** Y Y Y Y Y Y Y N Y Y Y N -
* Indicates whether above serotypes covered by 7-valent pneumococcal conjugate vaccine; 
y=yes, n=no
** Indicates whether above serotypes covered by 23-valent pneumococcal polysaccharide 
vaccine; y=yes, n=no
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Figure 1.  Number of cases of invasive pneumococcal disease reported through the
infectious disease notification system and EARSS in 2005
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European Antimicrobial Resistance Surveillance System
(EARSS)
In 2005, 401 cases of IPD were reported through EARSS,
which was almost identical to that reported in 2004 (n=400).
In 2005, 56% (n=144) more IPD cases were reported through
EARSS than through the infectious disease notification
system. A greater number of cases were reported through
EARSS for all age groups and in particular for the older age
groups (figure 3). The age specific incidence rates for the
EARSS IPD data followed a similar trend to that captured by
the notification data, with rates highest in the very young
(39/100,000 in <1 year olds) and the very old (105/100,000
in 85 year olds and older) (figure 1). Incidence rates in
infants, children and young adults were alike in both systems.
However, with increasing age the incidence rates of IPD cases
as reported through EARSS were substantially higher,
reflecting the higher number of cases being reported by this
system in these age groups (figure 1).
The geographical distribution of IPD based on the EARSS data
showed that the incidence ranged from 6.1 per 100,000
population in HSE-NE to 14.9 per 100,000 in HSE-NW, with a
national incidence rate of 10.2 per 100,000 total population
(figure 4). When the national rate is adjusted to take account
of the fact that EARSS data represents 98% population
coverage, the corrected rate was 10.4 per 100,000. For five of
the eight HSE areas, the incidence of IPD was higher based on
the EARSS data rather than on the notification data. The
exceptions were HSE-SE where identical numbers were
reported through both systems, the HSE-MW where three
additional cases reported via the infectious disease
notification system (2 possible cases which did not meet the
EARSS case definition and one case notified at the very end of
2005, which is on the EARSS database for 2006) and the HSE-
NE where seven more cases were reported on the notification
system than through EARSS. Serotype data was available on
24 IPD isolates from two of the 42 laboratories participating
in EARSS in 2005. Eleven of the isolates were from children
<5 years of age. Five of the isolates (45%) in this age group
had a serotype that would have been specifically covered by
PCV7 (table 1). These data are discussed in more detail in the
EARSS chapter within this document.
Discussion
Despite IPD being a notifiable disease, the statutory infectious
disease notification system does not accurately reflect the
true burden of this disease in Ireland. When compared with
EARSS reports, the burden of IPD in most of the HSE areas is
substantially underestimated by the notification data.
Similarly the burden of disease in each of the age groups, in
particular the older age groups, is also considerably
underestimated.
Based on the notification data, incidence of IPD was
considered to be significantly lower in HSE-M, HSE-NW and
HSE-S. However, when the EARSS data were analysed by HSE
area, it was found that incidence rates in these three areas
were notably higher and HSE-NW had the highest rate of all
the eight HSE areas at 14.9 per 100,000. Such discrepancies
in IPD data are in all probability a reflection of local reporting
practices, where laboratories are reporting directly to EARSS
at HPSC but are not simultaneously reporting these cases to
Departments of Public Health in the HSE areas through the
notification process. Therefore, for HSE areas to more
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Figure 2.  Age standardised and crude incidence rates with 95% confidence
intervals by HSE area for invasive pneumococcal disease reported through the
infectious disease notification system in 2005
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Figure 3.  Number of cases of invasive pneumococcal disease reported through the
infectious disease notification system and EARSS in 2005
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accurately ascertain the burden of IPD in their regions, it is
vital for all laboratories to notify cases through the statutory
notification process as well as through EARSS. However, as
more laboratories commence using the CIDR system the
discrepancy between the notification data and the EARSS
data should hopefully diminish.
Surveillance of IPD in Ireland is also hampered by the fact
that there is no comprehensive enhanced surveillance system
in place in this country for the disease. With the result that
detailed information is not available on cases as to whether or
not they: (i) were in any of the recognised “at-risk” groups, (ii)
had been vaccinated, and (iii) survived. Furthermore, at
present isolates of S. pneumoniae are not routinely serotyped.
In 2005, of the 401 isolates reported through EARSS, serotype
results were reported for just 24. Eleven of those serotyped
were isolates from children <5 years of age and the results
indicated that 45% of the cases would have been covered by
the PCV7. However, a far larger and more representative
sample of isolates would need to be serotyped to obtain an
accurate picture of the main IPD serotypes circulating in
Ireland and to determine the proportion of those covered by
the vaccines available. Reliable epidemiologic data is
important for making rational choices for public health issues,
such as vaccination strategies in the case of IPD.
In February 2006, the Chief Medical Officer in the UK
announced that a pneumococcal conjugate vaccine (PCV7 -
Prevenar, Wyeth) was to be added to the childhood
immunisation schedule in the autumn at two and four
months with a third dose given at 13 months. The current
approach to pneumococcal vaccination in Ireland is based on
selective vaccination of high-risk groups. The PPV23 vaccine
is recommended for those 24 months and older, and PCV7 is
recommended for infants and children. The National
Immunisation Advisory Committee (NIAC) of Ireland is at
present considering the necessity and feasibility of
introducing pneumococcal vaccination to the routine infant
immunisation schedule. Rigorous efforts should be made to
strengthen the current surveillance of IPD through enhanced
surveillance and routine serotyping of all isolates, in order to
best inform decisions on vaccination policy in Ireland and to
measure their impact thereafter.
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Epidemiology of Influenza in Ireland,
2005/2006 Season
Key Points
• Influenza activity was moderate during the 2005/2006
season, peaking in March 2006
• Influenza A (H3) and B co-circulated this season
• During the 2005/2006 season, avian influenza A (H5N1)
outbreaks continued to pose a significant global threat
to human health
Introduction
The 2005/2006-influenza season was the sixth year of
influenza surveillance using sentinel general practices in Ireland.
The Health Protection Surveillance Centre (HPSC) is working in
collaboration with the National Virus Reference Laboratory
(NVRL) and the Irish College of General Practitioners (ICGP) on
this project.
Influenza activity was moderate in Ireland for most of the
2005/2006 season, with the peak of activity occurring later
than usually observed, during week 10 2006. Influenza A (H3)
and B co-circulated this season. Influenza activity mainly
affected 5 to 14 year olds.
The most significant global event during the 2005/2006-
influenza season was the continuing global spread of poultry
outbreaks of avian influenza A (H5N1) associated with sporadic
cases/clusters of human infection and a significant proportion
of human deaths. 1, 2
Materials and Methods
Clinical data
Forty-six general practices (located in all HSE areas and
representing 4.1% of the national population) were recruited
to report electronically, on the number of patients who
consulted with influenza-like illness (ILI) on a weekly basis. ILI
is defined as the sudden onset of symptoms with a
temperature of 38°C or higher, with two or more of the
following: headache, sore throat, dry cough and myalgia. Cases
were those attending for the first time with these symptoms.
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Virological data
Sentinel GPs were requested to send a combined nasal and
throat swab on at least one ILI patient per week to the NVRL.
Swabs were tested for influenza using immunofluorescence
and PCR techniques and results were reported to HPSC. The
NVRL also tested respiratory specimens (predominantly
paediatric), referred mainly from hospitals.
Other indicators of influenza activity
The Departments of Public Health reported an influenza
activity index every week to HPSC. The activity index is
analogous to that used by the WHO global influenza
surveillance system and the European Influenza Surveillance
Scheme (EISS).3, 4 Each Department of Public Health also
established one sentinel hospital in each HSE area, reporting
total, accident and emergency and respiratory admissions
data on a weekly basis. Sentinel primary and secondary
schools were also located in each HSE area in close proximity
to the sentinel GPs, reporting weekly absenteeism data.
The Departments of Public Health also reported all notified
cases of influenza and all influenza/ILI outbreaks to HPSC
every week. An enhanced dataset on all hospitalised influenza
cases aged between 0 and 14 years of age was also reported
to HPSC from the Departments of Public Health. From
January 2005, HPSC was notified of all registered deaths on a
weekly basis from the General Registrar’s Office (GRO).
Weekly report and EISS
HPSC produced a weekly influenza report, which was posted
on the HPSC website www.hpsc.ie each Thursday. Results of
clinical and virological data were reported, along with a map
of influenza activity and a summary of influenza activity
worldwide. HPSC also reported the clinical and virological
dataset to the European Influenza Surveillance Scheme (EISS)
every Thursday.
Results 
It should be noted that enhanced surveillance and mortality
data for the 2005/2006 season are provisional.
Clinical data
Influenza activity in Ireland peaked later in the 2005/2006
season compared to the previous season. Activity was
moderate for most of the 2005/2006 influenza season, with a
peak during week 10 2006 at 82.5 per 100,000 population
(figure 1). During the peak of activity, the majority of ILI cases
reported were aged between 5 and 14 years.
Virological data
The NVRL tested 378 sentinel specimens for influenza virus
during the 2005/2006 season. One hundred and thirty-two
(34.9%) sentinel specimens were positive for influenza: 64
(48.5%) influenza A (61 A H3 and 3 A unsubtyped) and 68
(51.5%) influenza B. The predominant influenza virus subtype
identified was influenza A (H3), accounting for 95.3% of
positive influenza A specimens. The majority of positive
influenza sentinel cases were aged between 15 and 64 years
(78.5%).
The NVRL also tested 1,783 non-sentinel respiratory
specimens, 24 (1.3%) of which were positive for influenza A,
12 (0.7%) for influenza B, and 376 (21.1%) were positive for 
Season
Figure 1. ILI rate per 100,000 population and the number of positive influenza specimens detected by the NVRL during the 2000/2001, 2001/2002, 2002/2003, 2003/2004, 2004/2005
seasons, summer 2005 and the 2005/2006 season.
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RSV. The majority (90.2%) of influenza and RSV positive
specimens were between 0 and 4 years of age.
Vaccination status and antigenic characterisation
Of the 132 positive influenza virus detections from sentinel
specimens, 109 (82.6%) were unvaccinated, 10 (7.6%) were
vaccinated and vaccination status was unknown in 13 (9.8%)
cases. Of the 10 cases that were vaccinated, influenza A (H3)
was detected in five cases and influenza B in five cases.
Two influenza specimens were sequenced at the NVRL and
antigenic characterisation was undertaken at the WHO
laboratory (Mill Hill) in London. One influenza A (H3) isolate
was antigenically characterised as A/Hong Kong/4443/05 and
one influenza B isolate was characterised as being closely
related to B/Hong Kong/45/05.
Regional influenza activity 
Regional influenza activity peaked during week 10 2006, with
HSE-Eastern Region (HSE-ER), -Midland Area (HSE-MA), -Mid
Western Area (HSE-MWA), -South Eastern Area (HSE-SEA) and
-Southern Area (HSE-SA) all reporting localised influenza
activity (figure 2). Overall, influenza activity was most intense
in HSE-ER, -NE, and -MWA during the 2005/2006 season. The
highest ILI consultation rates were observed in HSE-MWA,
peaking during week 10 2006.
Outbreaks 
During the 2005/2006 season, four ILI/influenza outbreaks
were reported to HPSC. One ILI outbreak occurred during
week 4 2006 in a nursing home in HSE-NEA. The main
symptoms experienced were headache, malaise, nasal
symptoms and fever. All residents had received the
2005/2006 influenza vaccine. HPSC also received notification
of an ILI outbreak in a primary school in HSE-ER during week
9 2006. A further two ILI outbreaks occurred in HSE-MA
during week 10 2006, both occurred in sentinel schools, one
in a primary school and the other in a secondary school.
Influenza B was associated with the ILI outbreak in the
sentinel secondary school.
Sentinel hospitals & sentinel schools
Hospital respiratory admissions (as a proportion of total
hospital admissions) in sentinel hospitals peaked during week
52 2005 (figure 3), following the seasonal peak in RSV. A
second smaller peak in hospital respiratory admissions was
observed in week 12 2006, two weeks following the peak in
sentinel GP ILI consultation rates. Absenteeism in several
sentinel schools was also at elevated levels during the peak in
ILI consultation rates.
Enhanced influenza surveillance
A total of ten influenza cases were reported through the
enhanced surveillance system during the 2005/2006 season.
Two cases were hospitalised in February 2006, four in March
2006 and four in April 2006. All enhanced cases were in the 0-
4 year age group; seven were under 1 year of age and three
were in the 1-4 year age group. All ten cases were notified
from HSE-ER. This compares to 13 hospitalised influenza cases
in 0-14 year olds reported during the 2004/2005 season (also
from HSE-ER). ILI GP consultation rates were at elevated
levels during February and March 2006 in HSE-ER. Nine
enhanced cases were positive for influenza A and one was
positive for influenza B. Symptoms included fever (10/10),
Figure 2. Map of influenza activity by HSE area during the 2005/2006 season peak of
influenza activity, week 10 2006.
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Figure 3. Respiratory admissions as a percentage of total hospital admissions in seven sentinel hospitals and ILI rates per 100,000 population by week for the 2005/2006-influenza season
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cough (8/10), gastrointestinal manifestations (4/10), fatigue
(4/10), sore throat (1/10), difficulty breathing (1/10) and
myalgia (1/10). Complications included bronchitis,
bronchiolitis, acute otitis media, secondary bacterial
pneumonia, primary viral pneumonia and other respiratory
complications. The mean number of days in hospital was 6.7
(ranging from 3-14). Four cases were in at risk categories for
influenza vaccine, three of whom were not vaccinated and
one was vaccinated. Nine cases have recovered and one case
was lost to follow up.
Mortality data
There were 17,807 deaths from all causes and 3,567
pneumonia and influenza deaths (20.0% of all deaths)
registered with the GRO during the 2005/2006 season. One
death attributed to influenza was registered with the GRO
during week 15 2006 (from HSE-MA). Influenza was the
secondary cause of death and not the primary cause in this
case. This was the only registered death attributed to
influenza reported to HPSC during the 2005/2006 season.
Influenza notifications data
Influenza notifications for 2005 are discussed in a separate
chapter on infectious disease notifications within this annual
report.
Influenza activity worldwide
During the 2005/2006 season, the United Kingdom
experienced the sixth consecutive year of low levels of
influenza activity, peaking late in the season, with B/Hong
Kong/330/2001-like virus identified as the dominant
circulating strain. Seven hundred and seven school outbreaks
of ILI were reported from across England and Wales this
season, 70 of these were associated with influenza B.5
Influenza activity was moderate in the majority of European
countries this season, with influenza B virus identified as the
dominant virus circulating.3 In Canada and the US, influenza
activity also started late this season, with influenza A (H3N2)
predominating (the majority of strains were identified as
A/California/7/2004(H3N2)-like). 6,7
Discussion
Influenza activity was moderate and peaked late in Ireland
during the 2005/2006 influenza season, with influenza A (H3)
and B viruses co-circulating. Influenza activity also started
later in most of Europe, Canada and the US, with low to
moderate levels of activity reported.3, 5, 6, 7
Surveillance of hospital admissions and school absenteeism
data plays a significant role in the early detection of influenza
epidemics.8 This was demonstrated during the 2005/2006
season in Ireland, with elevated levels of respiratory
admissions in sentinel hospitals detected following peaks in
RSV and influenza activity. The value of collating school
absenteeism data as an indicator of influenza activity was also
highlighted with the detection of ILI/influenza outbreaks in
two sentinel schools.
The small number of influenza-attributed deaths reported to
HPSC for the last number of seasons is not unexpected.
Excess deaths due to influenza are often not registered as
influenza deaths. Monitoring all-cause deaths and influenza
and pneumonia deaths is one method of identifying these
influenza-non-attributed deaths and from this, estimating the
mortality burden caused by influenza each season.9 A pilot
project to monitor total deaths and deaths due to pneumonia
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and influenza weekly in Ireland has been completed at HPSC.
A system that monitors influenza deaths in Ireland could
prove to be a significant early warning tool and would be
invaluable for health system response planning in the event of
an influenza pandemic.
Avian influenza A (H5N1) outbreaks have posed a significant
threat to human health since 2003. Of greatest concern is the
risk that continuing transmission of the virus to humans will
give avian and influenza viruses an opportunity to reassort
their genes, thereby acquiring the ability to transmit easily
from human-to-human and thus triggering a pandemic.1, 2 As
of July 7th 2006, Spain became the 14th EU Member State to
report a case of highly pathogenic avian influenza A (H5N1) in
wild birds. The other countries include Greece, Italy, Slovenia,
Hungary, Austria, Germany, France, Slovakia, Sweden, Poland,
Denmark, Czech Republic and the UK. Avian influenza H5N1
was confirmed in poultry in five EU Member States: France,
Sweden, Germany, Denmark and Hungary.10 Avian influenza A
(H5N1) remains predominantly a disease of birds. A small
number of human cases have been reported in South East
Asia, Africa and Eastern Europe, all of which have been
associated with close contact with dead or dying poultry. In
all human cases to date there has been no evidence of
efficient human-to-human transmission. Human infections
remain a rare event.1
However, with the ever-greater threat of a pandemic posed by
influenza A (H5N1), EU Member States are strengthening
their preparedness for a potential human influenza
pandemic.11 As a result of this threat, a number of additional
measures have been put in place in Ireland to improve
surveillance of ILI/influenza. Work is in progress to increase the
number of sentinel GPs, thereby improving geographical and
population representation. Sentinel GPs are also currently
monitoring ILI on a year round basis. In addition, influenza and
all outbreaks became notifiable in Ireland on 1 January 2004.
Reporting of such events is critical to early detection of
influenza activity. An enhanced influenza surveillance system
was set up to detect all hospitalised influenza cases aged
between 0 and 14 years of age. Other activities that are being
implemented to improve the surveillance of influenza include
weekly surveillance of influenza and pneumonia registered
deaths, monthly surveillance of influenza vaccine uptake data
in those aged 65 years and older, and the construction of
baseline and epidemic threshold levels for influenza activity in
Ireland. An evaluation of sentinel hospital admissions and
school absenteeism data has been completed and
recommendations are currently being implemented. Contact
and attendance data is also currently being collated from GP
co-operatives, to act as a crude indicator of influenza activity.
Work is ongoing in several other areas including: case and
contact based reporting of avian influenza, surveillance of
unexplained deaths/increased deaths due to respiratory tract
infections in healthcare facilities, surveillance of ICU bed
occupancy by influenza and pneumonia cases and surveillance
of respiratory illness in healthcare workers. This information
will in turn inform continuing national progress on pandemic
preparedness and will be vital in the event of an influenza
pandemic for planning and control measures.
Further information on influenza is available on the HPSC
website at http://www.ndsc.ie/DiseaseTopicsA-Z/InfluenzaFlu/
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Key Points
• There were 432 new cases of TB notified in 2004, giving
a crude incidence rate of 11.0 per 100,000 population
• Two hundred and seventy nine (64.6%) of the cases
were culture confirmed with M. tuberculosis isolated in
268 cases and M.bovis in five cases
• Of the 432 cases reported in 2004, 310 (71.8%) had a
pulmonary component. Of the 310, 225 (72.6%) were
culture positive and 136 (43.9%) were smear positive
• One hundred and twenty nine (29.9%) of the cases were
born outside Ireland
• Outcome data were reported for 364 (84.3%) of the 432
cases 
• Five deaths were attributed to TB in 2004
• There were 461 cases of TB provisionally notified in
2005
Introduction
The World Health Organisation (WHO) has estimated that
globally, there were 8.9 million new cases of tuberculosis (TB)
in 2004, of which 3.9 million were smear positive.
Approximately 2 million TB deaths occurred in 2004.1
In Ireland, national epidemiological data on TB have been
collated by the HPSC since 1998. From January 2000, this
information has included enhanced surveillance data items
based on the minimum dataset reported to EuroTB, the
European agency that collates national TB data within Europe
and contributes that data to the WHO global TB control
programme.2 
Materials and Methods
An enhanced TB notification form was completed by public
health doctors for each case of TB notified in 2004. These
forms summarise all available clinical, microbiological,
histological and epidemiological data. Forms were then
collated in the regional departments of public health, where
data were entered onto an Epi2000 database (NTBSS). Each
HSE area provided finalised 2004 data with outcome
information to HPSC in early to mid 2006. Data were
validated with each area and national data were collated.
Provisional 2005 data were obtained from each area in August
2006.
Population figures, used as the denominator, were taken from
the 2002 census of population. In order to compare rates
between groups of interest, 95% confidence intervals were
used. Direct methods of standardisation were used to allow
comparison of rates between geographical areas using the
Irish population as the standard population.
Tuberculosis in Ireland, 2004
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As in previous years, the case definitions used were as
recommended by the National Tuberculosis (TB) Working
Group.3
Results
There were 432 cases of TB notified in 2004, giving a
notification rate of 11.0/100,000 population. This compares to
407 cases notified in 2003 and 408 cases notified in 2002.
Table 1 shows the number of TB cases, crude incidence rates
and three-year moving averages from 1991 to 2004. A
summary profile of the epidemiology of TB in Ireland from
2000 to 2004 is shown in table 2.
Age standardised rates by HSE area are provided in table 3.
The highest age standardised TB incidence rates were seen in
HSE East at 13.3/100,000 population followed by HSE
Midwest (13.0) and HSE South (12.6). HSE Midlands reported
the lowest age-standardised rates at 4.1/100,000 population
which was significantly lower than the national age-
standardised incidence rate (10.3/100,000).
Age and sex distribution
There were 257 (59.5%) cases of TB notified in males in 2004
and 175 (40.5%) in females giving a male to female ratio of
1.5:1. The average age of those diagnosed with TB was 44
years (range: 2 to 95 years). The highest age-specific rate was
observed in those aged 65 years and older (21.6/100,000
population). Figure 1 shows the 2004 cases by age and sex
and the male and female age-specific rates.
Geographic origin
Of the 432 TB cases notified in 2004, 290 (67.1%) were born
in Ireland, 129 (29.9%) were born outside Ireland and for the
remaining 13 cases, the country of birth was unknown. Cases
born outside Ireland originated from at least 38 countries. Of
the 129 born outside Ireland in 2004, 49 were born in Asia, 47
in Africa, 22 in Europe and 3 in America. The country of birth
was unknown for eight of the cases born outside Ireland. The
crude rate of TB notifications in the indigenous population
was 8.4/100,000 population while the crude rate in the
foreign born population was 32.2/100,000.
Site of disease
Of the 432 cases notified in 2004, 274 (63.4%) were
pulmonary, 121 (28.0%) were extrapulmonary, and 36 (8.3%)
were pulmonary and extrapulmonary TB. Site of disease was
unspecified for one case. Of the 310 cases with a pulmonary
disease component, 225 (72.6%) were culture positive and
136 (43.9%) were smear positive.
TB meningitis
There were six cases of TB meningitis reported in 2004 giving
an incidence rate of 0.15 per 100,000 population. All six cases
were aged between 24 and 54 years.
Between 1998 and 2004, a total of 41 cases of TB meningitis
have been reported giving a cumulative incidence rate of 8.9
per million population. Four of these cases were in children
aged less than 5 years.
Bacteriological results
Of the 432 TB notifications, 279 (64.6%) were definite cases
which were culture confirmed. Of the 279 culture-confirmed
cases, 268 (96.1%) were M. tuberculosis and five (1.8%) were 
Table 1. Notified TB cases in Ireland, 1991 – 2004, with 3-year moving averages, 
1992 - 2003
Year  Number    Crude rate per 100,000pop.  3 year-moving average
1991 640 18.2 
1992 604 17.1 612
1993 598 17 581
1994 524 14.5 526
1995 458 12.6 469
1996 434 12 436
1997 416 11.5 423
1998 424 11.7 433
1999 469 12.9 439
2000 395 10.1 410
2001 381 9.7 391
2002 408 10.4 401
2003 407 10.4 414
2004 432 11 
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M. bovis. No cases of M. africanum were reported in 2004. The
isolate was not specified in six culture positive cases.
Resistance
Of the 268 M. tuberculosis isolates, resistance was
documented in 22 cases (5.1% of total cases). Of the 22, 15
were resistant to isoniazid, including two cases of multi-drug
resistant TB (MDR-TB). One of the MDR-TB cases was
resistant to isoniazid and rifampicin and the other case was
resistant to isoniazid, rifampicin and ethambutol. Mono-
resistance to isoniazid was recorded in 12 cases,
monoresistance to rifampicin in three cases, to ethambutol in
one case, to pyrazinamide in one case and to streptomycin in
two cases. One further case was resistant to both isoniazid
and streptomycin. Thirteen of the 22 (59.1%) drug resistant
cases, including one of the MDR-TB cases, were born outside
Ireland.
Treatment outcome
Outcome was reported for 364 (84.3%) of the 432 cases
notified in 2004. Details on treatment outcome for all cases
and for smear positive cases only are shown in table 4.
Of the 364 cases, 283 completed treatment, 35 were lost to
follow up, 24 died, treatment was interrupted in 11 cases and
11 cases were still on treatment at time of reporting. Of the
24 deaths reported, five (1.2% of total) were attributed to TB.
Of the 136 smear positive pulmonary cases notified in 2004,
99 completed treatment, 12 were lost to follow up, treatment
was interrupted in four cases, four died and two were still on
treatment at time of reporting. The outcome was unknown in
15 of the cases.
Of the 22 drug resistant cases, 16 completed treatment while
one case was still on treatment, one case was lost to follow
up, treatment was interrupted in one case and treatment was
unknown for three of the cases. Of the two MDR-TB cases,
one case had completed treatment and one case was still on
treatment.
Case ascertainment
Of the 432 cases notified in 2004, 331 presented as a case of
TB, 28 were found by contact tracing, four by immigrant
screening, 13 by other methods of screening and 22 by other
means, not specified. The method of case ascertainment was
unknown for 34 cases.
Previous history of TB
Thirty six (8.3%) of the 432 cases were reported as having a
previous history of TB with previous year of diagnosis
provided for 27 cases. The year of diagnosis ranged from 1920
to 2003 with 13 of the 27 cases (48%) reported to have had
TB in the previous 10 years.
HIV Status
Of the 432 cases, 13 were reported as being HIV positive.
However, information on HIV status was not provided or was
unknown for 408 (94.4%) of cases notified in 2004.
Provisional 2005 data
There were 461 cases of TB provisionally notified in 2005. It is
important to note that these data are only provisional and
may change significantly following validation.
• There were 273 (59.2%) cases in males and 182 (39.5%) in
females. Sex was not reported in six cases.
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Figure 1: Cases of TB by age and sex, and age-specific rates per 100,000 population, 2004
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Table 2. Summary of epidemiology of TB in Ireland, 2000 – 2004
    2000 2001 2002 2003 2004
Total number of cases 395 381 408 407 432
Notification rate per 100,000 population 10.1 9.7 10.4 10.4 11
Foreign born TB patients 44 63 123 89 129
% Culture positive patients 58 58.8 61.0 64.4 64.6
M. tuberculosis 222 204 234 250 268
M. bovis   2 7 5 5 5
M. africanum 3 1 0 0 0
% smear positive pulmonary cases 47.2 44.4 38.4 48.8 43.9
Monoresistance to isoniazid 2 4 8 8 12
Multi drug resistant cases  2 2 0 1 2
Deaths attributed to TB 6 5 5 6 5
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• Two hundred and eighty eight cases (62.5%) were born in
Ireland, 142 (30.8%) were born outside Ireland and country
of birth was unavailable for 31 cases.
• Of the 461 cases provisionally notified, pulmonary TB was
diagnosed in 283 cases (61.4%), extrapulmonary TB in 126
cases (27.3%), and pulmonary and extrapulmonary TB in 36
cases (7.8%).
• Provisionally, of the 319 TB cases with a pulmonary
component, 155 (48.6%) were culture positive and 132
(41.4%) were smear positive.
• There were eight cases of TB meningitis provisionally
notified in 2005 giving an incidence rate of 0.2/100,000
population.
• Resistance was reported in six cases in 2005. Three cases
were mono-resistant to isoniazid and three cases were 
MDR-TB.
More detailed reports on the epidemiology of TB in Ireland
can be found on the HPSC website at www.ndsc.ie/hpsc/A-
Z/VaccinePreventable/TuberculosisTB/Publications/
Discussion
In 2004, 432 cases of TB were notified to HPSC giving a
national crude incidence rate of 11.0/100,000 population. This
rate is slightly higher than the rate in 2003 and 2002, which
was 10.4/100,000. However, it remains lower than the crude
incidence rates reported between 1991 and 1999, which
ranged from 11.5/100,000 to 18.5/100,000. The overall
notification rate in countries of the EU which reported to
EuroTB was 12.8/100,000 in 2004, ranging from 3.6/100,000
in Cyprus to 73.0/100,000 in Lithuania.2 
Differences in age-standardised TB incidence rates persist
between HSE areas with HSE East having the highest rate in
2004 followed by HSE Midwest and HSE South. HSE Midlands
had the lowest rate in 2004, followed by the HSE Northeast.
The highest age-specific rate in 2004 occurred among those
aged 65 years and over (21.6/100,000 population). This was
similar to the rate observed in this age group in 2003, 2002
and 2001. There were 10 cases in children under 15 years of
age in 2004 giving a rate of 1.2/100,000. This is a decrease
from the rate in 2003 (2.9) and 2002 (2.2). Between 2000
and 2004, the age-specific rate among the 25-34 year age
group increased from 10.5 to 19.8 per 100,000 population.
There was a notable difference in age between those born in
Ireland and those born outside Ireland. In cases born in
Ireland, there was a peak among those aged greater than 64
years with a median age of 50 years. In cases born outside
Ireland, the peak occurred in those aged 25-34 years old with
a median age of 30 years. There were 73 foreign born cases
out of a total of 122 (60%) in the 25-34 year age group in
2004 compared to 40 foreign born cases out of a total of 86
(47%) in this age group in 2003. Where available, data from
other countries in the EU and Western Europe show similar
trends with the highest rates in nationals aged greater than
64 years and the highest rates in foreign born cases in the 25-
34 year age group.2 
Table 4: Treatment outcome for all cases and smear positive cases, 2004.
Treatment outcome Total cases Smear positive cases
 Number  %  Number  %
Completed treatment 283 65.5 99 72.8
Lost to follow up 35 8.1 12 8.8
Treatment interrupted 11 2.5 4 2.9
Still on treatment 11 2.5 2 1.5
Died (attributed to TB) 5 1.2 1 0.7
Died (not attributed to TB) 19 4.4 3 2.2
Outcome unknown 68 15.7 15 11.0
Total 432 100.0 136 100.0
Table 3: Number of cases of TB in Ireland and age standardised incidence rates with 95% 
confidence intervals (CI) by HSE area , 2004
HSE area  TB cases  Age standardised incidence rate  95% CI
HSE E 189 13.3 11.4-15.2
HSE M 9 4.1 1.4-6.8
HSE MW 44 13 9.2-16.7
HSE NE 23 6.9 4.1-9.7
HSE NW 16 6.6 3.4-9.9
HSE SE 34 8.1 5.4-10.8
HSE S 73 12.6 9.7-15.5
HSE W 44 11.2 7.9-14.6
Ireland 432 10.3 9.3-11.4
HPSC Annual Report 2005110
Rates among males were higher than females for all age
groups. The highest rate among males was among those aged
65 years and over (28.0/100,000) while the highest rate
among females was among those aged 25 to 34 years old
(17.8/100,000). The male to female ratio (1.5:1) reported in
2004 was comparable with the rate reported in 2003 (1.6:1).
Thirty percent of TB cases notified in 2004 were born outside
Ireland. This compares to 21.9% in 2003, 30.1% in 2002 and
16.5% in 2001. In 2004, among countries in the EU and
Western Europe who reported data to the EuroTB network,
29% of notifications were in foreign born patients. In the
United Kingdom, France, Germany and Belgium, where crude
incidence rates are similar to those reported in Ireland, the
percentage of cases of foreign origin in 2004 ranged from 44
to 61%.2
There were six cases of TB meningitis in 2004, giving a rate of
0.15/100,000 population. All cases of TB meningitis reported
in 2004 were aged between 25-54 years. Between 1998 and
2004, four cases of TB meningitis were reported among 0-4
year olds.
There were 22 drug resistant cases notified in 2004, including
two cases of MDR-TB. There was no case of extensive drug
resistant TB (XDR-TB) notified to HPSC in 2004. Multi-drug
resistant cases and cases resistant to isoniazid represented
0.5% and 3.5% of total cases respectively. This compares to
0.3% and 2.7% respectively in 2003. In 2004, combined
multi-drug resistance and mean combined INH resistance
were 19% and 32% respectively in the Baltic States and 2%
and 8% respectively in the 15 other countries in the EU and
Western Europe. Drug resistance is an issue that needs to be
kept under close surveillance especially with the recent
emergence of XDR-TB.4
In recent years, the quality of the data, and in particular data
on treatment outcome, has improved greatly. In 2004,
information on treatment outcome was provided for 84.3% of
cases which is very similar to the proportion in 2003 (84.8%).
This compares to 77.2% in 2002 and 59.8% in 2001. It is of
critical importance to TB control in Ireland that surveillance of
TB and reporting of outcome data be maintained at a high
level.
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Antimicrobial Resistance in Ireland,
2005
Key Points
In 2005,
• 1,424 invasive isolates of Staphylococcus aureus were
reported. The proportion of isolates that was meticillin-
resistant S. aureus (MRSA) was 41.6%, which remains one
of the highest in Europe
• 401 invasive isolates of Streptococcus pneumoniae were
reported. The proportion that was penicillin-non-
susceptible S. pneumoniae (PNSP) was 11.7%, which is
moderately high compared to most other European
countries. Of the 47 PNSP isolates identified, 12
exhibited high-level resistant [minimum inhibitory
concentration (MIC), >2 mg/L] while 35 were determined
to have intermediate levels of resistance (MIC, 0.12-1.0
mg/L). The proportion of S. pneumoniae that was
erythromycin-resistant was 12.1%, which is also
moderately high compared to other European countries
• 1,445 invasive isolates of Escherichia coli were reported.
The proportions of isolates that were resistant to third-
generation cephalosporins (3GCs), fluoroquinolones and
aminoglycosides were 4.1%, 17.4% and 8.5%,
respectively. Multi-drug resistance (MDR) was reported in
7.6% of isolates. Resistance to 3GCs, fluoroquinolones
and gentamicin is increasing. Similar increases have been
observed in other European countries
• 290 invasive isolates of Enterococcus faecalis were
reported. The proportion of isolates that were
vancomycin-resistant was 2.5%. Although this figure is
low, it is still higher than observed in most other
European countries (<1%)
• 224 invasive isolates of Enterococcus faecium were
reported. The proportion of isolates that were
vancomycin-resistant was 31.7%, which is one of the
highest in Europe
• Enhanced surveillance of EARSS pathogens has shown
that central venous catheters are the commonest
identifiable source of S. aureus bloodstream infection.
Analysis of enhanced data also showed that meticillin
resistance is an independent risk factor for early
mortality among patients with S. aureus bloodstream
infection
Introduction
The European Antimicrobial Resistance Surveillance System
(EARSS) was established in 1998 and is funded by DG SANCO
of the European Commission. It is an international network of
national surveillance systems, encompassing approximately
800 laboratories serving 1300 hospitals in 31 countries, which
aims to collect comparable and reliable antimicrobial resistance
data on invasive infections caused by Staphylococcus aureus,
Streptococcus pneumoniae, Escherichia coli and Enterococcus
faecium/faecalis for public health action.1 Two new pathogens,
Klebsiella pneumoniae and Pseudomonas aeruginosa, were
added to this list in 2005.
Forty-two Irish laboratories participated in EARSS in 2005 –
two additional laboratories joined the program but one
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withdrew due to resource issues. Based on acute public
hospital activity data obtained from Department of Health
and Children (DoHC), the estimated population coverage of
EARSS in 2005 was approximately 98%, which was similar to
that in 2004. In 2004, EARSS coverage in other European
countries ranged from 11% in Italy and 14% in Spain to
100% in smaller countries such as Estonia, Iceland and
Slovenia (details of coverage in France and Luxembourg were
not available).1
Protocol
Data are collected on the first invasive isolate per patient per
quarter (Q) of S. aureus and enterococci from blood only and
of S. pneumoniae, E. coli, K. pneumoniae and P. aeruginosa
from blood and cerebrospinal fluid (CSF) in accordance with
the EARSS protocol, which is available on the EARSS website.2
Laboratories report routinely generated qualitative disc
diffusion data on:
• oxacillin, meticillin (Note: revised spelling in accordance with
new International Pharmacopoeia guidelines) or cefoxitin for
S. aureus
• oxacillin and/or penicillin; erythromycin and norfloxacin for
S. pneumoniae
• ampicillin; cefotaxime, ceftriaxone and/or ceftazidime
(3GCs); ciprofloxacin or ofloxacin (fluoroquinolones); and
gentamicin or tobramycin (aminoglycosides) for E. coli and
K. pneumoniae. Laboratories are also asked to specifically
test for the presence of extended-spectrum beta-lactamases
(ESBLs)
• ampicillin, high-level gentamicin (HLG) and vancomycin for
enterococci
• piperacillin or piperacillin-tazobactam; ceftazidime;
imipenem or meropenem (carbapenems); ciprofloxacin or
ofloxacin; and gentamicin for P. aeruginosa
All MRSA isolates are submitted to the National MRSA
Reference laboratory (NMRSARL) at St James’s Hospital,
where MICs are determined for oxacillin and vancomycin.
Laboratories are requested to submit data on MICs performed
in-house for penicillin and cefotaxime or ceftriaxone on all
PNSP isolates.
Epi Info 6 software (Centers for Disease Control and
Prevention, Atlanta, USA and World Health Organisation,
Geneva, Switzerland) was used to determine 95% confidence
intervals (CIs) for medians and to perform Chi-squared tests
(X2), and Chi-squared tests for trend (X2trend).
Rates of MRSA bacteraemia per 1,000 bed days were
calculated using the total number of patient bed days
obtained from the Acute Public Hospital Activity Data
provided by the DoHC for those hospitals that participated in
EARSS over the relevant time period. Data from all private
hospitals, even though participating in EARSS, were not
included in the calculations as activity data were not available
for these hospitals.
No. of MRSA bacteraemias reported to EARSS
Total No. of bed days used over the
surveillance period
{MRSA rate = x1000}
Table 1.  Summary of EARSS data by pathogen over the period 1999-2005 [with total 
numbers of isolates reported and proportion (%) resistance to the key antibiotics].
 1999 2000 2001 2002 2003 2004 2005
No. of labs* 12 19 20 23 28 41 42
S. aureus
No. of isolates 510 639 815 1042 1140 1323 1424
Meticillin 38.8% 39.0% 41.3% 42.7% 42.1% 41.8% 41.6%
S. pneumoniae
No. of isolates 157 201 245 278 364 400 401
Penicillin 19.1% 12.9% 12.2% 11.5% 11.8% 10.3% 11.7%
Erythromycin** 13.4% 12.0% 12.6% 12.7% 11.6% 14.2% 12.1%
E. coli
No. of isolates    741 991 1256 1445
3GC**    3.0% 2.4% 2.4% 4.1%
Ciprofloxacin**    5.4% 9.5% 12.5% 17.4%
Gentamicin**    2.7% 3.9% 5.7% 8.5%
E. faecalis
No. of isolates    168 218 242 290
Vancomycin**    2.4% 1.4% 1.3% 2.5%
HLG**    39.2% 34.1% 42.2% 43.1%
E. faecium
No. of isolates    85 135 187 224
Vancomycin**    11.1% 19.4% 23.2% 31.7%
HLG**    16.7% 54.7% 57.8% 50.5%
*, Maximum number of laboratories participating by year end; **, Not all isolates tested; 
3GC, 3rd-Generation Cephalosporin (e.g. cefotaxime, ceftriaxone, ceftazidime); HLG, 
High-Level Gentamicin
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Crude rates of invasive pneumococcal disease (IPD) per
100,000 population were calculated based on the estimated
population coverage of hospitals participating in EARSS over
the relevant time period and the total population of
3,917,203 in the Republic of Ireland as determined in the
2002 census.
The EARSS interactive database and the EARSS Annual Report
2004 were used to compare data from Ireland with the latest
European data for 2004 and 2005 and trends over the
relevant time periods for each pathogen under surveillance.1,3
Results and Comparisons With Data From Other Countries
Staphylococcus aureus
In 2004, 1,424 reports of S. aureus isolates from bacteraemia
were received from 38 laboratories, of which 592 (41.6%)
were resistant to meticillin (see table 1). By comparison, the
proportion of S. aureus isolates that was meticillin-resistant in
2004 was 41.8%. In 2005, there was a peak in Q1 when the
proportion of MRSA was 44.4% compared with the other
three quarters of the year when the proportion ranged from
38.5–42.0% (see figure 1).
The median age of patients with S. aureus bacteraemia was
65 years (95% CI, 64-66 years). The difference in median
ages of patients with meticillin-susceptible S. aureus (MSSA)
[60 years (95% CI, 58–62 years)] and MRSA bacteraemia [70
years (95% CI, 69–71 years)] was considered to be significant
as the CIs did not overlap. In patients with laboratory-
confirmed S. aureus bacteraemia, the probability of the
infecting organism being meticillin-resistant as opposed to
meticillin-susceptible was 1.75 greater in patients over 65
years than in patients under 65 years [Relative Risk (RR), 1.75;
95% CI, 1.53 to 2.00; X2 = 73.1, P <0.001]. There were
significantly more isolates from males than from females for
both MSSA (60% versus 39%; z-test = 6.4, P <0.001) and
MRSA (61% versus 39%; z-test = 5.3, P <0.001).
Rates are considered to provide a better indicator of the
burden of disease or infection in a population than raw figures
(or proportions in the case of MRSA bacteraemia) as the
denominator takes into account the population at risk while
the numerator is the total number of people with the disease
or infection. The national MRSA rate based on the EARSS case
definition of the first isolate of S. aureus per patient per
quarter (an MRSA isolate is not reported if it is isolated
subsequent to an MSSA isolate within the same quarter) was
0.15 per 1000 bed days in 2005, which compares with 0.15 in
2004 and 0.14 in 2003. In Northern Ireland, the MRSA rate
was 0.13 per 1000 bed days in 2005, a decrease from 0.14 in
2004.4 By comparison, the rate in England for the period
October 2005 to March 2006 was 0.17 per 1000 bed days.5
The rates in Northern Ireland and England are calculated using
a different case definition (a single episode of MRSA
bacteraemia is counted every 14 days). The rate in Scotland
fluctuated between 0.18 and 0.21 per 1000 bed days over the
four quarters of 2005.6 In Scotland, the system of data
collection has recently been changed by combining data from
two separate surveillance systems (from the Scottish Centre
for Infection and Environmental Health’s MRSA Reporting
System and EARSS) to ensure more complete and accurate
reporting on MRSA bacteraemia7 and thus the most recent
rates for Scotland are higher than those previously reported.
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Figure 1.  Trends for S. aureus by time period: by year for 1999-2005
and by quarter for 2005 – total numbers of S. aureus/MRSA and percentage MRSA
with 95% confidence intervals.
Changes in the numbers of laboratories participating in the surveillance system by
year-end are indicated above the chart.  
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In 2005, as in previous years, Ireland had one of the highest
proportions of MRSA reported to EARSS together with the UK
and the countries of Southern Europe (see figure 3).
Between 1999 and 2004, significant increases in MRSA
proportions were reported in 14 of 29 countries, including the
Netherlands and the Nordic countries, which still have the
lowest levels of MRSA in Europe. This trend is potentially
worrying according to EARSS as it indicates that MRSA could
get out of control even in countries with traditionally low
incidences of MRSA. By contrast, two countries, Slovenia and
France, have managed to reverse this increasing trend with
MRSA proportions in Slovenia decreasing significantly from
21% in 2000 to 12% in 2004 and in France from 33% in
2001 to 28% in 2004. Since 2001, the MRSA proportions in
Ireland and the UK have levelled off at approximately 42%
and 44%, respectively, which could simply represent
saturation effects or, more optimistically, reflect the
implementation of more successful control measures.1
Streptococcus pneumoniae
In 2005, 401 reports of S. pneumoniae isolates from
bacteraemia/meningitis were received from 31 laboratories
(see table 1). The majority of isolates (n=397) were from
blood but four were from CSF. Forty-seven isolates (11.7%)
were PNSP. By comparison, the proportion of S. pneumoniae
isolates that were PNSP in 2004 was 10.3%.
As in previous years, a seasonal variation was seen in the
numbers of S. pneumoniae isolates reported with a trough in
Q3, reflecting the quieter summer period (see figure 4).
Of the 47 PNSP isolates reported, MIC data for penicillin and
cefotaxime were available for 47 and 33 isolates, respectively.
Twelve isolates exhibited high-level resistance (HLR) to
penicillin (MIC, !2 mg/L) while the remaining 35 isolates had
intermediate levels of resistance (MIC, 0.12–1.0 mg/L). All
isolates were susceptible to cefotaxime (MIC, "1 mg/L).
Data on susceptibility to erythromycin were available for 379
isolates. Forty-six (12.1%) were resistant. By comparison,
14.2% of isolates in 2004 were erythromycin-resistant.
Twelve isolates were resistant to erythromycin in addition to
being non-susceptible to penicillin. Of these 12 isolates, nine
were intermediate and three were HLR. In 2004, 12 isolates
were co-resistant to both penicillin and erythromycin.
The median age of patients with invasive S. pneumoniae
infection was 60 years (95% CI, 55–64 years). The difference
in the median ages of patients with PNSP [63 years (95% CI,
51–73 years)] and penicillin-susceptible S. pneumoniae (PSP)
[59 years (95% CI, 55–64 years)] was not considered to be
statistically significant as the CIs overlapped. Males were
approximately 1.5-times more likely to have an invasive S.
pneumoniae infection than females (59.9% and 40.1%,
respectively; z-test = 4.05, P <0.001). By comparison, there
were approximately equal numbers of S. pneumoniae isolates
from males and females in 2004 (51.5% and 48.5%,
respectively; z-test = 0.61, P = 0.55).
Of the four CSF isolates reported in 2005, one (from a one-
year old child) was intermediately resistant to penicillin (MIC,
0.19 mg/L) but susceptible to cefotaxime (MIC, 0.064 mg/L)
Figure 2.  Map illustrating the distribution of MRSA in EARSS countries in 2005
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Figure 3.  Trends for S. pneumoniae by time period: by year for 1999-2005 and by quarter
for 2005 – total numbers of S. pneumoniae/PNSP and percentage PNSP with 95%
confidence intervals.
Changes in the numbers of laboratories participating in the surveillance system by
year-end are indicated above the chart.
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when interpreted using Clinical Laboratory Standards Institute
(CLSI) meningitis breakpoints. The other three isolates (one
from a four-month old child and two from adults aged 53 and
60 years) were susceptible to penicillin.
The crude incidence rate of IPD in Ireland was estimated to be
10.4 per 100,000 population, which is the same as in 2003
and 2004. In 2005, the crude incidence rates of IPD in Ireland
in children <5 years and adults !65 years were 21.6 and 40.8
per 100,000 population, respectively (the corresponding rates
in 2004 were 24.1 and 37.6 per 100,000 population,
respectively). These figures compare with projected
provisional rates of 21.3 and 38.8 per 100,000 population,
respectively, in the US in 2005, with an overall projected
national rate of 13.7 per 100,000 population.8
Pneumococcal serotyping data were available for 24 isolates
from 2 of the 42 laboratories participating in the surveillance
of this pathogen in 2005. This represents only 6% of all
pneumococcal isolates reported. From all age groups, the
following serotypes were identified: 14 (5 isolates), 1 (4
isolates), 7F and 9V (3 isolates each), 23F (2 isolates), and 6B,
8, 9N, 15C, 19A, 33F and 38 (1 isolate each). From children
aged <5 years, the following serotypes were found: 14 (3
isolates), 7F (2 isolates), 9V (1 isolate), 6B, 9N, 15C, 19A and
33F (1 isolate each). Of the latter 11 paediatric isolates
(representing 17% of the 64 isolates reported in this age
group), five would be covered by the new 7-valent vaccine
targeted at this age group. Of the remaining 13 non-
paediatric isolates, all are covered by the current 23-valent
polysaccharide vaccine. Of the 24 isolates for which serotype
data were available, four were PNSP (3 with serotype 9V and
1 with serotype 14) and the remainder were penicillin-
susceptible. In countries reporting serotype data to EARSS,
penicillin resistance is most common among isolates of
serotypes 9 and 14.1
In 2005, the proportions of both PNSP and erythromycin-
resistant S. pneumoniae in Ireland were at moderate levels
compared to other countries reporting to EARSS (see figure
4). France and Israel reported the highest proportions of PNSP
in 2005. Since 2001, the proportion of PNSP in Ireland has
stabilised at approximately 12%.
Escherichia coli
In 2005, 1,445 reports of E. coli isolates from
bacteraemia/meningitis were received from 39 laboratories
(see table 1). The majority of isolates (n=1441) were from
blood but four were from CSF.
The trends in total numbers of E. coli isolates and proportions
of resistance to 3GCs, fluoroquinolones and gentamicin
reported by year (2002–2005) and quarter for 2005 only are
shown in figure 5.
The proportions of isolates resistant to ampicillin, 3GCs,
fluoroquinolones and gentamicin were 67.6%, 4.1%, 17.4%
and 8.5%, respectively, compared with 65.0%, 2.4%, 12.5%
and 5.7%, respectively, in 2004.
MDR [defined as resistance to three or more of the
mandatory antibiotics (ampicillin, 3GCs, fluoroquinolones and
gentamicin)] was identified in 107 isolates as follows:
Figure 4.  Map illustrating the distribution of PNSP in EARSS countries in 2005
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Figure 5.  Trends for E. coli by time period: by year for 1999-2005 and by quarter for 2005 –
total numbers of E. coli and percentage resistance to 3GCs, ciprofloxacin/ofloxacin
(CIP/OFX) and gentamicin (GEN).
Changes in the numbers of laboratories participating in the surveillance system by
year-end are indicated above the chart
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• 18 isolates were resistant to ampicillin, 3GCs,
fluoroquinolones and gentamicin. Five of these were ESBL-
positive 
• 22 were resistant to ampicillin, 3GCs and fluoroquinolones.
Ten of these were ESBL-positive 
• 65 were resistant to ampicillin, fluoroquinolones and
gentamicin 
• Two were resistant to ampicillin, 3GCs and gentamicin
MDR isolates accounted for 7.6% of all E. coli isolates tested
against all four mandatory antibiotic groups in 2005
compared with 5.6% (66 isolates) in 2004, 3.6% (34 isolates)
in 2003 and 2.4% (17 isolates) in 2002. This increase in MDR
E. coli was statistically significant (X2trend = 32.54; P <0.001).
In total, 79% of the isolates (1144/1445) were examined for
the presence of ESBLs compared with 69% in 2004. ESBLs
were detected in 2.6% of these (30/1144) compared with
1.3% in 2004.
The median age of patients with invasive E. coli infection was
71 years (95% CI, 70–72 years). The difference in the median
ages of patients with MDR [70 years (95% CI, 66–73 years)]
and non-MDR isolates [71 years (95% CI, 70–72 years)] was
not considered to be significant as their CIs overlapped.
Overall, there were more isolates from females than from
males (57% versus 43%; z-test = -5.3, P <0.001) but there
were more MDR isolates from males than from females 
although this was only borderline significant (59% versus
41%; z-test = 1.87, P = 0.03).
The four CSF isolates from patients aged 24, 55, 69 and 78
years, respectively, were resistant to ampicillin but susceptible
to 3GCs, fluoroquinolones and gentamicin.
Ireland has seen an increase in the proportions of resistance
to fluoroquinolones (X2trend = 73.02; P <0.001) and
gentamicin (X2trend = 36.99; P <0.001) over the past four
years. In 2005, an increase in 3GC resistance from 2.4% to
4.1% was also observed (see figure 6). This increase was
found to be statistically significant (X2 = 6.05; P = 0.02),
although the 95% CIs overlapped. The apparent increase and
spread of 3GC resistance in Europe is thought to be due in
part to the emergence of a particular class of ESBL (CTX-M) in
E. coli.1 Between 2001 and 2004, increasing trends in
resistance to 3GCs, fluoroquinolones and gentamicin in E.
coli were observed in 12, 15 and nine European countries,
respectively. The lowest proportions of resistance to all classes
of antibiotics in Europe are typically observed in the
Scandinavian countries and the Netherlands while the highest
proportions are seen in Southern Europe.
Enterococcus faecalis
In 2004, 290 reports of E. faecalis isolates from bacteraemia
were received from 33 laboratories (see table 1).
The trends in total numbers of E. faecalis isolates and
proportion of resistance to HLG and vancomycin reported by
year (2002–2005) and quarter for 2005 only are shown in
figure 7.
Figure 6.  Map illustrating the distribution of resistance to third-generation cephalosporins
among E. coli in EARSS countries in 2005 
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Figure 7.  Trends for E. faecalis by time period: by year for 1999-2005 and by quarter
for 2005 – total numbers of E. faecalis and percentage resistance to ampicillin (AMP),
high-level gentamicin (HLG) and vancomycin (VAN).
Changes in the numbers of laboratories participating in the surveillance system by
year-end are indicated above the chart
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Ten isolates (3.5%) were reported to be ampicillin-resistant
(compared to 0.8% in 2004). Ampicillin resistance in
E. faecalis is unusual and further investigation of these
isolates is warranted to confirm their identity as it is generally
acknowledged that speciation of enterococci can be
problematic.
One hundred and seven isolates (43.1%) of the 248 tested
were HLG resistant, of which 48 were confirmed by MIC
determination. By comparison, 42.2% of isolates were HLG
resistant in 2004.
Seven isolates (2.5%) were reported to be vancomycin
resistant (one of which was confirmed by MIC). Six of these
were also tested for susceptibility to teicoplanin: four were
resistant and two were intermediately-resistant. By
comparison, 1.3% of isolates were vancomycin-resistant in
2004.
No isolates were resistant to all three “indicator” antibiotics
(ampicillin, HLG and vancomycin). Three isolates were
resistant to HLG and vancomycin but susceptible to
ampicillin.
The median age of patients with E. faecalis bacteraemia was
66 years (95% CI, 62–69 years). There were more isolates
from males than from females (58% versus 42%, respectively;
z-test = 2.61, P = 0.01).
Although the proportion of vancomycin-resistant E. faecalis
(VREfa) in Ireland is low, it is still higher than that reported in
most other countries reporting to EARSS (see figure 8). Only
Greece, Italy and Portugal had higher proportions of VREfa in
2005. HLG resistance is quite common throughout Europe.
There were no obvious trends in vancomycin and HLG
resistance in Ireland between 2002 and 2005.
Enterococcus faecium
In 2005, 224 reports of E. faecium isolates from bacteraemia
were received from 23 laboratories (see table 1).
The trends in total numbers of E. faecium isolates and
proportion of resistance to HLG and vancomycin reported by
year (2002–2005) and quarter for 2005 only are shown in
figure 9.
The proportions of isolates resistant to ampicillin, HLG and
vancomycin were 92.8%, 50.5% and 31.7%, respectively,
compared with 95.7%, 57.8% and 23.2%, respectively, in
2004. Globally, most E. faecium are ampicillin-resistant.
Forty-four of the 71 isolates reported as resistant to
vancomycin were additionally tested for susceptibility to
teicoplanin: 40 were resistant, one was intermediately-
resistant and three were susceptible. In addition, one isolate
was reported as intermediately-resistant to vancomycin and
susceptible to teicoplanin.
Fifty-three isolates were resistant to ampicillin, HLG (18 were
confirmed by MICs) and vancomycin (20 confirmed by MICs).
Such MDR isolates accounted for 25.6% of all E. faecium
reported in 2005 compared with 19.0% in 2004, 12.4% in
2003 and 3.6% in 2002. This increase in MDR E. faecium was
statistically significant (X2trend = 12.80; P <0.001).
Figure 8.  Map illustrating the distribution of resistance to glycopeptides among E. faecalis
in EARSS countries in 2005
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Figure 9.  Trends for E. faecium by time period: by year for 1999-2005 and by quarter for
2005 – total numbers of E. faecium and percentage resistance to ampicillin (AMP),
high-level gentamicin (HLG) and vancomycin (VAN).
Changes in the numbers of laboratories participating in the surveillance system by
year-end are indicated above the chart.
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The median age of patients with E. faecium bacteraemia was
63 years (95% CI, 59–66 years). There was no difference in
the median ages of patients with vancomycin-resistant versus
vancomycin-susceptible E. faecium [both 61 years (95% CI,
59–68 years)]. The difference in the median ages of patients
with MDR [65 years (95% CI, 59–68 years)] and non-MDR
isolates [67 years (95% CI, 63–70 years)] was not considered
to be significant as their CIs overlapped. There were slightly
more isolates from females than from males but this was not
statistically significant (52% versus 48%, respectively; z-test =
0.53, P = 0.60).
Ireland had one of the highest proportions of vancomycin-
resistant E. faecium (VREfm) in Europe in 2005 (see figure 10).
Of countries reporting to EARSS, only Greece, Israel and
Portugal had higher proportions of VREfm. The proportion of
VREfm increased significantly from 11% in 2002 to 32% in
2005 (X2trend = 73.02; P <0.001). The overlapping CIs from
year to year reflect the low numbers of isolates reported.
Ireland also had one of the highest proportions of resistance
to HLG. Between 2002 and 2003, there was a significant
increase in the proportion of HLG resistance from 17% to
55% (X2trend = 13.6; P <0.001). Between 2003 and 2005,
there was no obvious trend in HLG resistance.
Enhanced Surveillance of EARSS Pathogens
Collection of enhanced data on patient demographics, risk
factors and clinical features of the EARSS pathogens began in
2004. Data are analysed to determine the factors that
contribute to the acquisition of bloodstream infections (BSI)
caused by EARSS organisms and their resistant variants.
A report on the progress of the enhanced surveillance system
to 2005 was published in an Epi-Insight article.9 Eleven
hospitals contributed to the data over the two years, 2004-
2005. Enhanced data on 2,011 isolates were collected and all
seven EARSS organisms were discussed. Factors affecting S.
aureus BSI were examined further. A regression study showed
that age, length of stay (LOS) and stay in the intensive care
unit are significant predictors of MRSA BSI while skin/soft
tissue as a primary source is more relevant to MSSA BSI.
Factors found to be relevant to both MRSA and MSSA, were
surgical site infections and recent surgery, and central venous
catheter, which is the most common source of the 
S. aureus BSI.
An analysis of MRSA BSI mortality, using 2005 enhanced data,
was presented at an international meeting.10 Meticillin
resistance was found to be a significant risk factor for 14-day
mortality among patients who already have S. aureus BSI
when other risk factors, including age and LOS, are taken into
account. The other factors become more significant over
meticillin resistance for greater than 14-day mortality.
Analysis of 2005 enhanced data on fluoroquinolone-resistant
E. coli BSI found that resistant E. coli BSI isolates are more
likely to be hospital-acquired than sensitive forms. As reliance
on fluoroquinolone antibiotics in Irish hospitals continues to
rise, there is concern that the levels of this resistant pathogen
will also rise.
Enhanced data on resistance in enterococcal BSI,
K. pneumoniae and P. aeruginosa will be analysed once
sufficient data are collected over the following years. Analysis
Figure 10.  Map illustrating the distribution of resistance to glycopeptides among
E. faecium in EARSS countries in 2005
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of risk factors associated with BSI arising from the
community-acquired pathogen, S. pneumoniae, are more
difficult as the enhanced data collection is primarily hospital-
based. Further improvements in the data collection are
planned for 2006. The current surveillance form and protocol
are available from the HPSC website at:
http://www.ndsc.ie/hpsc/A-Z/MicrobiologyAntimicrobial
Resistance/EuropeanAntimicrobialResistanceSurveillanceSyste
mEARSS/EnhancedBacteraemiaSurveillance/
Additional Information
Surveillance of K. pneumoniae and P. aeruginosa commenced
from 1st October 2005.
The quarterly EARSS Newsletters and other reports and
documents produced by HPSC can be accessed on the HPSC
website at: http://www.ndsc.ie/hpsc/AZ/Microbiology
Antimicrobial Resistance/EuropeanAntimicrobial
ResistanceSurveillanceSystemEARSS/
Antimicrobial resistance data, including the most up-to-date
maps (in full colour) showing the distributions of resistance,
for all seven pathogens surveyed in the 31 countries
participating in this surveillance system can be obtained from
the interactive database available on the EARSS website at:
http://www.rivm.nl/earss/
Conclusions
The continuing high prevalence of MRSA and PNSP, along
with increasing resistance levels in E. coli and enterococci,
underline the importance of full implementation of the 
Strategy for the control of Antimicrobial Resistance in Ireland
(SARI).
The marked increase in fluoroquinolone resistance among
isolates of E. coli, and the finding that these isolates appear to
be mostly hospital-acquired, underlines the importance of
implementing the SARI recommendations on prudent
antibiotic prescribing in hospitals.
Central venous catheters are a common, and potentially
modifiable, risk factor for S. aureus BSI. Future surveillance of
healthcare-associated infection should include targeted
surveillance of central venous catheter-related BSI.
Serotyping data were only available for 6% of S. pneumoniae
isolates reported. Ready access to serotyping is required,
particularly in light of the proposed addition of the conjugate
pneumococcal vaccine to the routine childhood immunisation
schedule.
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Antibiotic Consumption in Ireland,
2005
Key Points
• Outpatient antibiotic consumption was 21.8 DDD per
1000 inhabitants per day in Ireland in 2005, mid-range
compared to other European countries
• Rate has gradually increased by 35% since 1993 when
the rate was 16.2 DDD per 1000 inhabitants per day
• Consumption of specific antibiotics showed accelerated
increases since 2000
• Wide regional variation, seasonal fluctuation, and
differences in consumption between private and non-
private patients were observed
• Hospital antibiotic consumption was 81.5 DDD per 100
bed-days, an overall rise on previous year's rate,
although some hospitals recorded a marked decrease
Introduction
Surveillance of antimicrobial use has been identified as a key
component of the Strategy for the Control of Antimicrobial
Resistance in Ireland (SARI) and Ireland now fully participates
in the European Surveillance of Antimicrobial Consumption
(ESAC). This report covers antibiotic consumption in both
outpatient (sometimes referred to as ambulatory, community
or primary care) and hospital care areas collected under ESAC
guidelines for 2005 in Ireland.1
ESAC uses the WHO Anatomical Therapeutic Chemical (ATC)
index to classify drugs through hierarchical levels.
Consumption is measured in Defined Daily Dose (DDD), which
is the assumed average maintenance dose per day for a drug
used for its main indication in adults.
Methods
HPSC has purchased Irish pharmaceutical sales data from IMS
Health. This dataset contains regional, monthly wholesaler to
retail pharmacy sales data for 2005 from over 95% of the
wholesalers and manufacturers in Ireland. Hospital prescribed
antibiotics data were supplied directly by clinical pharmacists
from a representative sample of 15 public acute hospitals for
each quarter of 2005. Hospitals having greater than 400 beds
were here classed as “large” and comprised all the tertiary-
care centres in the survey (n=4), and the remainder, “smaller
and medium” sized hospitals (n=11) were either acute general
or single speciality hospitals.
An automated data-extraction protocol was devised at HPSC
to obtain the ATC/DDD outputs for antibiotics. The WHO
ATC/DDD version 2005 was used throughout and
HPSC Annual Report 2005122 HPSC Annual Report 2005
retrospective data were re-analysed accordingly.
The 2002 Census of Population was used to calculate rates in
DDD per 1000 inhabitants per day (DID) for the outpatient
data. For a limited analysis, a linear interpolation method was
used to estimate the population for 2004 and 2005 from the
preliminary census of 2006 and the final census of 2002.
Hospital activity data were obtained from the Department of
Health and Children and used to calculate rates in DDD per
100 bed-days used (DBD).
Results
Outpatient Antibiotic Consumption
Overall rates
The overall outpatient antibiotic consumption for Ireland in
2005 was 21.8 DID, a rise from the previous year’s rate of
20.8 DID. Figure 1 shows the breakdown by antibiotic class for
each HSE area and for Ireland as a whole. In 2005 outpatient
consumption, penicillins accounted for the largest class used
(50% of total at 10.8 DID), followed by tetracyclines (16%,
3.5 DID), macrolides (15%, 3.3 DID), cephalosporins (9%, 2.0
DID), quinolones (4%, 0.9 DID) and sulphonamides (4%, 1.0
DID). “Others” comprising aminoglycosides and miscellaneous
accounted for 2% at 0.4 DID.
The outpatient rates using the interpolated population
estimates were 20.1 DID for 2004 and 20.5 for 2005, a rise of
2%.
Regional variation
There was little variation in outpatient antibiotic usage among
the different HSE areas (20.6 to 25.3 DID). However, as shown
in Figure 2, there was considerable variability in outpatient
antibiotic usage at county level (17.3 to 28.7 DID).
Time series analysis
Figure 4 shows consumption of antibiotics in outpatient care,
in DID, for Ireland by quarter since 1993. Antibiotic usage has
been rising steadily from 16.2 DID in 1993 to 21.8 DID in
2005, and was 23.8 DID for the last quarter of 2005. Overall
antibiotic use was highest during winter. For the complete
dataset of 13 years (1993-2005), the mean difference
between troughs (quarters 2 and 3) and peaks (quarters 1 and
4) in antibiotic use was 23% (range 12% - 34%), and was
15% for 2005.
The fluctuation in outpatient antibiotic utilisation during the
course of a year is further demonstrated in Figure 5. The mean
monthly rate for the last five years (2000-2004) dropped
steadily from January to July and stayed low for August. The
level rose sharply to a plateau in September, October and
November then peaked in December. The pattern was the
same for 2005, but higher than the previous years’ mean rate,
particularly in months March through to June.
Penicillins
Figure 3 shows the breakdown of penicillin usage by subclass
in outpatients. Penicillin in combination with beta-lactamase
inhibitor (such as amoxicillin/clavulanate) accounted for the
largest proportion of penicillins and showed a dramatic rise
over the last six years (2000-2005). Broad-spectrum
penicillins (such as ampicillin and amoxicillin) usage was
stable but high. Beta-lactamase resistant penicillins (such as
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Figure 1. Outpatient antibiotic consumption by therapeutic class in each HSE Area
in Ireland, 2005.
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Figure 2. Total antibiotic consumption by county in Ireland, 2005.
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flucloxacillin) and narrow-spectrum penicillins (such as
benzylpenicillins) usage were lower but showed slight
increases.
Cost estimates
According to IMS data, which represent private and non-
private community antibiotic sales, the total ingredient cost
of antibiotics for 2005 was E51.7 million. This is a rise of 5%
from 2004 when the cost was E49.5 million. The HSE
National Shared Services Primary Care Reimbursement Service
(formerly GMS Payments Board) stated that the antibiotic
ingredient cost for 2004 under its three main schemes was
E29.7 million, which is 60% of the total cost (private plus
GMS) while the eligible persons only represent about 30% of
the population.2
Hospital Antibiotic Consumption
Overall rates
The overall hospital antibiotic consumption for Ireland in
2005 is estimated at 81.5 DBD, a rise from the previous year’s
rate of 78.2 DBD. In 2005 hospital consumption, penicillins
accounted for the largest class used (47% of total at 38.6
DBD), followed by macrolides (16%, 13.1 DBD), quinolones
(11%, 9.0 DBD), cephalosporins (8%, 6.7 DBD),
sulphonamides (5%, 3.8 DBD) and tetracyclines (2%, 1.7
DBD). “Others” comprising aminoglycosides, imidazole and
nitrofuran antimicrobials accounted for 11% at 8.6 DBD.
Variation by hospital and changes over time
There was wide variation in terms of total antibiotic
consumption among the different hospitals (range 22.7 to
121.6 DBD). Figure 6 shows the breakdown by antibiotic class
for 2004 and 2005 for the sample of 15 Irish hospitals and by
approximate hospital size. For 2005, the rate for large
hospitals was 85.6 DBD and 78.3 DBD for small/medium
hospitals. The proportionate consumption of quinolones in
larger hospitals was 14% and 8.4% in small/medium facilities.
While, of the 15 hospitals taking part in the survey, three
showed a decrease with one showing a 15% drop, between
2004 and 2005, the overall rate rose slightly from 78.2 DBD
to 81.5 DBD. The rise was greater among the larger hospitals
(Figure 6). In terms of proportional amount of each class of
antibiotics, there was a decrease in cephalosporin usage (8.9%
to 8.2%), but rises in penicillins (46.6% to 47.3%) and
quinolones (10.0% to 11.0%).
Cephalosporins
The overall cephalosporin use in hospital care dropped from
7.0 DBD to 6.7 DBD. Figure 7 shows the breakdown of
cephalosporin antibiotics by generation in 2004 and 2005,
and by size of hospital. In 2005, first-generation cephalosporin
(such as cefalexin) was 9%, second-generation cephalosporin
(such as cefuroxime) was 61% and third-generation
cephalosporin (such as cefotaxime) was 30% of the total
usage. The relative proportion of third-generation
cephalosporin use was higher in 2004 at 34%. In 2005, this
level was higher in larger hospitals (35%) than in
small/medium sized hospitals (28%). Fourth-generation
cephalosporins (such as cefepime) are not used in Ireland.
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Figure 3. Outpatient consumption of penicillin subclass in Ireland, 2000-2005.
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Figure 4. Seasonal variation in outpatient antibiotic consumption in Ireland, 1993-2005.
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Figure 5. Variation in outpatient antibiotic consumption by month in Ireland,
mean of five years (2000-2004) and 2005.
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Figure 6. Hospital antibiotic consumption by therapeutic class in Ireland,
2004 and 2005. The sample of 15 Irish hospitals is divided into small/medium
sized hospitals (<400 beds), and larger hospitals.
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Cost estimates
The mean ingredient cost of antibiotics per hospital in the
survey was E807,998 in 2005, which equates to E33.7
million for all public acute hospitals in Ireland. The cost was
estimated as E33.5 million in 2004.
Discussion
In an ESAC report of 2002 data for 32 EU countries, the
range of outpatient antibiotic usage was 10.0 DID (the
Netherlands) to 32.2 DID (France).3 Outpatient antibiotic
usage in Ireland was 21.8 DID for 2005 and has been around
18-21 DID over the last 5 years, therefore the rate in Ireland
is mid-range in Europe. However, the marked seasonal
fluctuation coupled with a higher proportional of broad-
spectrum penicillin consumption in Ireland is consistent with
those countries having a higher level of resistance among
key indicator pathogens, as in Portugal and Italy, unlike the
Nordic countries, which generally have low levels of
resistance. Furthermore, the overall outpatient usage, and
particularly penicillins such as amoxicillin/clavulanate, is
increasing.
Outpatient antibiotic usage in some Irish counties appears
to be considerably different from the national rate. This
regional variation is similar to the pattern from 2004 and
may reflect differences in prescribing practices,
socioeconomic factors or pharmaceutical marketing.4 This is
further reflected in the analysis of the GMS data, which
showed that those entitled to reimbursement  (representing
30% of the population) are prescribed about 60% of the
antibiotics in terms of cost. Seasonal fluctuation has been
seen every year in outpatient antibiotic consumption and is
probably related to over-prescribing of antibiotics for
respiratory tract infections in winter months.
The three factors – regional, seasonal and socioeconomic –
may work together to produce very high rates of antibiotic
consumption in some primary care areas at certain times,
resulting in increased pressure for selection of resistant
variants of important bacterial pathogens.
The pattern of antibiotic usage in hospitals is different from
primary care usage but again the consumption in Ireland is
mid-range in Europe according to ESAC data.5 In another
ESAC report, aggregate data from 15 countries in 2002
produced a median of 2.1 with a range of 1.3 to 3.9
DDD/1000 inhabitants/day. [This unit of measure was
applied as the recommended bed-days denominator is not
obtainable in some countries. The figure is based on the
catchment population of each hospital studied and can be
only roughly estimated for the Irish data]. The equivalent
rate for hospital antibiotic consumption in Ireland is 2.2
DDD/1000 inhabitants/day, which is similar to the ESAC
median, although variation in therapeutic choice was
observed. The relative proportion of third-generation
cephalosporin usage in Ireland (30%) is similar to that of
high-level consumers of third-generation cephalosporins
including Belgium and Greece. In Ireland although there has
been a decrease in the proportion of third-generation
cephalosporin usage (34% to 30%), the level remains much
higher than those ESAC participants, such as Denmark
(<10%), that have low levels of resistant infections. The
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overall level of antibiotic usage has increased from 2004 when
the survey of hospitals began and quinolone use showed the
highest increase. This is of particular concern as high levels of
fluorquinolone use has been linked to increased rates of MRSA
and Clostridium difficile in hospitals.
While overall hospital antibiotic consumption increased, some
hospitals have shown a clear reduction in antibiotic usage in
2005. HSPC aims to continue to coordinate with regional
community- and individual hospital-based multidisciplinary
teams to target reduction of antibiotic consumption in Ireland
in the coming years.
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Invasive Group A Streptococcal
Disease in Ireland, 2005
Key points
•   Incidence of iGAS in Ireland in 2005 was 1.25/100,000,
lower than most EU countries with consistent data but
higher than 2004 rate in Ireland
•   Bacteraemia was common clinical feature. Necrotising
fasciitis, streptococcal toxic shock syndrome, and other
invasive conditions were also reported
•   Cluster of cases noted in early-2005 in HSE-W
•   Multidisciplinary sub-committee produced guidelines
on iGAS Diagnosis, Management and Surveillance.
Recommendations included need for enhanced
surveillance of iGAS in Ireland 
Introduction 
Group A Streptococcal disease (GAS) covers a wide range of
illnesses from pharyngitis and scarlet fever, to more severe
invasive illnesses such as necrotising fasciitis. Invasive Group A
Streptococcal diseases (iGAS) are infections associated with
the isolation of Streptococcus pyogenes from normally sterile
body sites, and carry significant risk of mortality. Clinical
features of iGAS are: streptococcal toxic shock syndrome
(STSS) which can result in multi-organ system failure early in
the course of the illness; necrotising fasciitis (NF)
characterised by extensive local necrosis of subcutaneous soft
tissues and skin; and other syndromes such as bacteraemia,
meningitis, pneumonia, peritonitis, myositis, septic arthritis,
puerperal sepsis, cellulitis, osteomyelitis and surgical wound
infections.1
Worldwide, cases of iGAS rose during the 1980s and 1990s
but the rates have since stabilised and remain around
3.8/100,000 in recent years in the United Kingdom (UK) and
other European countries with adequate surveillance.2 The
epidemiology of iGAS in Ireland was unknown until 2004
when the disease became notifiable. There were 35
notifications in 2004 (0.89/100,000). The HPSC Scientific
Advisory Committee set up a multidisciplinary sub-committee
in mid-2005 to produce guidelines on the Detection,
Surveillance and Management of iGAS Infections in Ireland.
The recommendations were published in 2006.
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Method
Reports of iGAS cases in Ireland in 2005 on CIDR were
analysed at the HPSC.3 Additional information was available
on some cases for which microbiology laboratories and
Departments of Public Health completed enhanced
surveillance forms. Rates were calculated using the 2002
Census of Population.
Results
In Ireland there were 49 cases (1.25/100,000) of iGAS notified
in 2005, a rise on the 35 cases (0.89/100,000) in 2004. There
were more cases reported in February and March of 2005
than in those months in 2004 (Figure 1). This was due to a
temporal and geographic clustering of cases of iGAS noted in
HSE-W (Figure 2). Typing data were available for 13 of the 17
isolates in the cluster. Serotype M-1 (six isolates), M-12 (two
isolates), M-87 (two isolates) and one isolate each of M-3, M-
5 and M-28 were reported. No epidemiological link was
established among the cases.
Enhanced surveillance forms were returned for 28 of the 49
cases in 2005 (table 1). There were three cases with NF (one
with bacteraemia) and one case of STSS (with cellulitis). In all,
there were nine cases of bacteraemia with or without a focus.
Clinical presentation for eight of the cases was unknown.
Age and sex breakdown for the two years, 2004 and 2005,
combined (Figure 3. and table 2.) showed that all age groups
were affected but the incidence was higher among the very
young and the elderly; 33% of all infections occurred in the
age-group 65 years or over. Overall, slightly more males
(52%) were affected than females.
No national-level data on antibiotic-resistance profiles of the
Streptococcus pyogenes isolates associated with invasive
disease were available.
Discussion
The rise in 2005 of cases of iGAS over 2004 was largely due
to an increase of cases reported in HSE-W, where 18 cases
were reported in 2005 while none were seen in 2004 in that
region. Most of the cases in HSE-W occurred in February and
March but there was a wide distribution of serotypes among
the cases in the cluster. The serotypes were those commonly
recorded internationally. Furthermore, the cases were not
epidemiologically linked and thus the cluster did not
constitute a single outbreak of iGAS.
The crude incidence rate for iGAS in Ireland in 2005 was
1.25/100,000. This is much lower than the rate reported in
recent years in the UK and other European countries
(3.8/100,000). It is possible that there is under-reporting of
cases, or that there is an actual low rate in Ireland. In either
situation, it is important to collect timely and detailed
information on each episode of the disease.
Table 1. Clinical features of cases in 2005
Clinical Feature Number of cases
 STSS, Cellulitis 1
 NF 2
 NF, Bacteraemia 1
 Bacteraemia 4
 Bacteraemia, Cellulitis 3
 Bacteraemia, Osteomyelitis 1
 Cellulitis 2
 Meningitis 1
 Pneumonia 1
 Peritonitis 1
 Septic Arthritis 1
 Others (both abscess) 2
 Unknown 8
Table 2. Sex and age-group distribution of iGAS cases for 2004 and 2005 combined
Age group (years) Females Males Totals (%)
<1 yrs 2 0 2 (2)
1-4 yrs 4 2 6 (7)
5-9 yrs 2 3 5 (6)
10-14 yrs 1 1 2 (2)
15-19 yrs 0 4 4 (5)
20-24 yrs 1 2 3 (4)
25-34 yrs 5 7 12 (14)
35-44 yrs 4 4 8 (10)
45-54 yrs 0 3 3 (4)
55-64 yrs 7 3 10 (12)
65+ yrs 14 14 28 (33)
Unknown 0 1 1 (1)
Total 40 44 84 
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Figure 1.  Notified cases of iGAS by month 2004 and 2005.
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Enhanced surveillance data were received for only two-thirds
of the cases in 2005, and most of the fields were marked as
“unknown”. The HPSC iGAS sub-committee is due to publish
its report in 2006. Included in the document will be a
recommendation that enhanced surveillance questions, which
are available on a form from the HSPC website and which will
be on CIDR in late-2006, are completed. Further
recommendations include strain typing and antimicrobial-
resistance monitoring of all of the iGAS bacterial isolates.
Adherence to these along with recommendations on disease
management in the report should provide a clearer
epidemiological picture and help to control iGAS.
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Figure 2. Epidemic curve for 2005 showing number of cases occurring in the Eastern and Western HSE-Health Areas
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